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Influenza A virus (IAV) is a highly infectious pathogen circulating in avian 
and mammalian species. Pigs are susceptible to both human and avian IAVs, owing to 
the existence of, SA-α 2,6-Gal and SA α 2,3-Gal-containing host cell virus receptors. 
This enables pigs to serve as intermediate hosts in the production of reassortant IAV 
strains, which facilitates cross-species transmission, and can lead to epidemics and 
pandemics. Due to the rapid antigenic evolution, traditional vaccines and licensed 
antiviral drugs are of limited effectiveness for controlling pandemic causing by newly 
emerging and re-emerging IAV strains. In this work, we apply CRISPR/Cas9-based 
approaches to engineer the pig ST6Gal1 coding gene, which impairs the biosynthesis 
of α 2,6-sialylated glycan structure exclusively on the airway cells, and thus reduces 
IAV entry. Moreover, the normal biological functions conducted by α 2,6-sialylated 
glycan receptors may be retained. We propose this work serves as proof of principle 
for generating genetic edited pigs for IAV host resistance as a strategy to achieve 















Influenza circulates in different mammalian and avian species, causing 
epidemics and occasional pandemics. This poses a substantial threat to agricultural 
productions, animal welfare, human public health, and economy. The causative agent 
of the disease is Influenza A virus (IAV), whose entry depends on its preference on 
the receptor molecules since the preference determines whether virus glycoproteins 
can employ the host cell surface sialic acid (SA) as ligands. There are two major types 
of sialylated glycans as receptors for viral recognition: one is Neu5Ac α 2,6-Gal (SA 
α 2,6-Gal for short) preferentially recognised by human IAVs, and the other one is 
Neu5Ac α 2,3-Gal (SA α 2,3-Gal for short) predominantly recognised by avian IAVs. 
Pigs harbouring both types of SA-containing receptors have the potential to play a role 
of ‘intermediate hosts’ or ‘mixing vessels’. Therefore, it is of great interest to develop 
methods aiming at reducing α 2,6-SA-containing receptors in pig cells, so that they are 
less susceptible to human IAV infections.  
β-galactoside α 2,6-sialyltransferase 1 (ST6Gal1) mediates N-linked α 2,6-
sialylation on cell surfaces by catalysing the addition of α 2,6-SA to the terminal N- 
glycans. ST6Gal1 is involved in a wide range of biological events, such as the 
generation of carbohydrate determinants on the cell surfaces, the immune regulation, 
and in various carcinomas. ST6Gal1 is encoded by the ST6GAL1 gene, which 
expression has been reported to display a tissue-specific pattern as a result of the 
regulations of multiple promoter regions and the differential combinations of 5’-
untranslated exons.  
Driven by the concern that inactivating the ST6GAL1 gene may have 
deleterious phenotypic effects given the widespread expression profile and the 
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diversity of its biological functions, I pursued a subtle approach to engineering the 
ST6GAL1 gene — that of removing a single promoter region to alter the expression 
profile. I hypothesised that reducing the biosynthesis of α 2,6-sialylated glycan 
structure exclusively on the respiratory tract could potentially block IAV entry without 
compromising humoral immune responses.  
To this end, I identified 5’ transcription starting sites (TSSs) and 5’ 
untranslated region (UTR) exons of transcripts expressed in nine pig tissues. Then we 
employed the CRISPR/Cas9 system to precisely engineer pig ST6GAL1 gene instead 
of the whole gene deletion. The consequence of deleting the region surrounding the 5’ 
TSS of ST6GAL1 transcripts predominantly expressed in airway was assessed (the 
resulting model was termed as ST6GAL1∆P). Moreover, I generated a ST6GAL1 
functional knockout model by inducing a frameshift mutation in pig trachea cells (the 
resulting model was termed as ST6GAL∆CD). Additionally, human IAV had reduced 
infectivity in ST6GAL1ΔP relative to non-edited cells, suggesting that a strategy to 
reduce the biosynthesis of α 2,6-sialylated glycan structure exclusively on the airway 
could offer an antiviral strategy, independent of inducing a humoral immune response. 
This work lays a solid foundation in generating engineered pigs for IAV host 
resistance modelling, and helps us to achieve the genetic improvement in swine herds; 
also, it provides a good understanding of the fundamental molecular basis of the IAV-
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Preface  
In this thesis, I utilise CRISPR/Cas9 system-based strategies to precisely 
engineer host receptors against IAV entry. The thesis is organised as follows. Chapter 
1 presents a general literature review. All the materials and methods used in this project 
are then described in Chapter 2. The target gene ST6GAL1, its tissue-abundant 
expression patterns, and its associated promoters are discussed in Chapter 3. Then, in 
Chapters 4, I evaluate strategies for precisely engineering the ST6GAL1 gene in pig 
trachea cells using the CRISPR/Cas9 system. In Chapter 5, the sialylation levels on 
the surfaces of edited cells and their susceptibility to IAV infection are assessed. 






1 General introduction 
1.1 General introduction to Influenza A virus 
1.1.1 Taxonomy 
Influenza is a contagious and acute disease circulating in mammalian and avian 
species. There are four influenza virus (IV) genera, influenza A, B, C and D, termed 
as IAV, IBV, ICV and D, respectively. These four genera are different in their 
morphology, surface glycoproteins, antigenic viral encoded matrix (M) and 
nucleoproteins (NP), and genome segments (IA/BV contains eight, whereas ICV has 
seven) (Dowdle, 2006). IAV circulates in a wide range of host species, such as humans, 
avian, horses, pigs, dogs, and marine mammals. It is associated with the emergence of 
annual flu epidemics, as well as the occasional pandemics in the human population 
(Michaelis et al., 2009); IBV is only found in humans and domestic pigs (Ran et al., 
2015); ICV was reported to have little clinical importance (Matsuzaki et al., 2006). 
IDV contains seven negative single-stranded RNA segments. IDV has 50% identity of 
amino acid sequence with those in ICV. IDV was isolated from pigs and then cattle. 
(Su et al., 2017). Therefore, among these four genera, IAV is the most important 
concern in public health. 
1.1.2 Virion structure 
IAV belongs to the Orthomyxoviridae family. It is pleomorphic, enveloped, 
and spherical or filamentous, with the diameter 80 to 120 nm (Pleschka, 2012). The 





Figure 1. 1 The schematic structure of IAV. A single viral particle contains a lipid and enveloped 
layer. HA (blue spike) and NA (red spike) are embedded into the layer surface. There are eight 
genomic negative-sense single-stranded RNA segments in each IAV. IAV: Influenza A virus. M: 
Matrix protein. NP: nucleoprotein. NEP: nuclear export protein. PA: polymerase acidic protein. 
NS2: non-structural protein 2. PB1/2: polymerase basic protein 1/2. 
 
Inside an IAV particle, there are eight segmented RNAs encoding 11 viral 
proteins: Haemagglutinin (HA), Neuraminidase (NA), Matrix proteins 1 and 2 (M1 
and M2), Nucleoprotein (NP), Non-structural protein 2 (NS2), Non-structural protein 
1 (NSP1), Polymerase acidic protein (PA), Polymerase basic proteins 1 and 2 (PB1 
and PB2), and Polymerase basic protein 1 – F2 (PB1-F2) (Samji, 2009). Each viral 
RNA segment is associated with a polymerase complex  (PA, PB1 and PB2), and 
multiple copies of NP, forming a viral ribonucleoprotein (vRNP) unit (Dawson et al., 
2017) (Figure 1.2). 
The viral glycoproteins HA and NA are responsible for the virus-host 
interaction: HA is for virus entering into host cells; and NA is for cleaving sialic acid 
(SA) receptors and releasing the viral progeny (Byrd-Leotis et al., 2017). To date, 18 
18 different IAV HA molecules (H1-18), and 11 different IAV NA molecules (NA1-
11) have been identified (Sleman, 2018). All the possible combinations of these two 
proteins are found circulating in wild aquatic birds and sporadically transmitting to 
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other species (Verhagen et al., 2017), except for H17 and H18, which have only been 
found in bats (Chavan et al., 2016). 
 
1.1.3 Replication process  
The interaction between the viral HA and the host SA-containing receptors is 
an important aspect of IAV infection along airway epithelium (Ibricevic et al., 2006). 
As shown in Figure 1.3, IAV is internalized into the cell cytosol by endocytosis 
(Edinger et al., 2014). In the host cells, the conformational changes of HA is triggered 
by the low pH of endosomes (endosomal acidification), leading to the fusion of viral 
and endosome surfaces (Hamilton et al., 2012). This allows a viral particle to 
incorporate into the cytoplasm through H+ ions activated M2 channel. vRNPs are then 




Figure 1. 2 One single vRNP complex.  
NP encapsidates the viral RNA and forms vRNP 
together with other polymerases. In the helix, 
there are ‘minor groove’, ‘major groove’, and a 
loose region. The 5’ and 3’ vRNAs end at the 
binding sites of the polymerase complex.  
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When entering into the nucleus, vRNPs are escorted by the importin proteins 
(Wu et al., 2007). In particular, the importin α can recognise the nuclear localisation 
signal (NLS) cargo and then binds to the importin β, which then mediates the 
translocation of the complex into the nucleus through the nuclear pore complexes 
(NPCs) (Wente and Rout, 2010). Once in nucleus, the negative-stranded viral RNA is 
converted to the positive-sense RNA as a template. Since a viral messenger RNA 
(mRNA) has a 3’ poly(A) tail but not a 5’ cap, viral PA cleaves off the 5’ methylated 
cap of host cellular messenger RNAs (mRNAs) through a cap-snatching mechanism. 
The cRNA can act as a template for the production of negative-sense vRNA (Samji, 
2009). New viral ribonucleoprotein (vRNPs) are imported into the nucleus and form 
new complementary RNPs (cRNPs) by associating with complementary RNAs. These 
matured vRNPs are trafficked to the cell membrane for packaging and budding, and 





Figure 1. 3 Schematic diagram of the IV life cycle. Attachment: IAV life cycle is initiated when viral 
HA binds to SA-containing cell receptors along the airway epithelium (1). This is followed by the 
endocytosis into the cell (2). Fusion and uncoating: In an acidified environment, HA mediates the fusion 
of viral and endosomal membranes, which is followed by viral materials being released into the 
cytoplasm (3). Transcription and replication: Then, vRNPs is transported into the nucleus (4), where 
the transcription and the replication begin (5) and (6). Assembly: viral RNAs are assembled and matured, 
and transported to the plasma membrane (7). Budding: the buddings of these progeny virions are 






1.2 Viral-host interaction 
The virus-host interactions of HA with SA-containing receptors on host cell 
surfaces are critical in initiating viral entry, involving viral attachment, uptake, 
trafficking, and fusion (Skehel and Wiley, 2003). HA is to SA as a ‘key’ (Section 1.2.1) 
is to a ‘lock’ (Section 1.2.2). 
1.2.1 ‘Key’—viral haemagglutinin 
The haemagglutinin (HA), as a homotrimer, is accounting for more than 70% 
of the spike glycoproteins on the viral lipid membrane (Wilks et al., 2012). HA is 
consisted of two structurally distinct regions: a stem/stalk region and a head region. 
The stem region has a triple-stranded coil of α-helics, and the head region contains an 
antiparallel beta-sheet (on the top of the stem). The HA precursor, HA0, can be cleaved 
by host proteases into two subunits in the lung: HA1 and HA2 polypeptides, which are 
responsible for receptor binding and mediating membrane fusion, respectively (Byrd-
Leotis et al., 2017). More precisely, HA1 harbours receptor binding sites (RBS) and 
preferentially interacts with the host SA receptor and antigenic sites (Lazniewski et al., 
2018); HA2 mediates a conformational change that causes the fusion of the viral and 
host membranes, allowing the IAV genome to enter into the cell via ion channels 
(Hamilton et al., 2012).
In summary, HA is responsible for the binding of viral particles to SA-
containing receptors on the hosts, as well as involved in the fusion into the host cells 
(Xu et al., 2010). The alterations of HA are critical in host adaptation and cross-species 
transmission for multiple IAVs (Armstrong et al., 2000).   
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1.2.2 ‘Lock’—host receptors 
The cross-species transmission of IAVs partially relies on the binding affinity 
of viral HA to specific sialylated glycans receptors distributed and exposed on exterior 
surfaces of cells (Mair et al., 2014). Surface sialylated glycans are covalently linked 
glycoconjugates on the cell surface, more precisely, sugar moieties attach to 
glycoproteins and/or glycolipids via asparagine residues (N-linked glycans) or 
serine/threonine residues (O-linked glycans) (Vasudevan and Haltiwanger, 2014). 
Sialylated N-linked glycans play a critical role in protein folding and stability, and 
cell-cell/pathogen interaction (Iijima et al., 2007), particularly it is essential for IAV 
entry (Chu and Whittaker, 2004).  
Sialic acids (SAs) are electro-negative charged nine-carbon sugar. They are 
widely distributed on the outmost termini of N- or O-linked glycans catalysed by the 
sialyltransferase (ST) family on the cell membranes of mammals and some lower 
vertebrates (Varki, 2008). There are two frequent occurring forms of SA: N-acetyl-
neuraminic acid (Neu5Ac), which is ubiquitous and most abundant form in all species; 
and 2-keto-3-deoxynononic acid (KDN), which is primarily found in prokaryotes and 
plants (Watson et al., 2015). N-glycolyl-neuraminic acid (Neu5Gc) is a derivative of 
Neu5Ac. It is formed when the amino group of Neu is replaced by an acetyl or glycolyl 
moiety (Mwangi and Bansal, 2003), and thus they are different in a single oxygen atom 
(Figure 1.4). Neu5Gc has been reported to be prevailed in pigs, but not generally in 
normal adult tissues of humans (Sriwilaijaroen et al., 2011).  
SA is attached to the penultimate galactose (Gal) residues in α 2,3-linkage or 
α 2,6-linkage, and these two linkages determine the trans- or cis- conformation is 





Figure 1. 4 Structures of Neu5Ac, Neu5Gc and KDN. Neu5Ac and Neu5Gc differ by an oxygen 







Figure 1. 5 Conformational structures of SA α 2,3-Gal and SA α 2,6-Gal. The left panel shows the 
SA α 2,3-Gal and the right panel shows the SA α 2,6-linked Gal. The conformational structure of SA 
has an impact on the affinity of HA binding (Datta and Paulson, 1997). Avian IAV prefers short and 
cone-shaped α 2,3-linked SA molecules and they have higher conformational flexibility (Wilks et al., 
2012); Human IAV prefers long and umbrella-shaped α 2,6-linked SA. The image is originally from 
Jongkon (Jongkon et al., 2009).  
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As the first step of IAV infection, the interplay between HA and host SA-
containing receptors is critical in IAV entry and efficient infection. Moreover, it is 
associated with IAV host switching, and viral interspecies adaptation. 
1.2.3 Reservoirs, evolution and transmission  
1.2.3.1 Host range and interspecies transmission 
IAVs can infect a wide range of avian and mammalian species, including 
humans, marine mammals (seals and whales), swine, minks (ferrets), dogs, horses, 
bats, cows and cats (Parrish et al., 2015). IAV is mutated frequently in its HA and NA 
glycoproteins and display rapid evolutionary dynamics across different hosts, causing 
zoonotic infections and interspecies transmissions (Shao et al., 2017). 
A comprehensive diagram of the interspecies transmission is shown in Figure 
1.6. Taking avian IAVs as an example, such as Anseriformes (geese, duck, and swans) 
and Charadriiformes (gulls, terns, and waders), wild aquatic birds are natural 
reservoirs of IAVs. The replication of avian IAVs occurs along the epithelium of the 
respiratory tract and the lower intestinal tract. Among these IAVs, the high pathogenic 
avian influenza viruses (HPAIVs) and the low pathogenic avian influenza viruses 
(LPAIVs) differ by the basic amino acids at the cleavage site of HA0 precursors. 
HPAIVs, such as H5N1, H7N7, and H7N9, are highly virulent, may cause influenza 
with high morbidity and mortality rates, which is also termed ‘fowl plague’ (Heider et 
al., 2015). Since 2003, HPAIV H5N1 has been reported to infect humans and transmit 
in species, posing a devastating impact on the agricultural production and public health 
(Alexander, 2006). HPAIV viral strains can result in a series of pro-inflammatory 
responses in a wide range of tissues, such as in brain, heart, liver and spleen. In contrast, 
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LPAIV only results in a mild infection along the respiratory and gastrointestinal tract 




Figure 1. 6 Interspecies transmissions. In the interspecies transmission, pigs play intermediate 
roles in the influenza viral transmission. In specific, H5N1, H7N7, and H7N9, as high HPAIVs, 
can infect humans, but not transmitting or causing pandemics.  Solid and bold arrows are the 
direct IAV transmission and dashed arrows shows limited infections. HPAIV: high pathogenic 
avian influenza virus; LPAIV: low pathogenic avian influenza virus.  
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1.2.3.2 IAV evolution by mutations and viral re-assortment 
Human-adapted IAVs are able to escape human immunity pressures, causing 
seasonal influenza in human populations. When mutations take place in viral 
glycoproteins, ‘antigenic drift’ can occur as a gradual and subtle evolution of IAV. 
The mutated viruses can escape the recognition of host immune systems. Sometimes 
this may result in outbreaks of seasonal influenza with high morbidity and low 
mortality, known as ‘epidemics’ (Shao et al., 2017).  
Pandemics may occur when annual epidemic events spread within human 
populations on a global scale (AB et al., 2018). Pandemics may outbreak in the naïve 
human population, and they are usually caused by ‘antigenic shift’. New subtypes of 
viruses are introduced through a viral re-assortment of genome segments from more 
than two distinct influenza strains (Van Poucke, 2013).  
1.2.3.2.1 Epidemics  
The seasonal epidemics of human Influenza cause 290,000 to 650,000 deaths 
every year globally (WHO, 2018). The occurrence of epidemics are closely associated 
with seasonal changes. In temperate climates (e.g., United States), the influenza season 
falls in the winter months, starting from late fall, and peaking in mid to late winter. 
This pattern mirrors in the temperate areas of the southern hemisphere. In tropical 
regions, seasonal variations of influenza are less evident, and periodic milder 




There have been five confirmed IAV pandemics since the twentieth century. 
Spanish 1918/H1N1, Asian 1957/H2N2, Hong Kong 1968/H3N2, Russian 1977/H1N1 
and Swine 2009/H1N1. All these human pandemics occurred were related with the 
introductions of avian or swine IAV to human populations. 
Hosts can be simultaneously infected by more than one viral strain, and viral 
genome from different strains can be mixed in one animal vessel. For example, this 
happened in the cases of ‘Asian 1957/H2N2’ and ‘Hong Kong 1968/H3N2’. Moreover, 
viruses from non-human hosts can cross the species barriers and infect humans, as in 
the cases of ‘Spanish 1918/H1N1’ and ‘Swine 2009/H1N1’ (Taubenberger and 
Morens, 2013). Specifically, ‘Spanish 1918/H1N1’ was the first devastating pandemic 
outbreak in the 20th century. It was spread from North America to Europe by soldiers 
during the World War I, resulting in an enormous economic burden and approximately 
50 million deaths globally in 1918. Firstly, ‘Spanish 1918/H1N1’ was considered a 
result of a genetic assortment between human, avian and swine IAV strains. However, 
Worobey later argued that it was a complete avian virus adapted to humans (Worobey 
et al., 2014). Although the accurate origin of the 1918 pandemic IAV still remains 
vague, all subsequent human pandemic IAV strains have been reported to be its 
descendants (Salomon and Webster, 2009).  
1.2.3.2.3 The roles of pigs in IAV cross-species transmission 
Swine H1N1 was the first IAV isolated from a pig (Shope, 1931). In 1976, the 
first case of a swine-to-human transmission of H1N1 was identified, although there 
was no pandemic immediately afterwards. It was not until 2009 that the Swine H1N1 
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influenza (pdmH1N1) took place in Mexico and spread to the rest of the world, killing 
almost half a million people. pdmH1N1 was reported to be a novel reassortant virus 
consisting of RNA segments from multiple sources: its PB1, PB2, PA, NP and NS 
genes were from a triple-reassortant North American H3N2 swine virus; its HA gene 
was from a classical swine H1N1 virus; its NA and M genes were from Eurasian avian-
like swine lineage (Garten et al., 2009).  
Therefore, although there is a major barrier in IAV interspecies transmissions, 
swine could act as an ‘intermediate host’ and a ‘mixing vessel’ for the generation of 
mutant IAVs, which can circulate in the human population with epidemic and 
pandemic potentials (Ma et al., 2009). It is thus of great practical relevance to come 
up with effective measures to prevent transmissions of IAVs to/from pigs and to reduce 
the susceptibility of pigs to IAVs.   
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1.3 Prevention and resistance 
The surveillance for IAVs in pig herds has not been fully developed, and this 
hindered our understanding of the emergence of novel IAV strains, the transmission 
in pig breeding herds and to human populations. 
1.3.1 Vaccines and drugs 
The identified IAV epitopes provide sources for the production of vaccination 
and the discovery of novel antiviral drugs.  
To date, vaccination against influenza has been applied as a cost-effective 
method to prevent influenza infection. In particular, live attenuated influenza vaccine 
(LAIV) strains have been proved to be safe, and genetically stable with a high level of 
efficacy against a broad range of influenza viruses (Jin and Chen, 2014). These cold-
adapted, temperature-sensitive, and attenuated vaccine strains are produced by reverse 
genetics using HA and NA genes from the viral strains recommended by WHO 
(Bridges et al., 2003). LAIV is, for example, delivered in an intranasal manner to 
stimulate a long-lasting host humoral and cellular immunity (Jang and Seong, 2012). 
However, LAIV is contraindicated in humans that are immunocompromised, and is 
less effective against avian zoonotic viral strains because they do not replicate along 
the human upper airway (Shinya et al., 2006). Inactivated influenza vaccine (IIV) is a 
subunit vaccine containing purified HA and is administered intramuscularly 
(Grohskopf et al., 2014). It is commonly used to combat antigenically closely related 
influenza strains. However, IIV displays low immunogenicity and requires high 
antigen doses.  
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Currently, antiviral drugs offer an alterntaive route against IAVs but achieve 
only limited success. Existing antiviral drugs are consisting of two predominant 
classes: one is NA inhibitors, which inhibit the release of the viral progeny. Currently, 
the only licensed NA inhibitors, Zanamivir (Ralenza) and Oseltamivir (Tamiflu), have 
been approved by FDA (Englund, 2002). The other one is M2 inhibitors, which prevent 
the fusion of the virus and the immigration of the vRNPs complex into the nucleus. 
Amantadine and Rimantadine are the two licensed M2 inhibitors developed (Boltz et 
al., 2010).  
However, the process of developing effective vaccinations and antiviral drugs 
for the novel viruses can be lengthy. Therefore, it is essential to study and develop 





1.3.2 Host genetic control  
To date there is little application of genetic strategies to mitigate IAVs. There 
has been considerable genetic research around this disease but the outcomes have 
largely been limited to the bench rather than the field or clinic. Reflecting this, host 
determinants and genetic variations have been less studied than viral factors. Since 
2009, WHO has identified the major role of host genetics in the susceptibility to avian 
and human IV infection (Ruiz-Hernandez et al., 2016). Thus, host genes variability for 
virus-host interactions is now seen as a priority by some, especially the key genes 
controlling sialylated glycan conformation, assisting viral activities and escaping host 
immune responses, and dominant genes regarded as the targets for vaccination. 
1.3.2.1 Animal model selection 
When conducting a genetic-control approach in the hosts, selecting suitable 
animal models is a priority. They should be susceptible to infection and present similar 
responses with humans regarding clinical signs, efficient replications, viral kinetics, 
and transmission patterns. Therefore, ferrets, mice, hamsters, guinea pigs, and pigs 
have been identified to be suitable for modelling IAV host resistance.  
Ferrets are suitable pathogenesis and transmission models, and have been used 
in IAV transmissibility and adaptation research for many years. They are naturally 
sensitive to human IAVs without prior adaptation, and present similar clinical signs in 
the upper airway tract with those of humans after infection. In 1933, a lab ferret was 
fortuitously inoculated with human IAV and was able to spread the virus to the co-
housed ferrets (Smith et al., 1933). Moreover, the 2009 pandemic influenza (swine-
origin H1N1) was reported to be highly transmissible among ferrets (Munster et al., 
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2009). However, ferrets have limited availability and economically cost, hard to 
manipulate, and space demanding. Compared to ferrets, mice are less expensive and 
easier to handle. They have similar symptoms and immune responses as humans once 
infected, and thus have been widely used for modelling infections of some IAVs. 
However, they have relatively low susceptible to human IAVs. Moreover, IAV 
transmission in adult mice can be inefficient due to the lack of viral shedding (Ortigoza 
et al., 2018). Hamsters have been used as an alternative small-animal model. They 
present pathogenic effects along the airway when infected by human IAVs without 
adaptations, and thus are suitable models for human IAV infection and transmission 
(Iwatsuki-Horimoto et al., 2018). Guinea pigs have been occasionally used in IAV 
research (Azoulay-Dupuis et al., 1984). Compared with humans, they have similar 
anatomical and physiological properties, and comparable IAV receptor distributions. 
However, guinea pigs display no clear clinical signs after IAV infection (Sun et al., 
2010). 
Pigs are a valuable animal model in IAV research. They are similar to humans 
in many aspects, including but not limited to the genetics, anatomy, physiology, social 
behaviour, and clinical signs after infection. The immune system of pigs is well studied, 
allowing us to better understand the immunological mechanisms of IAV infections and 
replications in the hosts (Rajao et al., 2011).  More importantly, pigs are natural hosts, 
and have ample susceptibility to both human and avian IAV strains (Meurens et al., 
2012). Also, monitoring IAVs circulating in pigs is useful for the detection of newly 
emerging IAV strains that have pandemic potentials since pigs can play the role of 
‘mixing vessels’ in generating novel IAV mutants (Ma et al., 2009).  
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1.3.2.2 Genetic-control approach in pigs  
Starting from the first transgenic (TG) pig in 1985 (Hammer et al., 1985a), 
there have been a few attempts to engineer pig genes for pathogen resistance, disease 
eradication, and food production. For example, the F18 receptor gene of pigs was 
successfully engineered against oedema disease and post-weaning diarrhoea (Petters 
et al., 1997). ‘Pig 26’, produced through the editing of the RELA locus, had a potential 
resisilence to Afican swine fever (Lillico et al., 2016). Another example is the CD163-
precisely-engineered pig, which is resistant to the Porcine Reproductive and 
Respiratory Syndrome (PRRS) virus (Christine Burkard, 2017). This study provides a 
potential strategy for host genetic resistance by precisely engineering host genes 
asscoiated with virus-host interactions, without sacrificing pigs’ multifaceted and 
immune functions. The introduction of disease-resistant animal models by genome 
engineering sets a milestone in animal production and breeding — most likely the 
PRRS-resistant pig project will be first. Genetic resistance now represents a realistic 
and alternative solution to our battle against infectious disease transmission, 
preventing the potential disastrous pandemics that IAV can cause humanity.  
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1.4 My approach  
The final goal of this project is to establish a pig model resistant to IAVs. To 
this end, based on a pig trachea cell model, I disrupt the IAV-receptor interaction by 
precisely engineering the α 2,6-sialyltransferase (ST6Gal1) coding gene, ST6GAL1.  
The ST6Gal1 protein catalyses the configuration of the SA α 2,6-Gal receptor 
and is thus important in the virus-host interaction. The SA α 2,6-Gal receptor is 
assembled when SA residues are transferred from a nucleotide mono-phospho-sugar 
donor, CMP-Neu5Ac, to the terminal position of N-linked glycans with α 2,6-linkage 
(Dall'Olio et al., 2000), and this process is mediated by the ST6Gal1 protein. Indeed, 
the close association between ST6Gal1 and viral entry has been confirmed by several 
reports. For example, Vero cells with ST6GAL1 overexpression are observed with 
higher levels of human IAV (H1N1 and H3N2) propagation (Li et al., 2011). Moreover, 
human airway cells with inhibited ST6GAL1 expression present reduced virus binding 
and internalisation (Wu et al., 2014). Inspired by this work, my aim is to apply the 
CRISPR/Cas9 system (detailed introduction is in Section 4.1) to create a pig trachea 
cell model deficient in ST6GAL1 expression, with a long-term goal to apply such a 
strategy in generating less susceptibility of pigs to IAVs in farmed pig herds.  
However, ST6Gal1 is a suitable but a complex target. ST6Gal1 has 
multifaceted roles in a wide range of biological processes, such as immune responses 
(Hennet et al., 1998), circulatory half-life (Manhardt et al., 2017), and inflammation 
(Bohm et al., 2012). Also, much effort has been made to clarify the roles of ST6Gal1 
in cell apoptosis (Anugraham et al., 2014, Antony et al., 2014), angiogenesis (Imamaki 
et al., 2018), cell metastatic behaviours (Schultz et al., 2016a), cancer stem cell 
maintenance (Schultz et al., 2016b), as well as tumour malignant progressions in 
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humans, including colon (Swindall and Bellis, 2011), liver (Harada et al., 1993), breast 
(O'Neill et al., 2004), cervix (Hockel et al., 1996), ovarian (Wichert et al., 2018) , 
pancreatic (Shyr et al., 2011), and choriocarcinoma (Rodrigues and Macauley, 2018). 
For example, ST6Gal1 deficient mice have normal physiology, morphology and 
behaviours, but present immunodeficiency, such as attenuated proliferation, reduced 
IgM levels in serum, impaired B cell responses (Hennet et al., 1998).  
Driven by the concern that inactivating ST6GAL1 could confer deleterious 
phenotyping effects to animals, I have pursued a subtle strategy towards precisely 
engineering pig ST6GAL1 gene by altering its transcriptional profile in the respiratory 
tract. With this approach, I aim to deepen our understanding of the relation between 
ST6GAL1 gene and viral infection in pigs. Moreover, the strategy could be promising 
in creating genetically engineered pigs that are less susceptible to IAVs.  
 I was enthused by the thought that my project could lead to a genetic-control 
or ‘self-protective’ pig model against the sneaking IAV at the ‘door’ of the airway. 
The hypothesized results are:  
(1) The expressions of pig ST6GAL1 mRNA transcripts are in a tissue-dependent 
manner; 
(2) The perturbation of ST6GAL1 gene expression will have an influence on IAV 
infection in vitro; 
(3) The precisely manipulation of ST6GAL1 gene will not compromise immune 
responses and other physiological activities that SA α 2,6-Gal receptors participate 
in.   
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2 Materials and Methods 
2.1 Cells and tissues  
2.1.1 Cells 
2.1.1.1 Cell strains and culture medium   
There were four types of cell lines used in this study, a new-born porcine 
trachea (NPTr) cell line, a pig kidney (PK) -15 cell line, an Madin-Darby Canine 
Kidney (MDCK) cell line and MDCK cells with the cDNA of human 2,6-
sialyltransferase 1 (MDCK-SIAT1) cell line.  
(1) NPTr cell line: It is epithelial-like, non-carcinoma and non-transformed cells 
generated from a 2-day-old piglet trachea, and the serial culturing of the primary 
cells (Ferrari et al., 2003). It provides a wide microbial susceptibility spectrum to 
pathogens. The cell line was kindly provided by Prof. Laurence Tiley (University 
of Cambridge) and it was originally established at the Istituto Zooprofilattico 
Spefimentale in Brescia.  
(2) PK15 cell line (ATCC® CCL-33TM): it is amenable to manipulate and thus has 
been well used for testing the cutting efficiency of CRISPR reagents.  
(3) MDCK and MDCK-SIAT1 cells are both provided by Prof. Paul Digard group at 
the Roslin Institute. They have been use to determine viral titre (Helen M. Wise, 
2012). 
There are four types of cell culture medium used in this study, complete 
medium, serum-free medium (SFM), conditional medium and freezing medium. NPTr, 
PK15, and MDCK cells were cultured in complete medium. MDCK-SIAT1 cells were 
cultured in complete medium supplementary with 2 mM Glutamine. All cells were 
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cultured at 37°C with a humidified and sterile atmosphere of 5% CO2. Media should 
be pre-warmed in a 37°C water bath unless otherwise stated.   
(1) Complete medium (culture medium): Dulbecco’s Modified Eagel Medium (D-
MEM, GlutaMAx and sodium pyruvate, Life Technologies, Cat# 31966-021) 
supplemented with 10% Fetal bovine serum (FBS, Cat#12657029, GibcoTM), 100 
U/ml penicillin, and 100 μg/ml streptomycin (10% pen/strep, stabilized solution, 
P4333, Life Technologies).  
(2) Serum-free medium (SFM): D-MEM supplemented with 10% pen/strep.  
(3) Conditional medium: sterile filtrated from spent culture medium of cultured cells 
through a minisart syringe filter (Cat# SLHA033SS, Merck Millipore). It was 
aliquoted and frozen for storage at -20°C.  
(4) Freezing medium: complete medium supplemented with 10% FBS plus 10% 
DMSO (Dimethyl sulfoxide).  
2.1.1.1 Cell subculture and counting  
All adherent cells were grown in cell culture treated vessels (e.g., flasks, petri 
dishes, or multi-well plates) with appropriate culture medium. When the cell 
confluence reached 80-90% of the surface area, the cells were sub-cultured. Cells were 
washed twice with Phosphate buffered saline (PBS, pH=7.2, Cat# 70013-016, Thermo 
Fisher Scientific), followed by dissociation from the surfaces of culture vessels using 
TrypleTM Express Enzyme (TE, 1x, Cat#12604013, ThermoFisher Scientific). 
Approximately 25 µl of TE per cm3 in added to the culture vessel, followed by the 
incubation at 37°C for approximately 5 min. Once the cells were detached, the TE was 
inactivated by adding at least a double volume of fresh culture medium. The mixture 
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was then transferred into a 15 ml falcon tube, centrifuged at 300 x g for 5 min at room 
temperature and the supernatant was removed. The cells were then passaged by gently 
re-suspending the pellet in fresh culture medium before seeding on the new culture 
vessel. All cells were grown in a 37°C, and 5% CO2 incubator, and were regularly 
inspected under a microscope to examine health status and contamination.  
If necessary, cells were counted using a hemocytometer and a coverslip 
according to the protocol (Abcam) . Briefly, 20 μl of cell suspension was gently mixed 
with 20 μl of 0.4% Trypan blue solution (Cat# T8154, Sigma-Aldrich) in an Eppendorf 
tube. 20 μl of the Trypan blue-treated cell suspension was applied to a hemocytometer 
by the capillary action, and live cells were counted under a light microscope with a 
10x objective. Therefore, the number of viable cells/ml were determined using the 
following calculation where the cell count was the average of the counts from the 4 
sets of 16 squares: Viable cells / ml = Cell count x Dilution factor x 104  
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2.1.1.2 Cell growth and viability  
The CellTiter-Glo® Luminescent cell viability assay (Cat# G7572, Promega) 
was used to detect cell viability. The assay was carried out with 104 cells seeded in 
white 96-well plates filled with 40 µl / well viral growth medium (VGM). At 0 h, 8 h, 
24 h and 48 h points of culturing, 40 µl of CellTiter-Glo® regent was added and gently 
mixed. The cells lysis reaction was incubated for 10 min at room temperature with 
moderate shaking. The resulting bioluminescence was then measured and it was 
correlated with the levels of released adenosine triphosphate (ATP) providing a read 
out of cell viability. 
2.1.1.3 Cell cryopreservation and recovery  
To freeze cells, 106 cells were harvested and re-suspended in 1.5 ml freezing 
medium and transferred to 1.5 ml cryo-tube vials. The tubes were placed in a Mr. 
Frosty™ (Thermo Fisher Scientific) and transferred to -80°C. The Mr. Frosty™ is an 
iso-propanol freezing container that can slow the freezing rate < 1°C/min. After 24 h, 
the cells were transferred to a -150°C freezer on dry ice for long-term storage. 
To recover cells, frozen cells were rapidly transferred to 37°C when it left -
150°C. The thawed cells were diluted with culture medium followed by the 
centrifugation in a 15 ml centrifuge tube at 200 x g for 5 min. The supernatant was 
aspirated and the cell pellet was gently re-suspended in fresh culture medium before 
transferring to a culture vessel.  
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2.1.1.4 Transfection  
Cells were transfected with DNA plasmids by NeonTM electroporation system 
(Life Technologies) and Lipofectamine® 2000 system (Life Technologies) according 
to the manufacturers’ protocols.  
2.1.1.5.1 NeonTM electroporation transfection 
NeonTM electroporation system and 100 μl reaction tips were used to transfer 
plasmids into PK15 cells. All bubbles should be avoided strictly. On the day of 
transfection, pre-seeded PK15 cells were anticipated to reach 80% confluence in a 6-
well plate. Cells were washed, digested, inactivated, and pelleted by the centrifugation 
at 200 x g for 5 min at room temperature (Section 2.1.1.2). The supernatant was 
removed and the cell pellet was re-suspended by gently pipetting up and down in 150 
μl Resuspension Buffer (R). 1 μg each plasmid was added in each well and mixed well, 
followed by taken up into a compatible pipette tip. The pipette tip was inserted into 
the chamber with a holder containing 3 ml of Electrolyte Buffer (E). The optimised 
condition was 1200 v pulse voltage, 20 ms pulse width and one electrical pulse. Once 
the process was complete, the pipette tip was unplugged from the device. Cells were 
then transferred into a new 6-well plate pre-filled with SFM and incubated at 37°C for 
downstream experiments.  
2.1.1.5.2 Lipofectamine® 2000 transfection 
Lipofectamine® 2000 system was utilized to transfect plasmids and/or HDR 
template into NPTr cells. NPTr cells were washed, disassociated, counted and 
inoculated 5 x 105 cells in 6-well plates prior to transfection. On the day of transfection, 
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once approximately 80% confluence, cells were washed, the wells were filled with 
culture medium, and they were prepared for transfection. Briefly,15 μl of 
Lipofectamine® 2000 regent was diluted with 150 μl Opti-MEM Medium (provided), 
labelled as ‘A’; 2 μg plasmid was diluted in 150 μl Opti-MEM Medium, labelled as 
‘B’. ‘B’ was added to ‘A’ at 1:1 ratio, and tubes were incubated at room temperature 
for 10 min. The plasmid-lipid complex was evenly dropwise on the cells and incubated 
at 37°C.  
In both protocols of transfection mentioned above, negative and positive 
controls should be included; in which same amount of cells were transfected with PBS 
and 1 μg empty pSL66 vector, respectively. Successful transfection was indicated by 
the observation of the expression of green fluorescent protein (GFP+). Fluorescent 
cells at 24 and 48 hours post transfection (h.p.t) were visualized using a Zeiss 
microscope fitted with a digital camera with Image J software (3x upright Widefield 
Fluorescence Microscopes). All single panels should be in a same green gain and an 
adjustable blue gain. The fluorescent cells were then individually sorted into multiple 
96-well plates by the Fluorescence-activated cell sorting (FACs) described below. 
2.1.1.5 Fluorescence-activated cell sorting  
At 48 h.p.t, cells were dissociated from the 6-well plates, and re-suspended 
with up to 300 μl PBS in sterile FACs glass tubes. FACs analysis was carried out using 
a BD FACS Aria IIIu 4 laser Cell Sorter in the Bioimaging centre (the Roslin Institute, 
UoE). Briefly, the cell suspension was converted into the stream of fluorescent and 
cells separated into individual cells through the vibration. The droplets then flow 
through an electrostatic orientation system allowing the GFP+ cells to be identified 
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and sorted individually into single wells of multiple 96-well plates pre-filled with 50% 
conditional medium and 50% culture medium. The remainder of the GFP+ cells were 
collected as ‘a mixed pool’. The cell clone expansion was followed for approximately 
20 days, during which period cells should be inspected weekly. Marking the wells in 
which cells are growing and refilling with culture medium. Confluent clones were 
transferred into new 96-well plates. Upon reaching 80%-90% confluence, transferred 
clones were divided into two 96-well plates. One was used for the further culture, and 
the other used for the quick extraction (QE) of gDNA, to allow the genotyping of the 
clones. 
2.1.2 Tissues 
2.1.2.1 Tissue collections and storage 
Tissue samples were harvested from piglets and adult pigs culled for other 
purposes with approval from the Institute’s Ethics Committee. Pigs were sedated with 
an intramuscular injection of ketamine (Vetalar) at a dose rate of 6 mg/kg, Azaperone 
(Stresnil) at a dose rate of 1mg/kg, followed by an overdose of anaesthetic agent 
(Pentoject).  
Tissues of interest were harvested, including the right and lower lobe of lung, 
the cartilage of trachea, the stem bronchus, the lower lobe of the liver, a section of 
spleen containing red and white pulp, the apex of the heart, the duodenum, the wall of 
the stomach and the renal cortex of kidney (Figure 2.1). Each tissue sample was then 
dissected into multiple portions of ~100 mg and submerged in 0.5 ml pre-chilled 
RNAlaterTM Stabilization Solution (100ml, Cat# AM7020, Invitrogen) and snap-
frozen on dry ice before long-term storage at -80°C.  
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2.1.2.2 Tissue manipulation  
To dissect pig tissues, each sample was transferred from the RNase inhibitor 
solution (Thermo Fisher Scientific) onto a 10 cm3 petri-dish on ice. Approximately 
1ml chilled TRIzol TM reagent (Cat#15596026, Invitrogen) was added into each 100 mg 
frozen tissue. The mixture was mixed well and then transferred into a lysing matrix D 
tube, followed by the homogenization in a FastPrep FP120 instrument 
(Cat#116006500, MP Biomedicals) at a speed of 2 m/s for 20 s. 200 μl 1-Bromo-3-
chloropropane (BCP, sublimed grade, 99.99% trace metals basis, Cat#699152, Sigma-
Aldrich) was added in to dissociate the homogenate. After the incubation for 5 min at 
room temperature, the reaction was centrifuged at 12,000 x g for 5 min at 4°C. 
Homogenates were removed, and the phase from the upper aqueous phase was 
collected for RNA extraction and RNeasy Clean up (Section 2.3.2.1).  
 
 
Figure 2. 1 Tissue extraction. Lung, trachea, bronchus, liver, spleen and heart 
samples collected are shown here. Dashed circles represent the portions isolated.  
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2.2 Microbiology techniques 
2.2.1 Manipulation with E. coli 
2.2.1.1 Agar Plates Preparation 
Ampicillin (Cat# A0166, Sigma-Aldrich) was diluted to 50 mg/ml in Nuclease-
free (NF) water. Luria broth (LB) liquid medium and agar were made by the Central 
Services Unit, the Roslin Institute. The final concentration of antibiotic-containing 
medium/agar was 100 μg/ml. The melted antibiotic-containing LB agar was evenly 
distributed on 90 mm single vent Petri dishes, which were then wrapped with cling 
film for storage at 4°C up to two weeks.  
2.2.1.2 Transformation 
Top10 competent cells (Life Technologies) were used in transformations. They 
were kept at -80°C before thawing on ice for transformation. 1-10 ng DNA (2 μl) was 
added in a vial of competent cells (50 μl). The reaction was mixed gently, and 
incubated on ice for 30 min. The tube had a heat shock at 42°C for 30 s, and was 
transferred on ice for further 2 min.  
2.2.1.3 Cell plating and colony picking 
Each transformation reaction was spread onto an antibiotic-containing LB agar 
plates. The plates were incubated overnight at 37 °C. The following day, a number of 
discrete colonies were picked up by a sterile tip and dip it into a colony PCR reaction 




2.2.2 Virology  
2.2.2.1 Viral strains and culture medium  
All experiments with IAV viruses were conducted under the biosecurity level 
three at the Roslin Institute. A lab-adapted strain (PR8: A/Puerto Rico/8/34), an H3N2 
swine isolate (Swine87: A/Swine/England/163266/1987), and a mouse-adapted 
derivative of the prototype (Cal04: A/California/04/2009) were generated by reverse 
genetics using a previously described an eight-plasmid system (de Wit et al., 2004). 
Virus titres were determined according to the standard procedures described 
previously (Klimov et al., 2012) 
There were two viral culture medium used in this study. Overlay medium: 
culture medium containing 0.14% (w/v) BSA, and this was used for plaque assay. 
Viral growth medium: culture medium containing 0.14% (w/v) BSA and 1 μg/ml 
TPCK-treated trypsin, and this was used for viral growth.  
2.2.2.2 Viral infection 
Cells were seeded on 24-well plates and cultured to achieve 80-90% 
confluence prior to viral infection. The culture medium was removed from cells. Cells 
were rinsed with SFM. Viral stock was quickly thawed at 37°C and diluted in an 
appropriate volume of VGM. The diluted virus was then inoculated in cells to provide 
a desirable multiplicity of infection (M.O.I), followed by the incubation at 37°C for 
one hour. Note that a negative control was included: one was not inoculated with virus.  
For a single-cycle infection, any non-internalized and inactivate absorbed virus 
were removed from cells by aspirating the inoculum. Then cells were then overlaid 
with overlay medium. The NP expression was characterised by western blot and 
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immunofluorescence (IF) analysis. For a multiple-cycle infection, cells were overlaid 
with VGM directly and cultured at 37°C. The supernatant was harvested at desired 
time points post infection. The samples were snap-frozen on dry ice, and stored at -
80°C for plaque assay (Section 2.2.2.3).  
2.2.2.3 Plaque Assay  
Growth kinetics in naïve and edited cells were performed using the three 
selected virus strains. Pre-seeded cells were washed with PBS and infection at an 
M.O.I of 0.001. Following absorption, cells were overlaid with VGM and samples 
were collected at 8, 24, and 48 hours post infection. All infected supernatants were 
collected and snap-frozen for being titrated plaque assay or storage at -80°C freezer.  
Regarding virus titres, they were determined according to the standard 
procedures described previously (Klimov et al., 2012). The plaque assay for PR8 and 
Swine87 viruses was performed using MDCK cells. The titration for PR8 or Swine87 
virus was performed using MDCK cells and for Cal04 virus was performed using 
MDCK-SIAT1 cells, allowing for individual plaques being readily discerned and 
counted after staining. Briefly, samples containing virus (Section 2.2.2.2) were ten-
fold serially diluted in SFM. 400 μl of each of the dilution series was inoculated into 
each well and incubated at 37°C for 1 h, with an agitation every 20 min. After 1 h, the 
cell monolayers were overlaid with 2 ml overlay medium, supplemented with 1.2% 
(w/v) Avicel. Cells were then maintained in a 37°C incubator for 48 h.  
For fixing and staining, the overlay medium was aspirated and cells were 
incubated with 2 ml of 10% neutral buffered formalin (NBF) at room temperature for 
20 min. After that, NBF was removed, cells were covered with 5% Toluidine blue stain 
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and left for 30 min or overnight. Plaques were then counted in the well in which more 
than 10 plaques presented. The viral titre was determined according to the number of 
plaque forming units (PFU) per ml:  
PFU/ml= Number of plaques/(dilution factor x volume of diluted virus).  
2.2.2.4 Immunofluorescence  
2.2.2.4.1 Immunofluorescent assay  
An efficient infection is confirmed by the immunofluorescence assay (IFA) of 
intracellular nucleoprotein (NP), which is a RNA-binding protein pivotal to the early 
IAV replication (Portela and Digard, 2002). Following the single-cycle infection 
(Section 2.2.2.2), cells on the coverslips were washed gently, and fixed using 200 μl 
PBS/4%(v/v) formaldehyde for 15 min. The negative control was the one not 
inoculated with virus. After the fixing, samples were washed in PBS and permeabilized 
in 200 μl 5% PBS/0.2%(v/v) Triton-100x for 10 min. Followed by three washes with 
PBS, each sample was blocked in 200 μl PBS/10% FBS for 60 min. For the primary 
antibody incubation, each well was incubated with 200 μl primary antibody–contained 
PBS/1% FBS (Anti-IAV-nucleoprotein monoclonal antibody [AA5H], 1:1000 dilution, 
Cat#ab20343, Abcam) for 1 h at room temperature or overnight in a cold room. Cells 
were then washed with PBS/1% FBS for three times. For the secondary antibody 
incubation, cells were then incubated for 1 h, with 200 μl secondary antibody-
contained PBS/1% FBS (Goat Anti-Mouse IgG H&L Alexa Fluor® 488, 1:1000 
dilution, Cat#ab150113, Abcam) and DAPI (1:10,000 dilution, Invitrogen). 
Subsequently, cells were washed three times in PBS/1% FBS. Coverslips were 
mounted on a microscope slide with ProLong Gold Antifade reagent without DAPI 
33 
 
(Cat# P36934, ThermoFish Scientific). All the mounted slides were covered with foil 
forms and kept overnight at 4°C. On the second day, the fluorescent cells were 
visualised on a Leica DMLB-upright Fluorescent Microscope.  
2.2.2.4.2 Flow cytometry analysis  
In this step, all centrifugations were performed at 400 x g for 5 min at room 
temperature, and all washing steps were repeated three times unless otherwise stated. 
After a single-cycle infection (Section 2.2.2.2), cells were rinsed, lifted, and 
transferred into deep round bottom 96-well plates (P-96-450R-C-5PK, Kinesis Inc.). 
The plates were then centrifuged. Cell pellets were fixed with PBS/4% formaldehyde 
for 15 min, followed by washing with PBS/0.2% Tween-20. Cells were then 
permeabilised in 5% PBS/0.2%(v/v) Triton-100x for 10 min, followed by washing 
with PBS/0.2% Tween 20.   
NP staining was performed essentially as described above (Section 2.2.2.4.1). 
The differences were as follows: the washing buffer was PBS/0.2% Tween 20 and the 
blocking buffer was PBS/2% BSA/0.2% Tween 20. Moreover, the primary antibody 
was diluted in 1:200 in PBS/0.2% Tween 20. The diluted primary antibody was added 
into cells and the reaction was incubated for 20 min at room temperature. Then, 
samples were be kept on ice and in the dark. Secondary antibody was in 1:700 dilutions 
in PBS/0.2% Tween 20, and added into the cells for a 15-min incubated. The final 
wash was in cold PBS/1% BSA buffer, followed by transferring cells into a 
polypropylene FCM tube. Data acquisition was performed using a BD LSR Fortessa 
X20 (14 colour Analyser) imaging flow cytometer with the filer B530-30A for Alexa 
fluorTM 488 analysis. The data analysis was performed using Flowjo_V10 workspace.  
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2.2.2.4.3 Cytometry data analysis using FlowJo V10 
A representative example of dot plots and the sequential gating strategy are 
described as follows: Forward-light scattering (FSC) and side-light scattering (SSC) 
were used to exclude the non-viable cells and cellular debris. After that, FSC-area 
(FSC-A) and FSC-height (FSC-H) were plotted to discriminate sticky or aggregated 
cell, and single cell events using a dot pot. Subsequently, a single-channel histogram 
plot was obtained, followed by the mathematical normalization. Therefore, the median 
fluorescent intensity (MFI) of each sample was measurement. A negative control was 
included to record the number of viable cell populations and the background signals. 
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2.3 Molecular biology techniques 
2.3.1 DNA techniques  
Please note that in this section, all procedures were performed at room 
temperature unless otherwise stated. 
2.3.1.1 Plasmid DNA extraction  
2.3.1.1.1 Small-scale of plasmid DNA (mini-prep)  
Small-scale plasmid DNA extraction was performed using the PureLink™ 
Plasmid Miniprep Kit (Cat#K2100-11, Life technologies) according to the standard 
protocol. Briefly, overnight bacteria culture was pelleted at 4,000 x g for 5 min, and 
the supernatant removed. Pellets were re-suspended in 250 μl of RNaseA (20 mg/ml)-
containing resuspension buffer (R3). 250 μl of lysis buffer (L7) was added to the cell 
pellet and the tube was gently inverted five times until the solution colour was 
uniformly blue. The lysis reaction was then incubated for 5 min, before adding 350 μl 
of Precipitation buffer (N4) to neutralise the reaction. The tube was then inverted 
gently until the solution became homogenous, followed by a centrifugation at 12,000 
x g for 10 min to separate the cell debris. To bind the plasmid DNA on the silica spin 
column, the supernatant was centrifuged through a filter cartridge at 12,000 x g for 1 
min, and the flow-through liquid was discarded.  The bound DNA was washed three 
times with 700 μl ethanol-containing wash buffer (W9), and centrifuged again at 
12,000 x g for 1 min. The DNA was eluted by adding 50 μl TE buffer to the centre of 
the column, and the flow-through DNA was collected in a clean recovery tube. The 
column was incubated for 1 min, before a final centrifugation at 12,000 x g for 1 min. 
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The concentration of plasmid DNA was quantified using a Nanodrop 
spectrophotometer (NanoDropTM 1000, Thermo Scientific) (Section 2.3.1.4). Plasmid 
DNA was stored at -20°C for downstream experiments. 
2.3.1.1.2 Large-scale of endotoxin-free plasmid DNA (Maxi-prep)  
Large-scale plasmid DNA extraction was performed using Qiagen Endotoxin-
Free (EndoFree) Plasmid kit (Cat#12362, Qiagen) according to the standard protocol. 
Briefly, 5 ml overnight bacteria culture was added into 100 ml antibiotic-containing 
LB medium, followed by the overnight culture at 37°C. On the following day, the 
overnight bacterial culture was centrifuged at 4,000 x g for 20 min at 4°C, and the 
supernatants removed. 10 ml RNase A and LyseBlue-containing resuspension buffer 
(P1) and was added in to re-suspend bacterial pellets by pipetting up and down. 10 ml 
lysis Buffer was then added in each reaction, and mixed by inverting the tube five 
times (no vortex), followed by the incubation for 5 min. Subsequently, 10 ml of pre-
chilled neutralisation Buffer (P3) was added in the lysate, and the reaction was mixed 
thoroughly by gently inverting the tube for five times until the lysate became less 
viscous. The whole volume was transferred into a QIAfilter cartridge and incubated 
for 10 min. 50 ml Buffer ER was added into each filtered lysate and kept on ice for 30 
min to prevent endotoxins binding. During the incubation, 10 ml of Buffer QBT was 
added to the QIAGEN-tip, and the column was equilibrated by the gravity flow. The 
lysate was transferred into the column, allowing it to flow through, and the reaction 
was washed with 30 ml Buffer QC for each. Then 15 ml Buffer QN was added on the 
centre of the column to elute the plasmid DNA into an endotoxin-free tube. The 
harvested DNA was then precipitated by adding 10 ml isopropanol, and the tube was 
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centrifuged at 4,000 x g for 60 min at 4°C. The supernatants were removed, and the 
DNA pellet was washed in 5 ml 70% endotoxin-free ethanol. The tubes were 
centrifuged at 4,000 x g for 30 min at 4°C, and then the ethanol was removed without 
disrupting the pellet. Subsequently, the tubes containing wet plasmid DNA were air 
dried in a clean hood for 5 - 10 min to evaporate ethanol residues. 100 μl of Elution 
Buffer (TE) was added to dissolve the DNA. The concentration of plasmid DNA was 
quantified using a Nanodrop spectrophotometer (NanoDropTM 1000, Thermo 
Scientific) (Section 2.3.1.4). Plasmid DNA was stored at -20°C. 
2.3.1.2 gDNA extraction 
2.3.1.2.1 Small-scale gDNA extraction  
Small-scale gDNA extraction was performed using DNeasy Blood & Tissue 
Kit (Cat# 69504, Qiagen) according to the standard protocol. Briefly, cell pellets 
harvested from 2-5 x 106 cultured cells were disrupted in 200 µl PBS, which contained 
20 µl proteinase K. 200 µl Buffer AL was gently added to the reaction, and the reaction 
was incubated for 10 min in a 56°C water bath. 200 µl absolute ethanol was then added 
to the sample and mixed by pipetting. The mixture was transferred into a DNeasy Mini 
spin column, and the flow-through liquid was discarded after the centrifugation at 
6,000 x g for 1 min. The column was inserted into a new collection tube, 500 µl Buffer 
AW1 was added, followed by the centrifugation and the removal of the flow-through 
liquid. Next, Buffer AW2 was added in the tube, followed by another centrifugation 
and a flow-through step. Finally, the column harbouring the gDNA of interest on the 
membrane was inserted into a clean 1.5 ml Eppendorf tube, and 100 µl of Elution 
buffer AE was added on the membrane of the column carefully. The tube was then 
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incubated for 1 min, and centrifuged at 12,000 x g for 1 min. A second elution was 
highly recommended to improve yields. The DNA can be directly used for PCR 
procedure (Section 2.3.1.3).  
2.3.1.2.2 Quick extract gDNA from single-cell clones in 96-well formats 
A rapid and efficient method of gDNA isolation was performed with 
QuickExtract™ extraction solution (QE, Cat#QE09050, Cambio). Well-grown cell 
clones were washed three times with PBS before adding 50 μl QE buffer. The reactions 
were mixed well, and transferred to skirted PCR 96-well plates. The plates were 
incubated at 65°C for 5 min, and 98°C for 2 min in a thermos-cycling PCR machine. 
The gDNA was then used for PCR amplifications (Section 2.3.1.3) or Sanger 
sequencing (Section 2.3.1.8). Alternatively, it can be kept at -20°C for long-term 
storage. 
2.3.1.3 DNA amplification  
PCR primers were designed using online tools Primer 3 Input 
(http://primer3.ut.ee/) and NCBI blast (https://blast.ncbi.nlm.nih.gov/Blast.cgi) unless 
otherwise stated. With some design criteria of primers for PCR, the general suggestion 
of GC content was ranged from 40 to 60%; annealing temperature was identified by a 
gradient PCR, with a range of temperatures setting from 50°C to 72°C; the optimum 
length ranged from 15 bp to 30 bp. After receiving the stock of lyophilised 
oligonucleotides, they were dissolved to 100 µM (stock concentration), and diluted to 
10 µM (working concentration). All primers were kept at -20°C for long-term storage. 




Table 2. 1 Primers for DNA amplification. Detailed information of primers is 
described in the corresponding result chapters. Among these primers, F2 and R2, F3 
and R3 were used to amply the region between coding Exon (1) and Exon (2); GSP-
1, GSP-2, AAP, NP and UAP were used in rapid amplification of cDNA Ends (5’ 













UAP       (CUA) 4 GGCCAGGCGTCGACTAGTAC (G) 14         
Validation of editing using PCR assays (below) 
F1                     GACCAAGACAACTCGGAGGA 
R7 TAGCCCCTGCGCTTTTTCTT          
F2 GGAAACACAGAGGGAGGTCG 
R2 GTCAGCCAGGAAGGAACCAA                       
F9 TGAATGGCTGGTTCGAGTCC 
R9 ACTGCTGTAAGCCTCGTGTC                        
F6 TGAATGGCTGGTTCGAGTCC 
R6 ACTGCTGTAAGCCTCGTGTC                                  
E1F1 CCTGCTGGTCTTTCTCCTGT 
E2R1 CACCCCAGAACCCACCTATT        
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2.2.1.3.1 Routine PCR with Phusion DNA Polymerase  
In this study, the reaction of routine PCRs were performed in a final volume of 
25 μl. The PCR components included 12.5 μl Phusion® high-Fidelity PCR Master Mix 
(Cat#M0531S, NEB), 1.25 μl volume of 10 µM forward and reverse primer, 2 μl of 20 
ng DNA and 8 μl NF water, and the final concentration of them, as well as the reaction 
protocol are shown in Table 2. 3. 
 
Component  Final Concentration 
DNA template   20 - 100 ng  
Forward primer  (10 μM)  0.5 µM 
Reverse primer (10 μM)  0.5 µM 
2x Phusion Master Mix  1 X 
Nuclease-Free (NF) water 
  
Up to 25 μl  
 
Thermocycler conditions 
98°C                                                                                 30s                                                        
98°C                                                                                 10s 
50°C-72°C                                                                       20s                                       
72°C                                                                            25s/kb 35 cycles 
72°C                                                                               5min 
 4°C                                                                                   ∞  
 
Table 2. 2 PCR conditions with Phusion DNA Polymerase. All the 
PCR reaction components were prepared on ice and quickly transferred 
to the preheated thermoycler machine (98°C). A negative control 




If required, colony PCRs were performed with the supernatant of bacteria 
culture as templates. Briefly, after the plasmid transformation (Section 2.2.1.2), cell 
plating and overnight incubation of bacteria (Section 2.2.1.3), 1 μl of the supernatant 
of lysed bacterial was added in a 25 μl volume of PCR reaction containing the 
components introduced above (Table 2.4). A negative control without any 
transformation was included. The PCR reactions were performed with the conditions 
shown above, followed by the band visualization on 2% agarose gel (Section 2.3.1.4).  
2.3.1.3.2 5’- RACE PCR with Taq polymerase 
5’ Rapid amplification of cDNA ends (5' RACE) PCR was performed using 
the kit (5' RACE System for Rapid Amplification of cDNA Ends, version 2.0, Cat# 
18374058, ThermoFisher Scientific) (Figure 2. 4) and all the volume of components 
were added according to the standard protocol.  
Briefly, prior to the 5’ RACE PCR, the first strand of cDNA was synthesized 
using of a gene-specific primer 1 (GSP1) from total mRNA (Section 2.3.2.1). After 
the first strand cDNA synthesis (Section 2.3.2.2), RNA and DNA heteroduplex 
molecules were removed by adding RNase Mix. Then the residues, containing the 
unincorporated dNTPs, GSP1, and proteins, were removed from the first strand of 
cDNA using S.N.A.P Column. Subsequently, terminal deoxynucleotidyl transferase 
(TdT) and Deoxycytidine triphosphate (dCTP) were added into the reaction to 





Figure 2. 2 Schematic overview of 5’ RACE procedure. AUAP contains an adaptor 
region which was homologous to the adpator region of the AAP, and can be used to 
reamplify primary 5’ RACE products. GSP-gene-specific primer; AAP-5’ RACE 
abridged anchor primer; AUAP-abridged universal amplification primer. 
 
After the tailing reaction, the first round of PCR was performed on the tailed 
cDNA with Taq DNA polymerase. The primers in this round of PCR were GSP2 and 
a deoxyinosine-containing anchor primer specificity of the PCR products, another 
round of PCR was performed with a nested Primer (NP) and Abridged Universal 
Amplification Primer (AUAP) using the first round of PCR product as a template (1:20 
dilution). The NP was located upstream of GSP2 within the cDNA product. The 
reaction conditions of these two rounds of PCRs were optimised and described as 
below (Table 2. 5).  
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The second round of PCR product then visualised on a 2% agarose gel 
electrophoresis (Section 2.3.1.4). All the visualised bands were extracted, purified and 
subcloned into a pCR™4-TOPO® TA vector (Cat# 450030, ThermoFisher Scientific) 











Table 2. 3 Optimized conditions of 5’ RACE. The steps of denaturation,  
annealing and extension were cycled for 35 times.  
2.3.1.4 DNA visualisation and quantification  
UltraPureTM Agarose powder (Cat#17852, ThermoFisher Scientific) was 
added to 1 x TAE solution (40 mM Tris, 20 mM acetic acid, 1 mM EDTA; supplied 
by Central Services Unit, Roslin Institute) to make agarose gels with certain 
percentages. The mixture was boiled in a microwave for approximately 3 min to 
dissolve the agarose completely. 10% total volume of SYBRTM safe DNA Gel Stain 
(Cat# S33102, ThermoFisher Scientific) was added to the agarose solution just before 
pouring the solution into a casting tray.  
Each restriction enzyme digested product or PCR product of interest was mixed 
with 6 x blue load dye (Cat# T8154, Sigma-Aldrich) (the final concentration was 1 x) 
and loaded into each well of a gel. GeneRuler 1 kb DNA ladderTM (Cat# SM0312, 
Thermo Scientific) was used as a size marker unless otherwise stated. Run the gel at 
80-100 voltage (V) for 1 h until the marker was clearly distinguished so that the 
Thermocycler conditions 
 PAD 94°C 1 min 
 
35 cycles 
Denaturation 94°C 1 min 
Annealing 55°C 1 min 
Extension 72°C 2 min 
 Final Extension 72°C 6 min 
  5°C Pause 
44 
 
approximate sizes of the products can be determined. Subsequently, the gels were 
visualised under a UV light released by an Ultraviolet (UV) Trans illuminator (256 
nm). 
DNA quantification was carried out using a Nanodrop ND-100 spectrometer 
(Nanodrop Technologies, Inc). After cleaning the sensor of the machine with water 
and a lint-free cloth, 1 μl of dilution buffer was loaded as a blank. Then 1 μl DNA 
sample was then loaded onto the clean sensor. The final concentration was reported in 
ng/μl.  
2.3.1.5 DNA Purification  
2.3.1.5.1 Gel bands isolation and purification  
PCR products excised from agarose gels were purified using the QIAquick Gel 
Extraction Kit (50, Cat# 28704, Qiagen) according to manufacturer’s instructions. 
Briefly, a gel slice was weighed in a 15 ml falcon tube before adding three volume of 
buffer QG of each gel weight (100 mg-100 μl). The sample was then incubated for 10 
min in a 50°C water bath until the gel slice was dissolved completely. The tube was 
gently vortexed every 3 min to solubilize the gel. After that, 1 volume isopropanol was 
added to the mixture and the reaction was transferred to a QIAquick spin column 
inserted in a 2 ml collection tube. The column was centrifuged at 12,000 x g for 1 min 
and the flow-through liquid discarded. The column was washed by the addition of 750 
μl Buffer PE followed by the centrifugation at 12,000 x g for 1 min. To elute the DNA, 
the column was transferred to a clean Eppendorf before loading 50 μl of elution buffer 
on the membrane of the column. The eluted DNA was quantified by the Nanodrop 
(Section 2.3.1.4) and stored at -20°C.  
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2.3.1.5.2 PCR products Purification 
To clean up PCR products, such as removing primer dimers, extra dNTPs and 
enzymes, and failed PCR residues produced from PCR reactions, PureLinkTM Quick 
PCR Purification Kit (Cat#k310001, ThermoFisher Scientific) was used according to 
manufacturer’ s instructions. Briefly, four volumes of Binding Buffer (B2) was added 
to 50 μl PCR volume and the reaction was mixed well. The mixture was then 
transferred to a PureLinkTM spin column inserted into a clean 1.5 ml collection tube, 
and centrifuged at 10,000 x g for 1 min. The flow-through liquid in the tube was 
discarded. 650 μl Wash Buffer mixed with ethanol was added to the column and 
centrifuged at 10,000 x g for 1 min. After this, the column was centrifuged at 12,000 
x g for another 2 min to remove liquid residues. Finally, 20 - 50 μl Elution Buffer (E1) 
was added on the membrane of the column, and the reaction was incubated for 1 min, 
before the spin at 12,000 x g for 1 min. The elution step was performed twice to 
increase the yields of the clean-up PCR product.   
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2.3.1.6 DNA subcloning 
PCR products amplified with Taq polymerase were subcloned into the 
pCR™4-TOPO®TA vectors using the TOPO™ TA Cloning™ Kit (Cat# 450030, 
Invitrogen) according to the standard protocol. Figure 2. 4 illustrates the structure of 
the pCR™4-TOPO®TA vectors. The ligation reaction is detailed in Table 2. 5. All the 
components were vortexed and incubated at room temperature for 5 min, followed by 





Figure 2. 3 pCRTM TOPO® TA cloning ® vector. The image was adapted from the 
manufacturer. M13: Forward/reverse priming sites; T7: promoter; Puc origin: LacZ. 
M13 Reverse primer: 5´-GTAAAACGACGGCCAG-3’;  




pCR™4-TOPO®TA vector 1 μl 
PCR product / gel purified product 10 ng 
Salt solution (1.2 M)  1 μl 
Sterile water  Up to 4 μl 
Final Volume  6 μl 
                Table 2. 4 Ligation conditions. 
2.3.1.7 DNA digestion 
NEB supplied all restriction endonucleases unless otherwise stated. 20 units of 
enzyme (no more than 10% of total reaction volume) was applied in a proper reaction 
volume. The reaction was incubated at 37°C for 5 min for routine gDNA digestion, or 
overnight for HMW gDNA digestion (Section 2.3.1.11).  
2.3.1.8 DNA Sequencing  
DNA sequencing was performed by Edinburgh Genomics. PCR products were 
purified (Section 2.3.1.3) and then diluted to the final concentration according to the 
standard requirements. Briefly, 1.5-3 ng of DNA was required for a fragment of 100-
200 bp product; 4.5-10 ng for 200 bp-500 bp product and 7.5-20ng for 500-1000 bp. 
Total 4 μl of PCR clean-up product and 1 μl of sequencing primer (6.4 pmol/μl) were 
mixed in a PCR-tube for sequencing.  
Dirty PCR products in 96-well plates were sent to the in-house DNA 
sequencing facility (Sequencing Technical Services) at the IGMM (MRC Institute of 
Genetics & Molecular Medicine, University of Edinburgh, UK) for clean-up and 
sequencing. The PCR products (up to 10 ng/μl) were purified with their automated 
clean-up service via a liquid handling robot (Biomek ® NX Laboratory Automation 
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Workstation), in accordance with the manufacturer’s instructions. Subsequently, 
Sanger sequencing reactions were performed utilising DNA Engine Tetrad ® 2 Peltier 
Thermal Cycler (BIORAD) PCR machines. The sequencing products were analysed 
on 3130xl (16 capillaries) and 3730 Genetic analysers (48 capillaries) (AB Applied 
Biosystems/Hitachi). All sequencing data was obtained as ABI files and analysed 
using Lasergene (DNASTAR series) and Geneious v1.2 Software.  
2.3.1.9 Bioinformatics 
The bioinformatics analysis was performed by Dr. Sylvia Beka. Firstly, the 
chromosomal location and sequence of pig ST6GAL1 were aligned to that in human 
ST6GAL1 gene using Ensembl genome browser, NCBI and the Blast software. Exonic 
and intronic sequences were predicted using Genscan 
(http://genes.mit.edu/GENSCAN.html) and Augustus (http://bioinf.uni-
greifswald.de/augustus/) prediction software. Alignments were also performed with 
MegAlign (DNASTAR) software; and similarities of gene sequences between pigs and 
human were detected using the EBI Clustal-Omega tool 
(https://www.ebi.ac.uk/Tools/msa/clustalo/). 
Promoter sequences were predicted using the promoter 2.0 prediction server 
(http://www.cbs.dtu.dk/services/Promoter/) and an online tool applied for the 
recognition of Pol II promoter sequences. Regulatory features were then predicated 
and identified by the level of highlights in the Ensembl browser. In parallel, 
evolutionary conservation of predicted pig promoters was based on 3 methods, (1) 
running multiple sequence alignments with predicted promoters using Clustal-Omega, 
(2) NCBI blast-blasting the predicted pig promoter sequences to look for significant 
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matches with other predicted mammalian promoters for same gene, (3) ECR browser 
searching for predicted promoters using the online tool ECRbase 
(https://ecrbase.dcode.org/). Finally, binding motifs in the pig promoters were 
identified using the Jasper database (http://jaspar.genereg.net/) and Transfac 
(http://gene-regulation.com/cgi-bin/pub/databases/transfac/search.cgi).  
2.3.1.10 Assembly of CRISPR/Cas9 reagents 
2.3.1.10.1 sgRNA design and synthesis  
The web tool CCTop (https://crispr.cos.uni-heidelberg.de/) was used to aid in 
the predicting and ranking candidate CRISPR sgRNAs to the genome region of interest. 
A workflow shows a specific example demonstrating how this website works (Figure 
2.5). 
Briefly, a 500 bp target sequence of pig ST6GAL1 gene was pasted into the 
CCTop software. All the parameters (e.g., protospacer adjacent motif (PAM) type, 
promoters and species) were input correctly. By clicking ‘Submit’, a list of eligible 
sgRNA candidates with on- and off-target scores were displayed. All evaluated sgRNA 
sequences were obtained and more detailed information of interest can be downloaded 





Figure 2. 4 CCTop online interface. In the screenshot, red arrows in (1) shows important input fields which are customizations for sgRNAs; 
(2) confirms the system is working normally; Consequently, from interface (3) and (4), sgRNA candidates are ranked according to their 
performance; More information of their genomic locations and GC abundance could be in further gained as shown in box 5; potential off-
target effects caused by each sgRNA and their positions can be predicted, as shown in box 6. If the sgRNA selected meets the standards, the 
forward and reverse sequences are provided.
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The sequences of all sgRNAs used in this study were detailed in the Table 2.5. 
Please note that the 5’ of the sgRNAs should be a ‘Guanine (G)’ nucleotide, as it was 
required for the efficient transcription of human U6 RNA polymerase III (Bannister et 
al., 2007). Moreover, an appropriated single-stranded oligodeoxynucleotide (ssODN) 
template spanning the target site and complementary to the targeted sequence with 
homology arms, was designed as a donor template. The repair strategy of the donor 
template is schematically diagrammed in Chapter 5.   




















































Introduction of a   
pre-mature stop codon by GGG 
(PAM)>TCT and an EcoRI 
restriction site   
 
 
Table 2. 5 Oligos for CRISPR work. ‘cacc’ (red) is the 5’ overhangs which were 




All oligos used in this section were synthesised by 
Integrated DNA Technologies, Inc. (IDT). Synthesised oligo powder was re-
suspended in TE buffer to reach a final concentration of 100 µm. 
2.3.1.10.2 Assembly of CRISPR/Cas9 reagents  
A cloning vector pSL66 containing BbsI restriction enzyme sites was used for 
the co-expression of the gRNA and Cas9 protein (Appendix 7). The pSL66 vector is 
a modified version of pSpCas9 (BB)-2A-eGFP (pX458) (Addgene plasmid # 48138) 
as described (Chen et al., 2013). The pSL66 vector contains a hU6 promoter driving 
the transcription of the gRNA; also, a hybrid cytomegalovirus (CMV) 
enhancer/chicken β-actin (CAG) promoter is involved in the pSL66 vector to enhance 
the expression levels of pSpCas9 (BB)-2A-eGFP in cells.   
The annealed gRNA oligonucleotides were ligated into the pSL66 vector at the 
BbsI sites. All the procedures are listed below in Table 2. 7. After this, the reaction 
was transformed into competent bacterial DH5α cells (Section 2.2.1.2), and the correct 
insertions were confirmed by PCR and sequencing. The correct pSL66-gRNA 
expression construct was then transfected into PK 15 cells or NPTr cells (Section 
2.1.1.5), followed by the estimation of the cutting efficiency of CRISPR-Cas9 









Components Volume (µL) 
sgRNA sense oligo (100 µM) 0.5 
sgRNA anti-sense oligo (100 µM) 0.5 
10x NEB Buffer 2 0.5 
NF water 3.5 
  
Thermocycling conditions 
37°C 30 min 
95°C 5 min 











pSL 66 vector  
Components Volume (µL) 
pSL66 (1 µg/ µl) 0.5 
Diluted oligo duplex 0.5 
10x buffer 1 
DTT (10 mM) 0.5 
ATP (10 mM) 0.5 
FastDigest BbsI (10 U/µl) 0.5 
T7 ligase (2000 U/µl) 0.25 
NF water 6.25 
  
Thermocycling conditions 
37°C        5 min 
6 cycles 






(c)Plasmid Safe  
Components  Volume (µL) 
Reaction from above  10 µL 
10x Plasmid Safe Buffer  2 µL 
ATP (10mM)  1 mM 
PlasmidSafe exonuclease  1 µL 
NF water  Up to 20 µL 
   
Thermocycling conditions 
37°C  30 min 
70°C  30 min 
 
Table 2. 6 The conditions of CRISPR/Cas9 construct assembly. Complementary 
gRNA oligos are synthesised and re-suspended in TE buffer to reach a final 
concentration of 100 µm (a). Then annealed oligos from reaction is diluted with TE 
buffer, followed by the insertion into PsL66 vector at BbsI restriction digest sites (b). 
To remove undigested and failed ligated products, a plasmid Safe exonuclease 
treatment is suggested (c).   
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2.3.1.10.3 Assessment of cutting activity of CRISPR guides  
T7E1 assay  
A 300-700 bp length of DNA sequence flanking the target locus was amplified 
and purified before the T7 endonuclease (T7EI; NEB) assay. 200 ng PCR product was 
subjected to a denaturing and annealing step. The detailed running parameters are in 
Table 2. 8. Subsequently, 1 µl T7EI enzyme was added into each reaction tube, mixed 
gently, and incubated at 37°C for 15 min. Then 10 µl was immediately loaded on a 1 % 
agarose gel, followed by the visualization and band intensity measurement by Image J 
analysis. The cleaved fraction (f) was calculated a: f (cut)=a/(a+b).  
In this formula, a is the intensity of cleaved products bands, and b is the 











                                        Table 2. 7 T7EI assay conditions. 
Temperature Time 
95°C 10 min 
95-85°C -2°C/s 
85°C 1 min 
85-75°C -0.3°C/s 
75°C 1 min 
75-65°C -0.3°C/s 
65°C 1 min 
65-55°C -0.3°C/s 
55°C 1 min 
55-45°C -0.3°C/s 
45°C 1 min 
45-35°C -0.3°C/s 
35°C 1 min 
35-25°C -0.3°C/s 
25°C 1 min 
25-4°C -0.3°C/s 




The online tool ‘Tracking of insertions and deletions (in/dels) decomposition’ 
(TIDE assay http://tide.nki.nl/) was utilised to quantify the editing efficacy of CRISPR 
reagents (Brinkman et al., 2014). Following the PCR amplification spanning the target 
region and sequencing analysis, sequencing trace files of a control and edited samples 
were input into the online TIDE software. The TIDE software can calculate the cutting 
efficiency and determine in/del frequencies. 
2.3.1.11 Southern blot 
The Southern blot was performed according to manufactures instructions and 
protocol from Edwin Southern (E.M.Southern, 1975). All work involving phenol was 
carried out in a fume hood, and all steps were carried out at room temperature unless 
otherwise stated. All homemade solutions in Southern blot are listed below:  
Solutions  Final Concentration 
Cell lysis buffer 
10 mM NaCl, 20 mM Tris-HCL, 1 mM EDTA, 0.5% 
SDS and 100 μg/mL proteinase K (pH=8) 
Depurination Solution 2.5 mM HCL 
Denaturing solution 0.5 M NaOH, 1.5 m Nacl (pH=13) 
Neutralising solution 1M Tris (PH=8), 1.5M NaCl (pH=7.5)  
Hybridisation Buffer 0.25 M, Na2HPO4, 7% SDS, 1mM EDTA (pH=7.2) 
Wash Solution A 2xSSC  2% SDS 
Wash Solution B 2 xSSC 1% SDS 





2.3.1.11.1 HMW gDNA extraction for Southern Blot 
Prior to the isolation of HMW gDNA, cells were cultured in a T150 flask 
(Cat#CLS431080-50EA, Eppendorf). Confluent cells were washed, and harvested into 
a 50 ml falcon tube as described in Section 2.1.1.1. Pellets were washed and dissolved 
in 5 ml lysis buffer. The reaction was mixed and incubated overnight at 55°C. The 
following day, 5 ml volume phenol (Cat#P1037, Sigma-Aldrich) was added in the 
lysate, followed by adding phenol-chloroform:isoamyl-alcohol (25:24:1 Saturated 
with 10 mM Tris, pH 8.0, 1 mM EDTA , Cat#25666, Sigma-Aldrich). The tube was 
gently inverted, followed by the incubation for 10 min. The reaction was then 
centrifuged at 12,000 x g for 20 min. The upper aqueous phase containing the nuclei 
acid was transferred into a fresh tube by a pipette (the top of the tip was cut to be 
wider), followed by DNA precipitation. 1/10 volume of 3 M sodium acetate (pH=5.5) 
and 2 volumes of 100% ice-cold ethanol was added into the reaction, and the reaction 
was mixed well before the incubation overnight at -20 °C. In the following day, the 
DNA was spooled by a bent, autoclaved and thin glass, followed by a wash with 70% 
ethanol. The DNA was air dried in a safety hood. Finally, the DNA pellet was 
dissolved in 100 µl TE buffer and kept at 4°C for long-term storage.  
2.3.1.11.2 HMW gDNA restriction digest and visualisation 
A 98 μl volume reaction, involving 10 μg HMW DNA, 10 μl of 10x reaction 
Buffer, 3 μl of the EcoR I restrict enzyme (10 units/μl) and NF water, was incubated 
overnight at 37°C. On the second day, another 2 μl EcoR I enzyme was added in the 
reaction, followed by the incubation for 2 h. 20 μl digested sample and 6x loading dye 
were mixed and loaded on a 0.7% agarose gel electrophoresis. DNA 1 kb ladder (Cat# 
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15615-024, ThermoFisher Scientific) and Hind III DNA ladder (Cat# SM0102, 
ThermoFisher Scientific) were loaded as molecular weight markers alongside. The gel 
was run at 20 V overnight, and followed by the visualisation under a UV-trans-
illuminator. A fluorescent ruler was placed alongside the gel and photographed as a 
measurement of the distance of DNA fragment migrated.   
2.3.1.11.3 Transfer 
The DNA fragment of interest was larger than 10 kb in size, so the gel was de-
purinated prior to the transfer. Briefly, the gel was soaked in denaturing solution for 2 
x 15 min, followed by another wash in distilled water. The gel was saturated soaked 
in the neutralising buffer for 2 x 15 min. The gel was then rinsed in distilled water, 
followed by the upward capillary transfer.  
All components were assembled as shown below. Setting a piece of glass plate 
on a clean glass baking tray and filling the tray with 20 x SSC (CSU, Roslin Institute). 
Three layers of filter papers (Cat# 88600, Invitrogen) were pre-soaked in 20 x SSC 
solution, and folded on the glass sheet with their bottom layers overhanging and 
dipping into 20 x SSC solution. Gently transferring the gel matrix to lay on the top of 
filter papers, and then placing Saranwrap over the entire glass plate. Cutting a window 
to fit edges of the gel. A gel-sized piece of Hybond N+ nylon membrane (Cat# 95038, 
GE Healthcare) was pre-wetted and placed over the gel. The left upper corner was cut 
and the comb was labelled using a pencil on the membrane. Subsequently, four pieces 
of pre-wet filter paper the same size as the gel were placed on the top of the membrane. 
A stack of green towels was placed on top and then covered with a glass plate. A 




Figure 2. 5 Southern blot transfer assembly.  
2.3.1.11.4 Crosslink  
On the next day, the blotting stack was dismantled, and crosslinked to the 
membrane using Stratagene Stratalinker® 2400 UV Crosslinker (Cat#53274-1, 
Agilent Technologies) for 120 s.  
2.3.1.11.5 Probe radiolabelling and hybridisation  
A 532 bp DNA fragment was amplified using forward primer (5’-
GGGATGGAACCTCAGTCACA-3’) and reverse primer (5’-
ACCACAGCTACCCACCTTAC-3’). The purified PCR product, as the template, was 
diluted to 25 ng/μl with MIlliQ water. The final volume was 14 μl. After this, the steps 
were conducted by Claire Neil (Whitelaw Group). Briefly, the reaction (14 μl) was 
incubated at 95°C for 5 min and transferred on ice for 2 min. The radiolabelling of the 
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probe was then carried out by adding 4 μl of High Prime (Cat#. No 11585592001, 
Sigma) and 2 μl of [α32P dCTP] (Cat# No BLU513H250UC, Perkin Elmer), followed 
by the incubation for 15 min at 37°C. The unincorporated dNTPs were removed 
through the spin-column chromatography (Illustra Nick Column, Cat# 17085501, GE 
Healthcare). The storage buffer from the column was discarded and the column was 
filled with TE buffer. Another 400 μl TE buffer was added to remove unincorporated 
[α32P dCTP]. A final 400 μl of TE buffer was poured onto the column, and the flow-
through which contained the labelled probe was collected. 30 μl 5 M NaOH was then 
added to the tube and the reaction was mixed well. The membrane was prepared for 
hybridisation by incubating in the hybridisation solution over at 65°C for at least 30 
min prior to the addition of radioactively labelled probe. The probe was then added in 
the hybridisation tube and incubated at 65˚C overnight.  
2.3.1.11.6 Blot wash, hybridisation and visualisation  
Hybridisation solution was removed and the membrane was rinsed in 50 ml 
wash solution A at 65°C for 20 min, followed by two washes (2 x 20 min) with 50 ml 
wash solution B. The hybridising membrane was placed on an imaging plate (Fujifilm, 
BAS-IP MS 2025) and exposed to pre-blanked with GE healthcare Image Eraser 810-
UNV for 24 h. Images were then taken using a Typhoon FLA 7000 
(https://www.gelifesciences.com/shop/protein-analysis/molecular-imaging-for-
proteins/imaging-systems/typhoon-fla-7000-p-00194?current=28955809).   
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2.3.2 RNA techniques  
Please note that all procedures were performed at room temperature unless 
otherwise stated. Care should be taken throughout the whole procedure to avoid RNA 
degradation and RNase contamination.  
2.3.2.1 RNA extraction, quantification and integrity 
Total RNA was extracted from frozen tissues using an RNeasy Mini Kit (Cat# 
74104, Qiagen) according to the manufacturer’s protocol. RNA samples were 
quantitated at an absorbance of 260 nm using the NanoDrop spectrophotometer as 
described (Section 2.3.1.4). The RNA integrity (RIN) was calculated using the Agilent 
2200 bioanalyzer (Cat#G2963-90002, Agilent Technologies) according to the 
accompanying protocol. The ratio of 28S:18S ribosomal RNA was estimated.  
2.3.2.2 Reverse transcription  
cDNA was prepared using the Superscript II cDNA synthesis system 
(Cat#11904018, Invitrogen) following the manufacturer’s protocol. Briefly, 1 μg of 
total RNA was mixed with 1 μl random primer, 1 μl of 10 mM dNTP. The reaction 
was made up to 10 μl reaction with NF water, and the mixture was incubated at 65°C 
for 5 min, before incubation on ice for 1 min. The cDNA synthesis reaction consisting 
of 4 μl of 25 mM MgCl2, 2 μl of 10 x RT buffer, 2 μl of 0.1 M DTT (1,4-Dithiothreitol, 
DTT-RO, Sigma-Aldrich), and 1 μl RNaseOUTTM (40 U/ μl) was mixed in a separate 
tube and added to the 10 μl RNA/primer reaction. The mixture was gently mixed and 
collected by a brief spin before the incubation at room temperature for 2 min. 
Subsequently, 1 μl of SuperscriptTM II RT (50 U/μl) was added. The reaction was 
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incubated at 42°C for 50 min, and was terminated at 70°C for 5 min. The reactions 
were then placed on ice. 1 μl RNAse H (2 U/μl) was added to remove RNA, followed 
by the incubation at 70°C for 20 min. The single-stranded cDNA was used as the 
template in the quantitative PCR reactions.  
2.3.2.3 Quantitative PCR 
Quantitative PCR (qPCR) was used to compare the expression levels fo 
ST6GAL1 mRNA transcripts derived from different pig tissues. To this end, qPCR 
was performed in a 7500 Fast Real-time PCR System (Cat# 4351107, Applied Bio-
system) using the SYBR® Green Master Mix (Cat#4309155, Invitrogen) following 
the manufacturer’s recommendations. The mRNA expression level in each tissue was 
normalised to  housekeeping genes, glyceraldehyde 3-phosphate dehydrogenase 
(GADPH) and ribosomal protein L4 (RPL4), which have been validated to be stable 
expressed in pig tissues (Nygard et al. 2007). The specific primers of ST6GAL1 gene 
and housekeeping genes used are detailed:  












In each cycle, the fluorescence intensity was determined by the binding of 
SYBR green dye and dsDNA, allowing the concentrations of samples quantified. Each 
reaction was in triplicate and the specificity of the amplification was determined by 
the analysis of melting curves. The final concentration of each component and the 
following thermal cycling conditions are described as below:  
Component  Volume (uL)  Final Concentration 
2 x SYBR® green Master Mix 10 1x 
Forward primers 5 200 nM 
Reverse primers  5 200 nM 
cDNA Variable  1 - 100 ng 
Distilled water  Up to 20 μl  - 
Procedure  and parameters  Temperature Time  
Activation 95°C 10 min 
Denature 95°C 10 s 
  40cycles 
Anneal/Extend 60°C 1 min 




2.3.3 Protein techniques  
All procedures were performed at room temperature unless otherwise stated. 
2.3.3.1 Western Blot 
All procedures were performed according to the protocol from Prof. Paul 




Primary antibody: Rabbit polyclonal Anti-myelin 
basic protein (MBP)-NP (2915) (1:1000 dilution) 
 
(Turnbull, 2017) 
Primary antibody: Rat monoclonal Anti-α-Tubulin 
(1:1000 dilution) 
 
Serotec (MCA77G), clone 
YL1/2 
Secondary antibody: IRDye® 800CW Donkey 
Anti-Rabbit IgG (H + L) (0.5 mg, 1:10,000 
dilution) 
P/N 926-32213 
LI-COR Corporate Offices 
Secondary antibody: IRDye® 680LT Donkey 
Anti-Mouse IgG (H + L) (0.5mg, 1:10,000 
dilution) 
P/N 926-68022 
LI-COR Corporate Offices 




Buffer Components and Supplier 
Laemmli’s solution 
20% (v/v) Glycerol 
2% (w/v) SDS 
100 mM DTT 
24 mM Tris 
0.016% (v/v) brompophenol blue 
0.016% (v/v) xylene cyanol solution  
4 x Resolving buffer (Protogel) 
0.375 M Tris-HCl 
0.1% SDS 
pH 8.8 (Cat#EC-892, ProtoGel) 
Resolving polyacrylamide gel 
30% acrylamide:bisacrylamide (37.5:1) 
4x resolving buffer 
10% (w/v) APS (Cat#09913, Sigma-
Aldrich) 
TEMED (Cat# T7024, Sigma-Aldrich) 
4 x stacking buffer (Protogel) 
0.125 M Tris-HCl 
0.1% SDpH 6.8 (cat#EC-893, ProtoGel) 
Stacking polyacrylamide gel 
30 % acrylamide:bisacrylamide (37.5:1) 
4 x stacking buffer 
10% (w/v) APS 
 TEMED 
SDS-PAGE running buffer (Bio-
rad) 
0.25 M Tris 
1.92 M Glycine 
1% w/v SDS 
1x transfer buffer 
0.025 M Tris 
1.92 M Glycine 
0.1% (w/v) SDS 
25% % (v/v) Ethanol 
Blocking solution 
10% (w/v) Semi-Milk Powder 
0.1% % (v/v) Tween 20/PBS 
Wash buffer                                          0.1% (v/v) Tween 20 
                                                              1 x PBS 
Table 2. 12 Buffers and solutions used in western blot.  
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Confluent cells cultured (4 x 104 cells) in 24-well plates were lysed with 200 
μl Laemmli’s solution, followed by being re-solubilised at 95°C for 5 min, and 
centrifuged at 12,000 x g for 5 min. Samples were kept at -80°C or loaded on the 
sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
(Cat#4561086, Bio-Rad). Mini-PROTEAN tetra system (Cat#1658035, Bio-Rad) was 
used to for SDS-PAGE apparatus. After loading up to 15 μl in each lane of the SDS-
PAGE, the tank was filled with 1x SDS running buffer. The gel was run at 80 V for 10 
min, and then switched to a constant voltage of 120 V for approximately 1 h. The 
colour pre-stained protein standard with a broad range (Cat#P7712S, NEB) was used 
as a marker. Protein was then transferred from the SDS-PAGE to a nitrocellulose 
membrane using trans-Blot TurboTM Transfer system (Cat#1704150, BioRad) 
according to the guideline of manufacture. Then the cassette was disassembled and the 
membrane was blocked in 5%(w/v) skimmed milk (Marvel) in PBST/0.1%(v/v) 
Tween 20 for 30 min.   
All primary antibodies were diluted in 5% (w/v) skimmed milk in PBST and 
membrane incubations were conducted on an orbital shaker for 1 h at room 
temperature or overnight at 4°C. Each blot was probed with a mixture of a primary 
antibody and a loading control at proper concentrations, followed by throughout three 
washes in PBST. Then the blot was incubated in a secondary fluorescent tagged Li-
COR antibody at room temperature for 60 min in the dark, followed by three washes. 
The visualisation of the blot was performed using Li-COR Odyssey imaging system 
(Lot#410, Li-COR Bioscience), according to the manufacture’s protocol. The band 
intensity was quantified with Image J.  
66 
 
2.3.3.2 Lectin staining   
All procedures were performed at room temperature unless otherwise stated. 
Fluorescein labelled lectins, Sambuccus nigra agglutinin (SNA) lectin, Maackia 
amurensis lectin (MAL II) and Canavalia ensiformis (ConA) lectin (Vector 
Laboratories) were used to detect α 2,6-linked SA, α 2,3-linked SA, and α-mannose 
activity on cell surfaces, respectively. 
For the confocal imaging, cells were pre-seeded on the coverslips in 24-well 
plates. Cells at a confluence of ~50% in a 24-well plate were washed in PBS and fixed 
with 250 μl 4% formaldehyde in PBS for 20 min. After this, cells were washed in 1% 
FBS/PBS (3 x 5 min), and then permeabilized with 250 μl of 0.2% Triton X-100/PBS. 
After washes (3 x 5 min) with 1%FBS/PBS, cells were blocked with 1% FBS/PBS for 
1 h, before the incubation with 50 μl of SNA, MAL II or ConA lectin solution (10 
μg/ml) for 1h or overnight at 4°C. Cells were then washed with 1%FBS/PBS, before 
the incubation with avidin-FITC conjugate (10 μg/ml) and Hoechst DNA dye (0.5 
μg/ml, Cat#62249, ThermoFisher Scientific Inc.) for 40 min in the dark. Final washes 
(3 x 5 min) were developed with 1x PBS before mounting and visualisation. The 
confocal laser scanning microscope (LSCM) coupled with Z-stack were used to 
capture images at focal distances according to the manufacture’s protocol. In this study, 
up to Z-stacking images at 80 μm vertically were captured and aligned under 63x 
objective lenses. The wavelength of FITC-A channel used was 488 nm. 
For quantitative analysis of surface SA expressions, confluent cells were 
seeded in 24-well plates and harvested as described in Section 2.1.1.1. The procedure 
of lectin staining was performed essentially same as shown above. More than 2,000 
stained cells were transferred to FACs tubes for flow cytometry analysis with a laser 
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violet 405 nm, which was according to the same instructions as previously described 
(Section 2.2.2.4.3).  
2.4 Statistical analysis   
Experiments were analysed with GraphPad Prism v6 and Microsoft Excel 
software. Data was presented as mean±SEM. A one-way analysis of variance 
(ANOVA) was used to determine the statistically significance, and p-values <0.05 was 






3 Identification of 5’ untranslated regions of pig 
ST6GAL1 mRNA transcripts 
3.1 Introduction 
β-Galactoside α 2,6-Sialyltransferase (ST6Gal1) is known to be an important 
sialyltransferase (ST) responsible for the addition of terminal sialic acid (SA) residues 
to Gal 1,4 GlcNAc disaccharide on N-glycans or O-glycans with α 2,6-linkage 
(Kitazume, 2014), termed as ‘α 2,6-sialylation’. Aberrant α 2,6-sialylation of 
glycoproteins has been reported to be associated with multiple physiological and 
pathological aspects, such as cell apoptosis (Swindall and Bellis, 2011), cell adhesion 
(Suzuki and Abe, 2014), and inflammation (Nasirikenari et al., 2010). Moreover, the 
upregulation of α 2,6-sialylation on the cell surface is characteristic of malignant 
carcinogenesis, such as in gastric cancer (Gretschel et al., 1998), liver cancer (Dall'Olio 
et al., 1999), breast cancer (Minami et al., 2013) and colorectal cancer (Zhang et al., 
2017b). Importantly, in mammalian immune system, ST6GAL1 is highly expressed in 
B cells (Jones et al., 2016) and α 2,6-linked SA can act as a ligand for CD22 in B-cell 
receptor activation as evidenced in ST6GAL1 homozygous deficient mice (Collins et 
al., 2006). It is also implicated in host-pathogen interactions for several diseases 






Figure 3. 1 Human ST6GAL1 mRNA expression levels in different tissues. The HPA data was obtaned from 
https://www.proteinatlas.org/ENSG00000073849-ST6GAL1/tissue . TPM stands for transcripts per million. 
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ST6Gal1 is encoded by the ST6GAL1 gene, which has been extensively 
studied in humans (Svensson, 1990), mice (Hamamoto et al., 1993), cattle (Mercier et 
al., 1999), rat (Weinstein et al., 1987), and chicken (Kurosawa et al., 1994). Taking 
human ST6GAL1 as a reference in the Human Protein Atlas (Uhlen et al., 2015), it is 
expressed differently from tissues to tissues (Figure 3. 1). This RNA-seq data is 
corresponding with the previous study, in which mammalian ST6GAL1 mRNA was 
detected in liver with the high levels (Petit et al., 2010).  
Regulation of ST6GAL1 expression is mainly at the transcriptional level. The 
different expression of ST6GAL1 across tissues is regulated by multiple promoters 
(Wang X 1993), generating several transcripts encoding the identical polypeptide (T 
P O'Hanlon, 1989). The multiple transcripts of ST6GAL1 in humans, mice, rat and 
cattle differ in their 5’ heterogeneous untranslated region (UTR) sequences. Totally, 
there are 22 transcript variants of ST6GAL1 mRNA reported in the human genome 
assembly (GRCh38.p12), six in the mice genome assembly (GRCm38.p4), two in the 
bovine genome assembly (ARS-UCD1.2), three transcripts in the rat genome assembly 
(Rnor_6.0), and two in chicken genome assembly (GRCg6a). However, compared 
with them, there was only one transcript variant in the pig assembly (Sscrofa 10.2), 
and a lack of 5’ UTR and detailed annotations of the transcriptional profiling.  
ST6GAL1 mRNA has three transcript variants (forms 1, 2 and 3) identified 
(Maksimovic et al., 2011), governed by at least three physically and independent 
promoter regions characterized (Lo and Lau, 1999), P1, P2 and P3. P1 sequence 
(NC_000003.12) generates mRNA form 1, which contains 5’ UT exons (UTE) H and 
I (Mercier et al., 1999). P1 activity has been characterised in liver of adult animals (YP 
Hu, 1997), involved in acute phase response (Kaplan HA 1983). P1 region is also 
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identified in colon and intestinal cells (Charles W. Hutton, 1987). The loss-of-function 
study showed that the ablation of ST6GAL1-P1 region resulted in strikingly depressed 
levels of ST6Gal1 levels in circulation (Jones et al., 2010). Moreover, ST6GAL1-P1 
deficient mice exhibit a normal B cell response, but a great burden of the pathogen 
Salmonella typhimurium in liver and spleen (Appenheimer et al., 2003b).  
P2 sequence (NC_000003.12) promotes the expression of ST6GAL1 mRNA 
form 2, containing 5’ UTE X, H and I (Lo and Lau, 1996). P2 region has been reported 
to contain a specific locus involving cis-acting regulatory elements responsible for the 
promoter activity in B-lineage cells (Lo and Lau, 1996), and thus it is important in B-
lymphocytes maturation (Appenheimer et al., 2003b). In particular, E(X) has been 
reported to be associated with with repressed expressions in a B-null precursor cell 
line and human liver cancer (HepG2) cell lines (Lo and Lau, 1999). 
P3 sequence contributes to the basal expression of mRNA form 3, which 
contains UTEs Y, Z, H and I (Dall'Olio, 2000). P3 region contains CpG islands, as 
short interspersed DNA sequences that are guanine-cytosine (CpG)-rich, is typically 
close to the transcription start site (TSS) of ST6GAL1(Bird, 2011). However, P3 
region is associated with a non-tissue-specific expressed pattern of ST6GAL1 
(Svensson, 1990), and responsible for the expression in other cell types (Appenheimer 










Figure 3. 2 Diagrammatically representations of ST6GAL1 mRNA transcripts in 
human, mice, rat and cattle. Associated promoter regions (P) are denoted by arrows, 
P1 is orange, P2 is grey and P1 is red. The data were summarized from the 
transcriptional profiling of ST6GAL1 in human, bovine and rat (L Meng et al., 2013).  
Translated exons are black boxes and untranslated ones in grey. 
 
It has been reported that the useage of diverse promoters in ST6GAL1 gene are 
evolutionarily retained in human, mice, cattle and rat ST6GAL1 (Appenheimer et al., 
2003b). Morover, cross-species comparisons of conserved non-coding sequences 
enable one to identify functional regulatory elements (Dubchak and Frazer, 2003). 
Therefore, the study of transcriptional profiling of pig ST6GAL1 mRNA enables us to 
gain a better understanding associated transcriptional mechanism expected from 5’ 
UTR in different pig tissues and organs. To this end, we perform reverse genetics 
techniques to investigate 5’ alternative splicing variants of pig ST6GAL1 mRNA. We 
then grouped those transcripts into various mRNA families, which differ by their 5’ 
divergent regions. The study provides resources to ST6GAL1 gene functions involved 
in a range of biological systems, especially its implications in infectious pathogen 




3.2.1 Revision of exon 1  
In the pig genome assembly Sscrofa 10.2, intron 1 in the coding region of 
ST6GAL1 mRNA contained a region of roughly 100 bp indicated by ‘N’s (Figure 3. 
3). We performed PCR using primer F3 and R3, using an optimized annealing 
temperature 68°C, followed by sequencing. Sanger sequencing revealed ‘AAG’ as the 
unknown gap between known exon 1 (E1) and exon 2 (E2). As this is too short to be 
a genuine intron (Jo & Choi 2015), these two exons were combined into a new exon 
re-defined as ‘exon 1’. We now have a complete and correct sequence of the first exon 
for ST6GAL1.  
 
 
Figure3. 3 Reconstruction of coding region in exon 1 sequences. The agarose gel 
exhibits the products, which were amplified by PCR using primers F3 and R3 
surrounding the unknown region between exons 1 and 2 (E1 and E2, black boxes). The 
unknown sequence between E1 and E2 was ‘AAG’.  
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3.2.2 Assessment of RNA integrity  
RNA, extracted from nine pig tissues-lung, trachea, bronchus, liver, kidney, 
spleen, stomach, heart and small intestine as described (Section 2.3.2.1), was assessed 
of RNA integrity (RIN) (Wilkes et al., 2010). RIN is commonly used to assess RNA 
quality. RNA quality is considered to be sufficient if the RIN value is greater or equal 
to 7. Low quality of RNA may compromise the results of downstream experiments 
(Schroeder et al., 2006). The metric scoring of 10 RIN means a lower level of 
degradation and >=7 guaranteed for transcriptomic analysis. The ratio of 28S and 18S 
ribosomal components was also measured. The pseudo electropherograms in which 
the total RNA bands at 28 and 18S ribosomal RNA (rRNA) bands are clearly 
distinguishable in the electrophoretogram, indicating that the extracted RNA was of 
good quality.  
 
       
 
Figure 3. 4 Assessment of RNA integrity. Results of the RNA assessment of nine 
tissues using the Agilent Bioanalyser 2100. The 28S and 18S RNA subunits are visible 
at ~4000 bp and ~2000 bp.  
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3.2.3 ST6GAL1 mRNA expression in various tissues  
ST6GAL1 mRNA expression in various tissues was determined by qPCR 
(Section 2.3.2.3). As can be seen, amongst all the ST6GAL1 mRNA transcripts 
detected, ST6GAL1 was most abundant in the liver tissue, which interestingly was 
also observed in the human ST6GAL1 levels (Figure 3. 1). Therefore, we hypothesis 
that the tissue-specific expression pattern of pig ST6GAL1 mRNAs is associated with 
5’ splice variants and differential utilization of regulatory elements, which is described 
in the later sections. This is the first study focused on tissue-specific expressions of 
pig ST6GAL1 mRNA.  
 
 
Figure 3. 5 Relative expressions of ST6GAL1 mRNA in different pig tissues. qPCR 
results show ST6GAL1 expression levels from various pig tissues. Data is normalised 
to housekeeping genes, GADPH and RPL4. The value of expression in lung is set as 




3.2.4 Identification of 5’ UTR of ST6GAL1  
5’ RACE was carried out to obtain 5’ UTR sequences of ST6GAL1 mRNA in 
various pig tissues. Prior to the experiment, the positive control provided with the kit 
was used to optimise the 5’ RACE system. The template used in this experiment was 
an in vitro transcribed RNA of the chloramphenicol acetyltransferase gene (Appendix 
1).  
The 5’ RACE of ST6GAL1 transcripts was performed as described in Section 
2.3.1.3.2. The nested PCR visualisation on the 2% agarose gel is shown in Figure 3. 
6a. This gel image was a representative one in three independent repeats. The 
supplementary results are in Appendix 2. Each tissue produced at least one cDNA 
amplicon, whose size ranged from 200 bp to 600 bp. The PCR amplicons with robust 
enrichment were marked with yellow stars. Each individual PCR product was 
numbered in a descending order according to its size. 
All these PCR products obtained were extracted, and sub-cloned into the 
pCR™4-TOPO® vector, followed by sequencing from M13 reverse primer. Each 
result showed the liner sequencing inserted into the vector. Taking spleen 1 transcript 
as an example, the sequencing trace file is shown in Figure 3. 6b. The sequence was 
treated as a distinct entity amplified between the 5’ anchor primer and nested primer 
(NP). More specifically, it was the sequence between the 5’ transcription start site 
(TSS) and the known sequence (~250 bp downstream of ATG start codon). The 
sequence obtained from each sample was then aligned to the pig assembly 10.2, 
showing that they were made up of different untranslated exons (UTE). We thus named 
them from E(-1) to E(-9) (3’ to 5’). Sequence of all nine UTEs was detailed in 
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Appendix 3. However, the sequence of lung 1 (Appendix 2) and heart 1 (Figure 3. 6-
a) transcripts was failed.  
To better illustrate the results and to more clearly characterise the pattern of 5’ 
spliced variants, transcripts were grouped into different mRNA families according to 
the 5’ divergent sequence. Ten mRNA families were isolated from 24 ST6GAL1 
transcripts. The schematic representation of these variants is shown in Figure 3. 7 
(upper panel). The most abundantly expressed transcripts in each tissue marked with 








Figure 3. 6 5’ RACE results and sequencing. In each lane, products were numbered according to the sizes in descending order. The gel 
was the most representative result, and other numbered products accordingly were in other repeats. Yellow asterisks indicate the most 





Figure 3. 7 Schematic representation of pig ST6GAL1 transcripts in nine tissues. Translated exons are shown in dark grey and UTEs 
are in light grey. Within each family, the asterisk indicates the most abundantly expressed transcript for that tissue. Negative numbers are 
used to record UTEs. 
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3.2.5 Sequence alignment 
The experimental findings of the transcriptional profile of ST6GAL1 were 
further validated by the computational prediction and now form a part of new pig 
assembly Sscrofa 11.1. The comparison of two datasets shown below suggests that 5’ 
RACE performed in this study is an efficient method to identify transcript variants.  
 
Figure 3. 8 Pig assembly 11.1 versus 5’ RACE data. Upper image shows the 
schematic map of pig ST6GAL1 mRNA transcripts from pig genome assembly 11.1 




The ancestral profile of the ST6GAL1 gene has been reported to be conserved 
in human, cattle, mouse and rat (Mercier et al., 1999). Moreover, the tissue-/cell-
specific expression manner of ST6GAL1 is determined by distinct usages of 5’ UT 
exons and multiple promoter regions (Dalziel et al., 2001). Following these early 
studies, our work focused on the identification of 5’ UTEs of pig ST6GAL1 transcripts, 
and obtained 24 spliced variants, which were grouped into 10 forms. These variants 
differ by their diverse 5’ TSSs.  
The transcriptional profiling of human ST6GAL1 has been previously obtained 
by homologous evolutionary alignment among species orthologues (Maksimovic et al., 
2010). Based on this, we aligned the DNA sequence of pig ST6GAL1 E(-5), E(-7) and 
E(-9) sequence with human ST6GAL1 E(H), E(Z) and E(Y), respectively (see 
Appendix 4). Moreover, we aligned 500 bp upstream of pig ST6GAL1 E(-5) with 
human P1 region (see Appendix 5). We observed similar regulatory motifs, suggesting 
that E(-5) expression might be driven by a functional promoter. This hypothesis was 
supported by a bioinformatics analysis performed by Dr. Sylvia Beka, a visitor in the 
Whitelaw group. Dr.Beka used several software (described in Section 2.3.1.9) to 
predict promoters associated with each mRNA family (see Appendix 6). The study 
helped us characterise alternative splicing patterns of ST6GAL1. It is known that 
alternative splicing is closely associated with the regulation of protein functions, and 
thus is an important mechanism in physiological processes, such as immune response, 
tumorigenesis, and cell apoptosis (Möröy and Heyd, 2007). Regarding the splicing 
pattern of pig ST6GAL1 transcripts, we found that the expression pattern was similar 
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to that of human ST6GAL1, suggesting that pig ST6GAL1 might be associated with a 
wide range of biological functions. 
We now discuss several technical limitations of our experiments. The first 
limitation is in obtaining full-length cDNA copies from mRNA. The reason is as 
follows. The homopolymeric tails added on the premature and mature cDNAs are 
similarly efficient. Therefore, cDNAs made up of large amounts of premature cDNAs 
cannot be efficient amplified. Also, high GC content at 5’ends could inhibit reverse 
transcription. Another one is the unstable performance of PCR (Chen et al. 2016; Liu 
et al. 2002). This can be improved by the optimisation of PCR conditions, as well as 
increasing amplification cycles.  
Yet another limitation is the inefficiency of the DNA sequencing technique to 
obtain the long DNA sequence due to inefficient primer binding, or DNA degradation, 
or sample contamination. For example, with lung 1 and trachea 1, we obtained PCR 
product but failed to obtain their sequencing data. A possible improvement is to apply 
a ‘walking primer’ strategy in which the successive PCR primers are used to obtain 
the 5’ or 3’ amplicon ends. Another limitation is to distinguish the splicing donor and 
acceptor sites of UTEs because the sequencing results we obtained were the 
combinations of different UTEs.  
To characterise the tissue-specific expression pattern of ST6GAL transcripts, 
there are alternative methods, such as Northern blot and high-throughput RNA-seq. 
Northern blot can exclusively detect tissue-specific mRNA transcripts in RNA mixed 
pools. RNA-seq is a versatile and unbiased technique performed by next-generation 
sequencing (NGS). RNA-seq data allows a digital identification of transcript 
expression profiles derived from diverse tissues (Castle 2014). Alternatively, another 
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method, serial analysis of gene expression (SAGE), could be applied. In SAGE, a 
library with short sequence tags can be constructed. SAGE allows transcripts to be 
assessed according to on the tag frequency (Brufsky 2003). Among all possible 
techniques, 5’ RACE was chosen for the following reasons. Compared with other 
options, it is cheaper, more accessible and less time-consuming. 5’ RACE allows us to 
explore and isolate unusual transcripts of ST6GAL1 and characterise the 5’ cDNA 
ends in tissues of interest. Unlimited numbers of clones can be generated using 5’ 
RACE. The spliced variants can be visualised, isolated and cloned separately.  
To the best of our knowledge, this study is the first one to obtain multiple pig 
ST6GAL1 transcripts across nine pig tissues. Moreover, the tissue-expressed pattern 
is revealed, which has critical homologies with that in human ST6GAL1. What we 
discovered is consistent with those in the newly released pig assembly 11.1. The data 
provide resources to decipher the tissue-associated expression of ST6GAL1 in diverse 
tissues and cells, which is more complicated than previously discovered.  
Important regulatory elements are commonly located around 5’ TSS, and 
upstream 200 bp proximal to the TSS is typically referred to as core promoter (Lee et 
al. 2012). Therefore, we will manipulate 5’TSSs in airway-abundant transcripts, which 
will be detailed in Chapter 4.  
3.4 Conclusion  
We obtained 5’UTR sequences in nine pig tissues. Then we grouped them into 
ten mRNA families depending on their unique or similar 5’TSS. The transcriptional 
profile of pig ST6GAL1 gene was thus constructed.  
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4 ST6GAL1 editing in pig trachea cells 
4.1 General introduction 
4.1.1 DNA damage and repair  
During the life cycle of an organism, DNA in the cells can be damaged due to 
various exogenous or endogenous factors (Jin et al., 2016). DNA damage, in turn, 
impacts a wide range of biological processes encompassing mutagenesis, 
carcinogenesis, normal progression of cell replication and ultimately lifespan (Lieber, 
2010).  
DNA damage occurs when its structure changes as a result of oxidative damage 
or DNA hydrolysis (Gates, 2009), hydrolytic deamination (Dabney et al., 2013), O6-
methyl-guanines(Srivenugopal and Ali-Osman, 2002), exposure to high-energy 
radiation or DNA replication fork collapse (Rodgers and McVey, 2016). DNA damage 
can result in DNA lesions, intra-/inter-strand crosslinks, and single-/double-stranded 
DNA breaks (Taylor et al., 2015). Among these varieties, double-stranded DNA break 
(DSB) is a relatively common event. The frequency of DSB-induced events in rats, for 
example, is estimated to be around 7.4x10-5/cell/day (Scott and Pandita, 2006). 
Therefore, DSB is arguably the most severe hazard to genome integrity, potentially 
causing local mutations, chromosome rearrangements or abnormal numbers of 
chromosomes in cells (Cheng et al., 2012). 
Cells deal with this damage by inducing various repair mechanisms, termed as 
‘DSB repair (DSBR)’. When DNA is repaired, the broken DNA ends are bridged 
together between the gaps, and stochastic insertions or deletions (indels) are sometimes 
introduced into the genome at the break site. Two principal pathways have been well 
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studied for DNA DSB repair (DSBR) in eukaryote cells, non-homologous end-joining 
(NHEJ) and homologous recombination (HR). The critical bifurcations of them are the 
fidelity of the repair, the requirement for a template and the initial processing of DNA 
ends (Symington, 2014).  
4.1.1.1 Non-homologous ending joining (NHEJ)  
NHEJ is an error-prone mechanism that does not require extensive sequence 
homology in order to recombine the DNA ends. In most eukaryotic cells, the 
predominant pathway of DSBR is canonical NHEJ (C-NHEJ) (Chiruvella et al., 2013). 
It can occur throughout the cell cycle. In brief, when a DSB is formed, the two 
diffusing ending points of the dissected DNA overhangs are stabilised through binding 
by the ring-shaped Ku heterodimer, preventing end resection and recruiting other 
factors such as DNA-dependent protein kinase catalytic subunit (DNA-PKcs). This 
results in the tethering of DNA ends into a synaptic complex (Agrawal and Schatz, 
1997), followed by the recruitments of other essential factors, such as the complex of 
X-ray cross-complementing protein 4 (XRCC4) (Yano et al., 2008) and DNA ligase 
IV (Costantini et al., 2007) to the site of the DSB. The conjunction ends are then 
cleaved, followed by the final ligation at the gap of DSB. DNA alterations can occur 
during these processing steps, resulting in the introduction of small indels at the sites 
of breaks.  
DSBs can be also repaired through one or more alternative NHEJ (alt-NHEJ) 
mechanisms (Deriano and Roth, 2013), such as single-strand annealing (SSA) and 
microhomology-mediated end joining (MMEJ). In SSA pathway, DSB ends are 
bridged by homologous and complementary repeats (more than 25 nt), causing a intra-
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chromosomal deletions and/or DNA rearrangements in mammalian cells (Sallmyr and 
Tomkinson, 2018). MMEJ initiates when DNA breaks are unwound, resulting in 
exposure of short, single-stranded micro-homologies. These are annealed, the 3’ 
overhangs are cleaved, and the DNA gaps are filled resulting in a variable level of 
genetic information loss (Sekelsky, 2017). Compared with C-NHEJ, MMEJ is Ku 
motif independent and increased during the S phase of the cell cycle. 
4.1.1.2 Homologous Recombination (HR) and Homology-Directed 
Repair (HDR)   
Another critical pathway for repairing DSB is HR, which occurs in G2 and late 
S phases of the cell cycle (Langerak and Russell, 2011). During HR, cells use the intact 
complementary strand DNA or sister chromatid as a template to repair the break 
without introducing errors. DNA ends are processed and 3’-ends bound by Rad51, 
which is a DNA-dependent ATPase and strand-exchange protein. Strand invasion 
occurs when this nucleoprotein filament invades the intact DNA template (ssDNA) 
(Liu et al., 2011), followed by the establishment of a connection between the invading 
DNA strand and intact DNA template. A Rad51-dsDNA hetero-duplex (D-loop 
formation) is generated. In the final step, the invading 3’-ends acts as a primer and 
Rad51 is released from the dsDNA, followed by DNA strand extension. Therefore, the 
repair is completed.  
HDR has been utilised to introduce exogenous DNA templates at the site of 
DSB. It occurs during S/G2 phases and M phase of cell cycle, during which sister 
chromatids are naturally positioned to be the templates (Zaboikin et al., 2017). Donor 
DNA can be either single-stranded oligodeoxynucleotide (ssODN) (from 40 bp up to 
several Kbps) or double-stranded DNA (dsDNA) containing a modified sequence 
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flanked by homologous arms from the targeted locus. When the DSB event occurs, a 
globular protein, the meiotic recombination 11 (MRE11) can bind to the ends of DNA, 
where ataxia-telangiectasia mutated (ATM) signalling is activated (Langerak et al., 
2011); thus ATM regulates DNA resection, with the generation of small deletions at 
the 5’ terminal DNA.  
HDR pathway occurs in a very low frequency (<5%) (Cong et al. 2013). To 
enhance HDR integration into the target locus, several strategies have been 
investigated, such as the selection of specific cell and tissue types, cell cycle 
manipulation or careful selection of target locus (Miyaoka et al. 2016). For example, 
NHEJ is naturally suppressed during S/G2 phase, resulting in a relative increase in the 
probability of an HDR event. For this reason, cells can be treated with DNA 
polymerase inhibitors so that cells are arrested in S/G2 phase due to the inhibition of 
microtubule multimerisation and integration (Hu et al., 2009). It has been reported that 
the inhibition of DNA ligase IV results in a significant reduction in NHEJ activity, and 
enhanced HDR efficiency (Canny et al., 2018). Moreover, it has been demonstrated 
that when the DNA replication inhibitor Geminin is fused with the N-terminus of Cas9, 
Cas9 activity is restricted to the S/G2/M phases of the cell cycle thereby promoting 
the probability of HDR (Gutschner et al., 2016).  
The predominant DSBR pathways discussed above are schematically depicted 




Figure 4. 1 Schematic presentation of dominant models of DSBR. During c-NHEJ 
repair of a DSB (a), the Ku70-Ku80/DNA-PKcs heterodimer binds to DNA ends, 
followed by DNA resection, synthesis and ligation, often resulting in small (1-4 bp) 
in/dels (dark blue box). Other repair pathways actively prevent end resection; micro-
homologies are recognised by the MRN complex (light blue oval) and PARP1 (purple 
circle), inhibiting DNA resection. In MMEJ (b), the overhangs are removed, and the 
gap is filled and ligated by DNA ligase III-XRCC1, resulting in deletions of variable 
sizes (blue box). In HR (c) and HDR (d), a DNA tail exposed after DNA resection is 
bound by the Rad 51 complex, forming a homologous template for strand invasion. 
Subsequently, dsDNA is ligated and Holliday junctions are resolved. The cell cycle 
stages during which each repair mechanism predominantly functions are indicated 
above each scheme. NHEJ is active during all cell cycle stages and highest during 
G2/M. HR is most active in S phase, with a reduced activity during G2/M phases when 




As mentioned above, NHEJ and HR pathways are alternative pathways for the 
repair of DNA resections. The probability of repair by each repair pathway is 
associated with a wide range of factors, such as the species of organism, cell type, cell 
cycle progression, the presence of appropriate template molecules for HR and the level 
of DSB end resection. Because of the differences between the two central repair 
pathways, a diverse set of genome manipulation tools have been developed to precisely 
engineer the genome at the site of DNA repair.  
 NHEJ HR 
Donor template  No requirement for 
templates 
Template DNA molecule 
required (ssODN/plasmid) 
Fidelity of repair Low  High 
Initial DNA end 
processing  
No/limited processing of 
ends 
Resection of 5’ strands to 
form 3’ tails.  
Predominant cell 
cycle stage 
Any phases, although repair 
during G1 predominates  
S and G2 phases  
(Heyer et al., 2010) 
Efficiency and 
precision  
high but error-prone  Low but fewer errors 
 
Table 4. 1 The critical bifurcations of NHEJ and HDR events. The summary is 
based on the report by Shuren Liao (Liao et al., 2016).   
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4.1.2 Genome manipulation  
4.1.2.1 Animal transgenesis (TG) 
Selective animal breeding has been widely used to promote favourable traits in 
animal herds. While there are several advantages to this approach, only half of the 
alleles pass from each parent to their offspring, so traits requiring a homozygous 
complement can skip generations. Although selective breeding is used in many 
agricultural systems, it can also result in inbreeding, reduced genetic diversity and 
potentially perpetuate negative co-segregating traits. Furthermore, selective breeding 
can only be based upon the existing genetic characteristics present in the animal herds. 
In order to introduce specific novel traits in animal breeding, several strategies have 
been applied to animal breeding to generate genetically modified organisms (GMOs).  
GMOs are the organisms whose genome has been purposefully modified using 
genetic engineering techniques. GMO includes the alteration or deletion of 
endogenous genes. The first GMO was exemplified in 1972, when a constructed 
plasmid encoding a toxin gene was transformed into the bacterium Escherichia coli, 
and inserted into the bacterial genome (Stanley N. Cohen, 1972). The first GM birds 
were produced using a retroviral vector delivery system in 1997. Moreover, GMO 
includes the introduction of exogenous genes. The term transgenesis (TG) was first 
used in 1981 to describe pronuclear injection (PI) of SV40 DNA into the zygotes of 
mice to produce animals harbouring a foreign DNA (Gordon and Ruddle, 1981). 
Subsequently, the techniques was applied to livestock. There are some limitations, 
however, including random insertional mutagenesis in the genome, the inefficiency of 
electroporation, high efforts in time and money. Other viral delivery systems such as 
retrovirus, adeno-associated virus (AAV) and Herpes simplex virus (HSV) were 
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developed to transfer the foreign transgene to an organism. Some sequential landmarks 
of GM/TG development over the 46 years since the 1972 report are shown: 
Year Milestones of GMO/TG Reference 
1972 First report of GMOs- bacteria Escherichia coli  (Stanley N. Cohen, 1972) 
1974 First chimeric mouse by blastocyst microinjection (Jaenisch and Mintz, 1974) 
1975 First retrovirus-mediated nucleic acids delivery (Jaenisch et al., 1975) 
1981 First pronuclear injection (PI) of foreign DNA in mouse  (Gordon et al., 1980) 
1982 First GM insect with germ line transformation    (Rubin and Spradling, 1982) 
1983 First GM plants with Agrobacterium tumefaciens (Bevan et al., 1983) 
1985 First PI of foreign genes in pigs and sheep (Hammer et al., 1985b) 
1986 Embryonic cloning by NT in sheep (Willadsen, 1986) 
1989 First GM birds with retroviral vectors (Bosselman et al., 1989) 
1991 First TG sheep producing altered milk  (Wright et al., 1991) 
1991 First TG cattle  (Krimpenfort et al., 1991) 
1992 First cloned pig (Fischer, 1992) 
1992 TG pigs in resisting IAV infection  (Muller et al., 1992) 
1997 First mammal cloned from somatic cell (Dolly) (Campbell et al., 1996) 
1997 TG livestock for modelling retinitis pigmentosa (RP)  (Petters et al., 1997) 
1997 First NT associated with in vitro cell cultured sheep (Schnieke et al., 1997) 
2002 Alpha 1,3-Gal KO cloned pigs (SCNT) (Dai et al., 2002) 
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2005  TG cow in resisting mastitis infection                  (Wall et al., 2005) 
2008 CFTR-KO/deltaF508 pigs  (Rogers et al., 2008) 
2011 GGTA1 biallelic KO pigs (ZFNs) (Hauschild et al., 2011) 
2011 eGFP KO pigs (ZFNs) (Whyte and Prather, 2011) 
2012 LDLR KO pigs (TALENs) (Carlson et al., 2012) 
2013 RELA pigs (ZFNs and TALENs) (Lillico et al., 2013) 
2014 Mx1 overpressing TG pigs  (Yan et al., 2014a) 
2014 Rosa26-targeted pig model (TALENs) (Li et al., 2014) 
2014 MSTN KO pigs (CRISPR/Cas9) (Paquet et al., 2016) 
2017 RPPSV resistance pigs (CRISPR/Cas9) (Christine Burkard, 2017) 
2017 PERVs inactivated pigs   (CRISPR/Cas9)  (Niu et al., 2017) 
2018 Huntingtin KI pig models PERVs inactivated pigs (CRISPR/Cas9) (Yan et al., 2018) 
2019 
TGEV and PEDV resistant pigs 
PERVs inactivated pigs   
(CRISPR/Cas9) 
(Whitworth et al., 2019) 
Table 4. 2 Significant landmarks of GM/TG development. SCNT: somatic cell 
nuclear transfer; TG: transgenic; CSF: classic swine fever; CFTR: Cystic fibrosis 
transmembrane conductance regulator; GGTA: porcine alpha 1,3-
galactosyltransferase; LDLR: low-density lipoprotein receptor; Mx1: myxovirus 
resistance gene; MSTN: myostatin; PRRPv: Porcine reproductive and respiratory 
syndrome virus; PERV: Porcine endogenous retrovirus; TGEV: gastroenteritis virus; 
PEDV: Porcine epidemic diarrhea virus.   
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Current genome manipulation methods still require improvements in terms of 
efficiency, time and cost. To enhance gene targeting by accurately manipulating DNA 
repair pathways, more efficient methods involving genome editing (GE) have been 
developed and discussed below. 
4.1.2.2 Genome editing (GE) 
Genome editing (GE) refers to a process in which the genome of living 
organisms is altered in a deliberate manner. Many of the current genome editor 
reagents create a nuclease-induced DSB to cut in the genome proximal to a site of 
interest with subsequent repair either creating in/dels or including precise 
modifications to the DNA sequence. GE has shown its powerful utility in basic 
scientific research and industrial applications.  
4.1.2.3 FokI 
FokI, a type-IIS restriction endonuclease isolated from Flavobacterium 
okeanokoites (Chandrasegaran and Smith, 1999), recognizes the non-palindromic 
nucleotide sequence 5′-GGATG(N)9/13-3′ (Sugisaki H et al., 1981). There are two 
separate domains to FokI, a DNA recognition domain and a catalytic cleavage domain. 
The latter domain lacks sequence specificity and can be further split into two subunits 
that require dimerization to be functional (Dorner et al., 1999).  
4.1.2.4 Zinc-Finger (ZF) and ZF-nuclease (ZFN) 
Miller described a short (~30 amino acids) DNA-binding motif, which 
consisted of nine repeated units in the transcription factor TFIIIA of Xenopus laevis 
(Miller et al., 1985). Each unit contains one α–helix and two β-sheets with an oriented 
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direction, and a central zinc ion (Pavletich and Pabo, 1991). These motifs formed a 
single protein structure, the zinc finger (ZF), which specifically recoginises three 
successive DNA bases, with the α–helix binding to the major groove of the target DNA. 
As these repeats harboured a high frequency of cysteine (Cys) and histidine (His) 
residues, they are referred to as the Cys2-His2-ZF proteins. By fusing several fingers 
into an array, it became possible to expand the recognition sequence of a synthetic ZF 
protein, providing a high degree of DNA binding specificity.   
The endonuclease domain of FokI can be fused to a synthetic ZF protein by 
means of a spacer to produce a chimeric restriction enzyme, the zinc finger nuclease 
(ZFN), allowing scientists to design de novo nucleases with high sequence specificity 
for a target sequence shown in Figure 4. 2. Typically, ZFNs are deployed as a pair 
proteins, each with specificity for a 9 bp genomic sequence and fused to half of the 
FokI deterodimer. Each half of the pair binds in an inverted position to the 
complementary strands of DNA, binding the two halves of the FokI into position to 
dimerise. A DSB was thereby created. ZFNs have been employed in research in 
numerous species including human (Gaj et al., 2013), zebrafish (Doyon et al., 2008), 
pig (Hauschild et al., 2011), rat (Geurts et al., 2009), C.elegans (Wood et al., 2011) 
and drosophila (Bibikova et al., 2002) to induce a gene disruption; and in human 
(Hockemeyer et al., 2011) and mouse (Perez-Pinera et al., 2012) to facilitate a site-
specific integration of a transgene. For example, CCR5, as a receptor of HIV-1, has 
been deleted in CD4+T lymphocytes by ZF nucleases, providing robust approaches in 
HIV resistance (Perez et al., 2008); pigs with a biallelic KO of an endogenous and 
immune-related gene, α 1,3-galactosyltransferase (GGTA1), were created. This could 
be applied in the generation of pig KO strains, and the generations of the novel 
96 
 
therapies in biomedicine (Hauschild et al., 2011).   
However, the ZFNs system did not have huge uptake by the scientific 
community, predominantly because sequential ZF domains often have crosslinks that 
can influence the sequence specificity (Cornu et al., 2008). Therefore, many designed 
ZFNs failed to work as intended, and pricing for commercial design and synthesis was 
often prohibitive.   
4.1.2.5 TALE and TALEN 
Transcription activator-like effectors (TALEs), secreted by the from 
Xanthomonas bacteria, bind specific promoter sequences in the host and upregulate 
genes that enhance bacterial infections (Römer et al. 2009). The basic unit structure of 
the TALE protein is a 33-35 monomer, 2 amino acids of which confer specificity for 
binding a single DNA base. The array of amino acid repeats and the DNA nucleotide 
sequence interact in a one-to-one recognition mode. This recognition pattern makes 
TALEs ideal for binding DNA loci. Like ZFs, a TALE array can be fused with a FokI 
endonuclease to create a transcription activator-like effector nuclease (TALEN) 
(Christian et al., 2010). TALENs are typically employed in pairs, targeting opposing 
DNA strands to allow dimerisation of FokI as shown in Figure 4. 2b. 
TALENs are easier to construct and engineer than ZFNs. However, TALENs 
are approximately three times the length of ZFNs, meaning that their cDNA is not 
compatible with some vector systems. This results in more labour, and difficulties in 
transfer from in vitro studies to in vivo application such as biomedical therapies 
(Holkers et al. 2013). In addition, TALENs were initially reported to require a 5’ 
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thymidine (T) in the recognition sequence with deviation resulting in significantly 








Figure 4. 2 ZFN and TALEN structures. The DNA binding domain of ZF (a) or 
TALE (b) can be fused to the catalytic domain of FokI endonuclease to induce a DSB 
in the genome. DNA-binding domains and FokI catalytic domain work in pairs and 
locate in the opposite of DNA double strands separated by a spacer sequence. ZF motif 
binds to DNA triplets (gradient orange and blue boxes), while each TALE repeat binds 
to a single nucleotide (coloured boxes).  
  
N N N
N N C N N C N N C
N N N N N N N
G N N G N N G N N
N N N N
N N N
N N G N N G N N G
N N N N N N N
C N N C N N C N N











4.1.2.6 CRISPR and CRISPR/Cas9 system  
In 1987, small DNA repeated motifs separated by a DNA spacer were found in 
E. coli (Aasheim et al., 1993), and were subsequently coined ‘Clustered Regularly 
Interspaced Short Palindromic Repeats’ (CRISPR) (Diez-Villasenor et al., 2010). The 
functions of these repeats remained unclear until Barrangou revealed CRISPR 
provided acquired resistance against foreign DNA in prokaryotes and characterised 
Archaea (Jansen et al., 2002). a 20 bp fragment of DNA from an invading pathogen is 
inserted into the bacterial genome and transcribed into a target-specific CRISPR RNA 
(crRNA). crRNA hybridises with a second, target-independent trans-activating crRNA 
(tracrRNA) (Deltcheva et al., 2011), to form a complex, which in turn complexes with 
by bacterial CRISPR-associated (Cas) protein. If the bacterial cell reencounters the 
same foreign DNA, the 20 bp crRNA can hybridise with the complementary invading 
sequence, targeting the Cas protein to cut the DNA proximal to a short protospacer 
adjacent motif (PAM) (Figure 4. 3).  
There are two classes of the Cas proteins have been characterised to date, class 
one (type I, III, IV) and class two (type II, V, VI) (Seed et al. 2013). The class one 
system employs a multi-protein complex while the class two system uses a single 
effector protein to mediate the cleavage of target DNA. As the class two system is 
more amenable to manipulation, it has become the most utilised system for the tool 
design. A wealth of class two Cas proteins have now been identified from a range of 
bacterial species. Streptococcus pyogenes cas9 (SpCas9) protein, has been the most 
widely utilised. A CRISPR RNA (crRNA), which encodes the guide RNA by base 
pairing, and a trans-activating RNA (tracrRNA), which is a endogenous component 
(Garneau et al., 2010), can be fused to create a chimeric, single-guided RNA (sgRNA). 
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The sgRNA and SpCas9 complex can bind to DNA complementary to the sgRNA and 
5’ to a PAM (5’-NGG-3’). After this, two distinct nuclease domains in SpCas9, HNH 
and RuvC, cleave complementary and non-complementary domain of DNA strands, 
respectively. The cleavage occurs at approximately 3–5 bp upstream of the PAM. This 
blunt end produced will be repaired by one of the DSBR mechanisms introduced 
previously (section 4.1).  
So far, the rate of both technological advances and community uptake of 
CRISPR/Cas9 system-mediated editing has been stunning and is now broadly applied 
in basic biological research and biomedicine (Eid and Mahfouz, 2016). Cas9 has been 
applied in different organisms, such as human cells (Pattanayak et al., 2013), mice 
(Cong et al., 2013), rats (Doyon et al., 2008), rabbits (Yan et al., 2014b), fruit flies 
(Awata et al., 2015)and plants (Shan et al., 2013).Very importantly, edited pigs have 
been made for a wide range of applications using the CRISPR/Cas9 system: first 
genome-modified pig (Hai et al., 2014), MSTN KO pigs (Bi et al., 2016), PRRSV 
resistant pigs (Christine Burkard, 2017), PERVs inactivated pigs (Niu et al., 2017), 
UCP1 KI pigs (Zheng et al., 2017), Huntingtin KI pig models (Yan et al., 2018), IGF2 







Figure 4. 3 Schematic representation of the CRISPR/Cas9 complex. In the 
CRISPR/Cas9 system, a single guide RNA (the complex contains crRNA and 
tracrRNA) recognises and binds to a specific sequence on the genome (blue box). It 
guides Cas9 endonuclease enzyme (blue) to target and cleave the genome. This 20 nt 





4.2 Strategy overview 
4.2.1 Editing the transcriptional profiling of pig ST6GAL1  
In the first strategy, we used CRISPR/Cas9-based system to target ST6GAL1 
mRNA transcripts predominantly expressed in the respiratory tract, which were 
identified experimentally in Chapter 3. We anticipated that the alteration of 
ST6GAL1 transcriptional profile would render trachea cells deficient in using the 5’ 
transcription start site (TSS) to initiate the transcription in a promoter-mediated 
manner. To this end, two CRISPR gRNAs targeting 500 bp upstream E (-5) and 500 
bp downstream E(-4) were designed. This was because DNA sequence involving 200 
bp upstream of the 5’ TSS is defined was defined a promoter region (Pieter Meysman, 
2014). Dual sgRNAs were designed to remove the interval (~2.9 kb region) between 





Figure 4. 4 5’ UTR region of pig ST6GAL1 transcripts. The target region is in the 
dashed pink box. Double sgRNAs (pink scissors) were designed spanning untranslated 
E(-4) and E(-5), and an associated predicted promoter region (the light red circle). All 
transcripts enriched in respiratory tracts are labelled on the right. UTEs are denoted by 
grey boxes, and the first coding exon is the black box.   
103 
 
4.2.2 Functional knockout of pig ST6GAL1  
In the second strategy, a CRISPR guide was designed downstream of the third 
AUG in the first coding exon of the ST6GAL1 gene. The target site was accordingly 
located between the co-localization domain (CLD) and the catalytic domain (CAD) of 
the protein (Figure 4. 5). It was anticipated that frameshift mutation within coding 
sequence might be introduced, and thus the translation of protein could be influenced.  
 
 
Figure 4. 5 ST6Gal1 protein. (a) The structure of the ST6Gal1 protein, with the 
catalytic domain (CAD) and the co-localization domain (CLD) highlighted. The 
conserved and functional peptides are L, S, and VS sialylmotifs. L and S motifs are 
important in site-directed mutagenesis. Specifically, L-sialymotif is associated with 
donor substrate binding; S-sialymotif is with both donor and acceptor binding. (b) 
CRISPR gRNA (green scissor) was designed accordingly downstream the third AUG.  
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4.3 Result 1—precisely engineering ST6GAL1 
4.3.1 CRISPR/Cas9 reagent construction  
Candidate sgRNAs with high specificity and minimal predicted off-target Cas9 
binding activities were selected as described previously (Section 2.3.1.9). Each 
sgRNA was then inserted into a Cas9 expression vector, pSL66 (map in Appendix 7), 
which has been successfully used for gene editing in pig cells (Christine Burkard, 
2017). The vector contained a designed gRNA sequence which was driven by a human 
U6 (hU6) promoter, as well as the SpCas9-2A-GFP sequence which was driven by a 
chicken β-actin promoter (CBh) promoter (Figure 4. 5-a).  
Oligonucleotides encoding sgRNAs were annealed and cloned into the pSL66 
vector via BbsI restriction sites with resultant expression plasmids being assigned an 
‘oDY’ number. The visualization of bacterial PCR products on a 2% agarose gel 
exhibited correct PCR fragments amplified (about 360 bp) (Figure 4. 5-b). Each PCR 






Figure 4. 6 Successful CRISPR assembly. (a) Schematic representation shows that 
the sequence on the cloning sites was inserted by the annealed oligos such that sgRNA 
expression would function from the hU6 promoter in pSL66 vector; the gRNA 
sequence was inserted downstream hU6 promoter via BbsI sites. (b) The colony PCR 
result exhibited an example of PCR products resolved on a 1% TAE gel; (c) The 
alignment of Sanger sequencing analysis of colony PCR products, with unmodified 
pSL66 (pSL_U6_oSL35) as reference. hU6-human U6 promoter; CBh-chicken β-actin 
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4.3.2 Transfection and CRISPR guides validation  
4.3.2.1 Transfection efficiency in PK15 cells  
We first tested the transfection efficiency of sgRNA in porcine kidney cell line 
(PK15) cells by electroporation. Briefly, we transfected 1 µg CRISPR/Cas9-GFP 
plasmid in ~5 x 105 PK15 cells with the optimised conditions using a NeonTM 
electroporation system, i.e., 1400 V (pulse voltage), 30 ms (pulse width), and one 
electrical pulse. As shown in Figure 4. 7a, the mock-transfection, in which PK15 cells 
were not transfected (-ve), exhibited no fluorescent signals. Positive control was a 
sample transfected with the pSL66 vector without inserted sgRNA sequence (+ve), 
exhibiting fluorescent GFP signals (green). All the transfected cells showed GFP 
expression, indicating successful transfection.  
At 24 hour post transfection (h.p.t), positive cells were enriched by fluorescent 
activated cell sorting (FACs), based on the GFP fluorescent signals (Section 2.1.1.5). 
Forward scatter (FSC) and side scatter (SSC) properties were used to gate the healthy 
cells and the single cell events. The quantititive analysis of GFP expression in positive 
control is shown in Figure 4. 7b as an example. The cell viability at 24 h.p.t was 69%, 
compared to that from mock-transfected cells. Transfection efficiency was then 
determined as 2.8%, which was the percentage of GFP+ cells in a transfected cell 
population. Similarly, the transfection efficiency with oDY4, 5 and 6 were 2.4%, 0.8%, 
and 0.7%, respectively; the transfection efficiency with oDY10, 11 and 12 were 5.2%, 





Figure 4. 7 DNA transfection using the NeonTM electroporation system and flow 
cytometry analysis. (a) PK15 cells were transfected with CRISPR/Cas9-GFP plasmid 




4.3.2.2 Evaluating the cutting efficiency of sgRNA using T7E1 assay  
A T7 endonuclease 1 (T7E1) assay was performed to evaluate the on-target 
CRISPR/Cas9 editing events (Vouillot et al., 2015). Firstly, a pair of primers was 
designed to amplify a 500-1000 bp DNA sequence surrounding the CRISPR gRNA 
target site. Prior to PCR amplification, the annealing temperature of primers was 
determined across a gradient of 12 temperatures ranging from 50°C to 72°C. The 
optimal annealing temperature was determined when a single robust amplicon was 
produced on a 2% agarose gel. The result of gradient PCR is shown in Appendix 9. 
68°C was determined to be the optimal annealing temperature for primer pair 2 (for 
sgRNA4, 5, and 6), and 65°C for primer pair 7 (for sgRNA10, 11, and 12).  
Using the optimised PCR conditions, PCR was performed with gDNA isolated 
from each GFP+ cell population. PCR products were then denatured and re-annealed, 
followed by a mock digestion and T7E1 digestion. Mock-digested and T7E1-digested 
products were resolved on a 1% agarose gel, as shown in Figure 4. 8.  
For sgRNA4, 5, and 6, primer pair 2 (F2 and R2) was used to amplify a DNA 
sequence (964 bp) flanking the DSB site (Figure 4. 8-a). Compared with the mock-
digested product, each T7E1-digested product presented two successful cleavage of 
DNA, which were labelled below the gel (Figure 4. 8-b). sgRNA4 had 40.22% cutting 
efficiency, and sgRNA5 had 41.01% cutting efficiency. sgRNA6 exhibited the highest 
cutting activity (47.97%). It was noted that all T7E1-digested PCR products had an 
extra band of ~700 bp. This indicates the probable presence of single nucleotide 
polymorphisms (SNP) within the amplicon, either present within the genome of the 
PK15 cells or introduced during PCR amplification. Given that this fragment was 
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present in each experimental sample, it seems likely that this SNP was a feature of the 
PK15 cells. Therefore, this band was excluded from the densitometry analysis in DNA 
cleavage.  
The same procedure was performed on the gDNA isolated from GFP+ cells 
individually transfected with oDY10, 11 and 12 (Figure 4. 8-d). The PCR performed 
using primer F7 and R7 resulted in a PCR product with a size of 792 bp. The cutting 
efficiency of sgRNA11 and 12 was estimated at 13.2% and 33.23%, respectively; 
sgRNA10 showed no evidence of cutting. Therefore, sgRNA6 and 12, which exhibited 
relative higher cutting efficiencies than the other sgRNA candidates, were co-
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Figure 4. 8 T7E1 assay. (a)Diagram shows the schematic diagram of PCR 
surrounding the target site of sgRNA4, 5 and 6 using primer pair 2 (964 bp). 
(b)Expected cleaved products of digested PCR products. Yellow arrows indicated the 
anticipated DNA cleavage in each T7E1-digested product. Red arrows indicated the 
extra bands. (c) PCR surrounding the target site of sgRNA10, 11, and 12 using primer 
pair 7 (792 bp). (d) Expected cleaved products of digested PCR products. Yellow 
arrows indicated the anticipated DNA cleavage in each T7E1-digested product. The 
cutting efficiency of each sgRNA was below the gel. The band intensity on the gel was 




4.3.2.3 Co-transfection with dual CRISPR guides in PK15 cells 
Co-transfection of Cas9 expression plasmids encoding sgRNA6 and sgRNA12 
were performed to remove the interval between sgRNA6 and sgRNA12 in PK15 cells. 
GFP+ cells were enriched at 24 h.p.t by FCSs, followed by the measurement of 
transfection efficiency (see Figure 4. 9): the mock-transfection (-ve) exhibited no GFP 
fluorescent signals. The positive control (+ve), in which PK15 cells were transfected 
with 2 µL pSL66 vector without a guide sequence, had a 13.3% transfection efficiency. 





Figure 4. 9 Transfection efficiency of dual sgRNAs in PK15 cells. Co-transfection 
dual sgRNAs/Cas9 plasmids oDY6 and oDY12 in PK15 cells by NeonTM 









gDNAs were then isolated from WT cells and GFP+ cells for PCR 
amplifications. The PCR amplification using primers CoF1 and CoR1 was anticipated 
to result in a ~3.5 kb product in WT, and a ~0.6 kb product due to the absence of the 
2.9 kb target region in the DNA sequence of edited cell (Figure 4. 10a) The results 
are shown in Figure 4. 10b: there appeared no bands in WT, due to the suboptimal 
efficiency in amplifying a large WT fragment. The PCR result of GPF+ cells exhibited 
a correct cleaved product (~0.6 kb), indicating the successful deletion mediated by two 








Figure 4. 10 Genetic deletions with dual sgRNAs. (a) Schematic overview of the 
guide sites and PCR assay for assessing the genetic deletion. Two PCR primers (red 
arrows), spanning the target region, were used to amplify a ~3.5 kb DNA fragment in 
WT cells and a ~2.9 kb product in edited cells. (b) PCR products were resolved on a 
2% agarose gel. The anticipated size of the WT and deletion amplicons were shown 





4.3.2.4 Assessment of CRISPR guides in NPTr cells 
PK15 cells were a good starting point used in the optimisation of the 
transfection protocols and testing CRISPR reagents in PK15 cells. Since the aim of the 
project was to assess the IAV infection in ST6GAL1 edited cells, we performed the 
similar transfection protocol in a newborn pig trachea (NPTr) cell line, which was a 
proper cell model for IAV infection. We optimised conditions of NeonTM transfection 
by varying the concentration of Cas9/sgRNA plasmid, the number of cells, and the 
electric pulse in NPTr cells. However, the performance of NeonTM transfection at 24 
h.p.t was poor in NPTr cells despite adjusted parameters (Figure 4. 11-a). For example, 
compared to that in A2, the number of live cells in B6 was reduced with the increasing 
level of the electricity pulse and the concentration of the plasmid DNA (Figure 4. 11-






Figure 4. 11 NeonTM transfection optimization in NPTr cells. (a) Transfected cells 
at 24 h.p.t with conditions labelled in red. (b) The expanded views of A2 and B6 show 
the cell viability and GFP+signals. The parameters are listed here: A1-1.5 µg, 0.75E+5 
cells, 1500V, 20ms; A2-3 µg, 0.75E+5 cells, 1500V, 20ms; A3- 5 µg, 0.75E+5 cells, 
1500V, 20ms; A4- 1.5 µg, 0.5E+5 cells, 1500V, 20ms; A5- 3 µg, 0.75E+5 cells, 1500V, 
20ms; A6- 5 µg, 0.75E+5 cells, 1500V, 20ms. B1-1.5 µg, 0.75E+5 cells, 1600V, 20ms; 
B2- 3 µg, 0.75E+5 cells, 1600V, 20ms; B3- 5 µg, 0.75E+5 cells, 1600V, 20ms; B4- 
1.5 µg, 0. 5E+5 cells, 1600V, 20ms; B5- 3 µg, 0. 5E+5 cells, 1600V, 20ms; B6- 5µg, 
0. 5E+5 cells, 1600V, 20ms. All samples were performed with one electric pulse. Scale 




Lipofectamine® 2000 system has been widely used in in vitro and in vivo 
mammalian cells transfection (Colosimo et al., 2000) with higher editing efficiency 
and less cell toxicity (Yu et al., 2016). Therefore, Cas9 protein and sgRNA-containing 
plasmids (oDY6 and oDY12) were transfected in NPTr cells using the 
Lipofectamine® 2000 system. The transfection was performed according to the 
manual protocol. Briefly, 15 µl Lipofectamine® 2000 reagent and 2 µg DNA (1 µg 
for each plasmid) were mixed in 300 µl, and the mixture was added to 5 x 105 cells in 
6-well plates. At 24 h.p.t, transfected cells were visualised and quantitatively assessed 
(Figure 4. 12-a). The negative control showed no GFP+ fluorescence, and the positive 
control (+ve) exhibited 2.7% transfection efficiency. The cells with dual 
sgRNAs/CRISPR co-transfection exhibited 6.5% transfection efficiency.  
To improve the transfection performance, we optimised the conditions 
empirically, i.e., 12.5 µl Lipofectamine® 2000 reagent and 3 µg plasmid (1.5 µg for 
oDY6 and 12 plasmid) were mixed in 300 µl transfection volume, and 200 µl mixture 
of the mixture was applied dropwise in about 2 x 105 NPTr cells. This approach 
resulted in a substantial improvement of the transfection efficiency (Figure 4. 12-b). 
The positive control gave 23.8% and co-transfected oDY6 and oDY12 gave 22.9% 
GFP cells at 24 h.p.t. These efficiencies were deemed acceptable for subsequent 









Figure 4. 12 LipofectamineTM 2000 transfection optimization in NPTr cells. NPTr 
cells were analysed by GFP expression at 24 h.p.t in fluorescent microscopy (left), and 
FACS (right). Due to the gating was not proper, the actual transfection efficiency 




4.3.3 Validation of homozygous deletion  
After the transfection with Cas9 protein and sgRNA-containing plasmids 
(oDY6 and oDY12) (Figure 4. 12), and single cell isolation in 96-well plates, gDNAs 
were harvested from well-grown cell clones for PCR amplifications. The -/-∆P 
candidates selected by PCRs were then processed by Sanger sequencing (Section 
2.3.1.8) and Southern blot (Section 2.3.1.11).  
GFP+ cells were individually sorted into one 96-well plate, followed by the 
cell clone expansion. gDNAs isolated from clones surviving expansion were used as 
templates for PCR. A pair of primers CoF1 and R7 spanning the target region was used 
to amplify a PCR product of 3.6 kb. R7, instead of CoR1, was used here because they 
were more efficient on amplifying PCR product more than 3 kb, comparing to CoF1 
and CoR1 (Figure 4.10). Due to the absence of the ~2.9 kb target region, the PCR using 
these two primers was anticipated to yield a product ~0.7 kb, as shown in the mock gel 
(Figure 4. 13-a, right panel). This PCR was termed as ‘spanning PCR’. Among all 
the cell clones (Figure 4. 13-b), the negative control (-ve) showed no PCR products 
in the absence of DNA templates. The spanning PCR on the gDNA extracted from WT 
cells yielded an amplicon with a visualised size between 3.5 kb and 4 kb. The PCR 
product of clone 6 exhibited a WT allele (~3.6 kb). The PCR products of cell clones 1, 
3, 4, 5, 8, 9 and 11 presented a mutant allele (~0.7 kb). They were thus prepared as 
candidates for further processing. We noted that the PCR on resulted in another faint 
band (~1.7 kb), suggesting that a mutation, for instance a random genomic integration 





















Figure 4. 13 Detection of 2.9 kb deletion by spanning PCR. (a) Schematic diagram showed that primers (CoF1 and R7) were used to 
amplify region spanning the target region. On the mock gel (right), a fragment of ~3.7 kb from a WT allele and/or ~0.7 kb from an edited 
allele were anticipated to be generated. CRISPR/Cas9s RNA guide sequences are depicted in two pink scissors. (b) The PCR results show 
clone1, 3, 4, 5, 7, 8, 10 and 11 harboured the editing. A PCR band in C1 lane was unexpected and indicated by a yellow arrow. It might 




After that, the PCR band with the size of ~0.7 kb was cut out, purified and send 
for Sanger sequencing. Unexpectedly, successful sequencing results were only 
obtained from clone1, 3, and 4, and no trace files from other samples though repeated. 
The alignment is shown in Figure4.14, the sequencing of WT genome was used as a 
reference, and aligned with those of edited cells. The sequencing result showed the 
excision between the CRIPSR target sites, indicating the editing event was successful 
in these 1, 3, and 4 cell clones. It was noting that two alleles of clone 1 harboured 
different trace files, indicating that the bi-allelic event with each allele being unique 










Figure 4. 14 Validation of editing by Sanger sequencing. The red nucleotides are PAM locus and the expected cutting site was pointed 
by the red arrows. Both clones present ~2.9 kb excision. Clone 1 harboured different sequencing results in two alleles, indicating an event 
of bi-allelic mutation or any other reasons which can be in further explored.
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Considering the adequate performance of clones 4, 5, 8, 9, 10 and 11 in PCR 
results, we still included them in the Southern blot. The schematic overview of 
Southern blot is depicted in Figure 4. 15a, we used EcoR I enzyme to digest HWM 
gDNA isolated from each cell clones. An 11.3 kb fragment surrounding the target 
region was obtained. The homozygous edits were anticipated to have an ~8.4 kb allele 
in the presence of a ~2.9 kb excision. There was a mistake that the ladder of 
hybridization blot was not imaged properly. In order to measure the band sizes of the 
digested gDNAs on the blot, two blots had to be scaled horizontally according to the 
two undigested gDNA bands appeared in C11 sample (top of the blot, Figure 4. 15-
b). The approximate sizes of the products on the hybridization blot could be reasonably 
speculated according to the ladder on the 0.7% agarose gel (Figure 4. 15-b, left panel). 
The result of hybridization blot (Figure 4. 15-b, right panel) showed Southern blot 
analysis failed in the C5, C8, C9, C10 and C11 samples (due to the poor enzyme 
digestion). There was only one fragment of ~11.3kb in WT, as a WT allele. A single 
fragment of ~8 kb appeared in C1, suggesting C1 was a homozygous allele (-/-). C3 
and C4 appeared to have two bands, suggesting they were heterozygous edited (-/+).  
These results suggest that C1 is a -/- cell clone and C3 is a -/+ cell clone. As 
several mistakes were made and discussed above, to achieve better outcomes of 
Southern blot, many improvements could be corrected accordingly. It was decided that 
for further experiments, more positive edited clones, an appropriate ladder, and more 












Figure 4. 15 Southern blot. (a) The schematic representation of the Southern blot. 
The probe (black box) 3’ to the target locus and within an EcoR I-digested DNA 
fragment (~11.3 kb). The two sgRNAs are depicted by yellow scissors. A WT allele 
was ~11.3 kb and a mutant allele was ~8.4 kb. (b) Restriction digestion and 
hybridization results on candidate clones. EcoR I digested gDNA from each sample 
were hybridized with the probe. The hybridisation step was conducted by Claire Neil 
(Roslin Institute). 1 kb DNA ladder is on the left of the 0.7% agarose gel (left panel) 
but was excised prior to blotting. The blot was scaled horizontally by using the two 
undigested bands in C11 as a reference (red asterisk). Arrows indicated the expected 






In the second round, GFP+ cells were individually sorted into 15 x 96-well 
plates, and the remaining GFP+ cells were enriched as a mixed pool (MP). We 
performed PCRs to detect the deletion in each clone. A schematic overview of the PCR 
screening strategy is shown in Figure 4. 16. Four rounds of PCR amplification were 
performed on the gDNA isolated from each clone surviving expansion, unless 
otherwise stated.  
The first PCR reaction was performed spanning the target site with external 
primers designed to anneal ~300 bp upstream and downstream from the PAM sites of 
two sgRNAs (a, F1 and R7). The PCR product was anticipated to harbour ~3.5 kb in 
a WT allele, and ~0.6 kb amplicon in a mutant allele analysed on the 2% agarose gel. 
Two junction PCRs were performed using a pair of primers F2 and R2 or F9 and R9 
(b). In the presence of a WT allele, fragments of ~0.9 kb and ~0.7 kb in size could be 
amplified, respectively. An internal PCR with primers F6 and R6 (c) was anticipated 
to produce a fragment of ~0.8 kb in the presence of a WT allele. Each mock gel is 















Figure 4. 16 PCR strategies for the validation of homozygous edits. (a)Spanning 
PCR is anticipated to generate a fragment of 3510 bp from a WT allele or 624 bp in an 
edited allele. (b)Junction PCRs are anticipated to generate a fragment of 963 bp 
(F2+R2) or 764 bp(F9+R9) in the presence of a WT allele. (c)Internal PCR would 
generate a fragment of 838 bp in the presence of a WT.  














In the result of spanning PCR (Figure 4. 17), the positive control (+ve), which 
was a paternal WT, and the MP sample failed to present a WT allele (~3.5 kb), 
indicating the PCR was suboptimal in amplifying the large WT fragment. Most of 
samples presented amplicons of 624 bp in size, indicating that most samples harboured 
a mutant allele.  
 
Figure 4. 17 Detection of deletion by spanning PCR. The samples were amplified 
using primers F1 and R7. The concentration of each extracted gDNA was normalized 
to approximately 20 ng/µl. The positive control (+ve) failed to show a WT allele, and 
the mixed pool (MP) showed only one mutant allele. Samples labelled in red harboured 





Junction PCR was then performed using PCR primers flanking each CRISPR 
target site. The left junction PCR was using primers F2 and R2, and anticipated to 
result in a ~0.9 kb DNA product in the presence of a WT allele. As can be seen in 
Figure 4. 18, clones B3, B10, B12, C11, D12, F1, F4, F5, F7, F9, G2, G6, H7, H8, a1, 
a2, b1, b3, c1, c3, e1, f1, f3, g1, g3, h1, h3, e2 did not produce a PCR product. Some 
samples, such as F11 and H2, which presented faint bands, were not confirmed. This 
might be due to the leaky loading, or other reasons. 
 
Figure 4. 18 Detection of deletion by left junction PCR. The samples were amplified 
using primers F2 and R2. WT allele was anticipated to produce a product which size 
was ~0.9 kb, and -/- edits would not produce any products. Samples identified as -/- 
candidates were labelled in red. WT and MP samples were forgotten to be included in 




In the right junction PCR (c), clones A2, F1, G2, E3, B3, E5, F4, F5, H6, C7, 
F7, H7, F9, D9, A10, B10, C11, F12, D12, a1, a2, a3, b1, d1, e1, f1, f3, g1, g3, h1, h3 
did not produce a PCR product, in the presence of a WT allele. Other samples, such as 
H4, E11, and G11, which showed faint bands, were not confirmed. This might be due 
to the leaky loading, or other reasons. 
 
Figure 4. 19 Detection of deletion by right junction PCR. The samples were 
amplified using primers F9 and R9. WT allele was anticipated to produce a product 
which size was ~0.7 kb, and -/- edits would not produce any products. All the eligible 
samples were red labelled. WT and MP samples were forgotten to be included in the 




The internal PCR was then performed using primers within the target region. 
It was anticipated a fragment of ~0.8 kb in size would be generated in the presence of 
a WT allele, but that would not occur in homozygous clones. Figure 4. 20 shows that 
clones B3, B10, C11, D12, F1, E2, F4, F5, F7, F9, G2, H7, a1, f3 and e2 produced 
either no PCR products or a very faint signal.  
 
Figure 4. 20 Detection of deletion by internal PCR. The samples were amplified 
using primers F6 and R6. WT allele was anticipated to produce a product which size 
was ~0.7 kb. -/- edits would not produce any products. Most of the PCR samples show 




After the PCRs on all clones, B10, C11, F1 and F7 were eligible to four rounds 
of PCR screening. We also involved B3, D12, E2, F4, F5, F9, G2, H7, a1, a2, a3, e1 
and f3 as -/- candidates as they were eligible to all PCRs except the internal PCR, and 
the reason would be discussed in Section 4. 5. In fact, B3 actually included 
inadvertently as B3 did not present a mutant allele in the spanning PCR.  
All PCR products were sent for Sanger sequencing analysis (Section 2.3.1.8). 
Selectively, the sequencing results of -/- candidates are shown below. Apart from B3, 
D10, a1, e1 and f3, other clones exhibited successful excision of DNA sequencing. 
The sequencing data and trace files of all clones for sequencing were shown in 
Appendix 10. We observed the contig aligned with the excised nucleotides, indicating 





Figure 4. 21 Validation of editing by Sanger sequencing. The samples selected here 
were identified to be homozygous by PCR assays. Compared with WT sequence (top 
line), samples (except B3, D12, a1, e1, and f3) show the correct excision in the genome. 
All trace files are in the Appendix 10.     
Wild Type G A G G G C C T C T A C T C T - - 2 . 9 k b - -- - A G G G C T T T G G G G A C A T G A C A -





B10 G A N G G C C T C T A - - - - - - 2 . 9 k b - - - - - - - - T T T G G G G A C A T G A C A - 3 ’5’-













G A N G G C C T C T A - - - - - - 2 . 9 k b - - - - - - - - T T T G G G G A C A T G A C A - 3 ’5’-
G A G G G C C T C T A - - - - - - 2 . 9 k b - - - - - - - - T T T G G G G A C A T G A C A - 3 ’5’-
G A G G G C C T C T A - - - - - - 2 . 9 k b - - - - - - - - T T T G G G G A C A T G A C A - 3 ’5’-
G A G G G C C T C T A - - - - - - 2 . 9 k b - - - - - - - - T T T G G G G A C A T G A C A - 3 ’5’-
G A G G G C C T C T A - - - - - - 2 . 9 k b - - - - - - - - T T T G G G G A C A T G A C A - 3 ’5’-
G A G G G C C T C T A - - - - - - 2 . 9 k b - - - - - - - - T T T G G G G A C A T G A C A - 3 ’5’-
G A G G G C C T C T A - - - - - - 2 . 9 k b - - - - - - - - T T T G G G G A C A T G A C A - 3 ’5’-
G A G G G C C T C T A - - - - - - 2 . 9 k b - - - - - - - - T T T G G G G A C A T G A C A - 3 ’5’-
N N N N N N N N N N N - - - - - - 2 . 9 k b - - - - - - - - N N N N N N N N N N N N N N N - 3 ’5’-
G A N N G C C T C T A - - - - - - 2 . 9 k b - - - - - - - - T T T G G G G A C A T G A C A - 3 ’5’-
G A G G G C C T C T A - - - - - - 2 . 9 k b - - - - - - - - T T T G G G G A C A T G A C A - 3 ’5’-
N N N N N N N N N N N - - - - - - 2 . 9 k b - - - - - - - - N N N N N N N N N N N N N N N - 3 ’
N N N N N N N N N N N - - - - - - 2 . 9 k b - - - - - - - - N N N N N N N N N N N N N N N - 3 ’
N N N N N N N N N N N - - - - - - 2 . 9 k b - - - - - - - - N N N N N N N N N N N N N N N - 3 ’








Southern blot analysis was then performed as described previously (Section 
2.3.1.11). As shown in Figure 4. 22, the EcoR I digested DNA appeared as a smear 
on the 0.7% agarose gel (a). In the result of hybridisation (b), WT was anticipated to 
be a ~11.3 kb; and -/- edits presented as a ~ 8.4 kb product. Among all the candidates, 
four clones (D12, F4, F7 and a3) were identified to be homozygous edited and one 
clone (f3) were identified to be heterozygous edited. B3, B10, C11, E2, F5, F10, H7, 
a2 were identified to be WT, which results were not consistent with previous PCRs 
and Sanger sequencing results. Moreover, F1 contained an extra band, which was 
thought to be as ~20 kb according to the ladder, suggesting a random integration in the 
genome.  
Taken together, C1, which was identified in the first round of selection, and 
D12, F4, F7, and a3, which were identified in the second round of selection, were 
confirmed to be homozygous edited cells. There were cultured for the phenotype 






Figure 4. 22 Southern blot. (a) EcoR I digested HMW gDNA appeared to be a smear 
on a 0.7% agarose gel, followed by the transferring and blocking steps. (b) The blot 
was hybridised with a radiolabelled PCR product. From three rounds of PCRs and 
sequencing selection based, four -/- edited clones (D12, F4, F7 and a3) and one -/+ 
edited clone (f3) was identified. The gel and the blot were scaled horizontally 
according to the well and the biggest size of DNA (red asterisk). L1: Lambda 




4.4 Result 2—functional knockout of ST6GAL1  
4.4.1 CRISPR reagent construction  
sgRNA was designed according to the strategy we described in Section 4.2. 
Each annealed oligos (sgRNA) were subcloned into the Cas9-contained pSL66 vector. 
Sanger sequencing was used to confirm the inserted sequence in each CRISPR plasmid 
(Figure 4. 23-b). In the figure, the upper line (pSL_U6-oSL35) was the WT sequence 
with a block of 20N denoting the intended position of the inserted oligonucleotide 











Figure 4. 23 CRISPR reagent assembly. (a) The schematic diagram depicted sgRNA4, 10, and 13, locating downstream of the third ATG 
which is in the same open reading frame with the first ATG in coding exon1. (b) Sanger sequencing result showed that sgRNA was 




4.4.2 Transfection and CRISPR guides validation  
Following the plasmid maxi-prep, 1.5 µg CRISPR/Cas9 reagents containing 
sgRNA4, 10 and 13, assigned as P4, P10, and P13, was respectively transfected in 
NPTr cells using the same protocol as described in Section 4.3.2.4. GFP+ cells were 
enriched for the assessment of transfection efficiency. The transfection results showed 
there were no GFP fluorescent signals in the mock transfected control (-ve). The 





Figure 4. 24 Analysis of transfection in NPTr cells. (a) Bright and fluorescent 
images of cells transfected with CRISPR plasmids. Because of the computer issues 
during the experiment, the images were taken using a mobile phone through the ocular 
lens. Scale bar=100 µm.  
4.4.2.1 Mismatch cleavage assay by T7E1 and TIDE assay 
T7 Endonuclease 1 (T7E1) and TIDE assay were performed to test the cutting 




previously (Section 2.3.1.10.3). Before that, a fragment of 626 bp was amplified using 
gDNA isolated from each GFP+ population using primers E1F1 and E1R1. Each PCR 
products were mocked-digested and T7E1-digested, respectively. All products were 
visualized on a 1% agarose gel (Figure 4. 25-b). The heteroduplex DNA was 













Figure 4. 25 T7E1 assay. (a) The schematic overview of sgRNAs and the primer pair E1F1 and E1R1. (b) Each amplified PCR product 
was incubated with either T7EI or water (control). The table shows the expected sizes of cleaved products, which are indicated by yellow 




The TIDE assay was then applied to estimate the editing efficiency of sgRNA4. 
This is based on the decomposition of the sequence trace to estimate indels introduced 
by NHEJ during DSBR (Brinkman et al., 2014). As seen in Figure 4. 26, the result of 
TIDE assay showed sgRNA4 had 10.2% cutting efficiency.The predicted in/dels were 
shown in upper panel. In the middle panel, the region of decomposition was depicted 
as a disruption of the tracing. The deviating sequence downstream the break site of 
sgRNA4 was aberrant with the reference sequence of WT (vertical dotted line).The 







Figure 4. 26 TIDE assay. The panel presents the comparison of the tracing sequence 
between the reference (WT, top trace) and P4 (Mutant, bottom trace). The aberrant 
sequence signal and in/dels spectrum (R2) are shown in the histogram. The cutting 








4.4.2.2 The design of the ssODN template  
As sgRNA4 was identified to be the best guide by both T7E1 and TIDE assay, 
a single strand donor DNA template was designed to introduce a homology directed 
repair at the cut site of sgRNA4. As shown below, a single-stranded donor 
oligonucleotides (ssODN) donor template (130 nt) sequence with 40 nt of 5’ homology 
to the DSB and 90 nt of 3’ homology. This asymmetrically design has previously been 
reported to result in a high HDR efficiency (Richardson et al., 2016). As shown in 
Figure 4. 27, a mutation was introduced to convert the PAM sequence GGG to TCT 
(GGG>TCT). This mutation was intended to have an effect of introducing a novel 
EcoRI restriction site (red arrow), destroying the endogenous PAM such that re-cutting 
following successful HDR is unlikely (Paquet et al., 2016), and introducing a 
premature TAG stop codon in frame (black box with *).  
 
Figure 4. 27 The HDR template. The lower oligo strand is the HDR template. Grey 
shadow is stop codon and lined sequence is the restiction enzyme site (EcoR I). Red 




4.4.3 Validation of editing  
4.4.3.1 Co-transfection of the CRISPR reagent and ssODN template 
1.5 µg P4 or 1.5 µg P4 plus 1.5 µg HDR template were chemically transfected 
into NPTr cells with optimised transfection conditions (Section 4.3.2.4). The 
fluorescent images at 24 h.p.t are shown in Figure 4. 28. The transfected cell 
population with both P4 and the HDR template exhibited fewer GFP+ cells than those 
transfected with only P4.  
To assess the HDR efficiency, the cells transfected with sgRNA4 and HDR 
were cultured, and gDNA isolated, followed by the incubation with EcoR I and T7EI, 
separately. No EcoR I digestion products were observed (Figure 4. 28-b), indicating 
that if HDR did occur it was at very low levels. The T7E1-digested PCR products did 
show the anticipated cleave profile, corresponding to the previous result (Figure 4. 
25-b). Taken together, this suggests that NHEJ is the primary method of DSBR 
following these transfections, and that producing a frameshift mutation via NHEJ may 
be a more viable approach than the introduction of a precise missense mutation by 
HDR. Therefore, GFP+ transfected cells with sgRNA4 were individually seeded into 








Figure 4. 2 Co-transfection and HDR validation. (a) Cells were transfected with P4 
with/without the HDR template, and visualized at 24 h.p.t. GFP+ cells were single cell 
sorted into 9 x 96 well plates for expansion. (b) gDNAs of WT and P4+HDR 
transfected cells were amplified using the primer shown in Figure 4.25-a, followed by 




4.4.3.2 Validation of editing in ∆CD cells  
4.4.3.2.1 PCR-based assay  
After approximately 50 days’ clonal expansion, approximately 120 cell clones 
were confluent. gDNA was isolated from each clonal candidate using the 
QuickExtract™ approach (Section 2.3.1.2.2) for PCR amplification using primers 
E1F1 and E1R1, resulting in an amplicon with an anticipated size of 562 bp from WT 
cells, as shown in Figure 4. 29. The water control (-ve) showed no amplicons. All 
transfected samples labelled in red presented the connect size of band. Consequently, 






Figure 4. 29 Spanning PCR. gDNA was extracted from each clone using 
QuickExtract™ reagent. ~20 ng gDNA was used for PCR amplification using primers 
E1F1 and E1R1, resulting in a 562 bp product. A negative control (-ve), and three 





4.4.3.2.2 Sanger sequencing on ∆CD clones  
The alignment of sequencing surrounding the target site between reference 
(WT) and homozygous edits is shown below. Raw sequencing data for all clones are 
in Appendix 11. Below each DNA sequence is the corresponding protein sequence. 
The event of the premature termination (the stop codon) is highlighted with an asterisk. 
It was noting that clone H10 and A1, the PAM sequence (GGG) was changed to TCT 
(Figure 4. 30 and Appendix 12). A premature stop codon (TAG) was thus introduced, 
leading to a termination of translation successfully as described previously (Section 
4.4.2.2). Therefore, we could conclude that the HDR event in H10 and A1 had a 
successful HDR event, though we did not observe the anticipated ECoR I digested 
product on the 1% agarose gel (Figure 4. 28-b). In cell clone F6 and G2, we detected 
a deletion of 55 bp and 8 bp, respectively. In other cell clones, they all presented 1 or 






Figure 4. 30 Sanger sequencing on ∆CD clones. The reference sequence is at the bottom (E1_ORF). The DNA identity is shown in grey. 
sgRNA4 and PAM sequence (GGG) are labelled in pink and red, respectively. * represents a premature stop codon; ----- represents the 




4.5 Discussion  
In this chapter, we evaluated two CRISPR/Cas9-based strategies to precisely 
edit the ST6GAL1 gene. We then identified homozygous edited clones after gene 
editing experiments. In the first strategy, we generated a homozygous NPTr cell line, 
-/-∆P, which harboured an altered transcriptional profiling of ST6GAL1 in airway cells. 
In the second strategy, we created functional knockout of ST6GAL1 in NPTr cells, -/-
∆CD, by introducing a frameshift mutation in the coding sequence of ST6GAL1. 
We now discuss how we optimised cell transfection efficiency. In particular, 
we preliminarily applied the NeonTM electroporation system to transfect 
sgRNA/CRISPR plasmids in NPTr cells with the optimised (Section 4.3.2.1). 
However, the transfection efficiency for NPTr cells turned out to be extremely low 
with these conditions using electroporation. Therefore, we used the Lipofectamine® 
2000 transfection system instead, which has been widely applied for the delivery of 
CRISPR/Cas9 constructs into mammalian cells (Yu et al., 2016). A much higher 
transfection efficiency was achieved (Figure 4.12-b). Alternatively, we could use the 
viral delivery to send Cas9/sgRNA components into NPTr cells, such as lentivirus. We 
could transduce LV vectors, among which sgRNA and Cas9 were integrated in one 
plasmid (Sanjana et al., 2014). However, for this to work properly, both the titres of 
lentivirus and the size of lentiviral vectors have to be optimised and considereed, which 
can be time consuming, labour intensive and cost ineffective. Therefore, 





All primers and annealing temperatures should be optimised prior to T7E1 
assay. For example, if the primers and the annealing temperatures in PCR 
amplifications are suboptimal, then the cleavage products of T7E1 assay would not be 
discriminated from other non-specific PCR products or SNP events (Figure 4. 8-b). 
Therefore, PCR conditions should be optimised. 
Validating the modification to the ST6GAL1 gene in -/-∆P cells is crucial. To 
this end, we used four rounds of PCR amplifications, Sanger sequencing, and Southern 
blot. Spanning PCR was the first one applied to verify whether the deletion occurred. 
106 out of 114 clones showed a band of the expected size of the mutant allele (see 
Figure 4. 17), indicating that these clones were homozygous or heterozygous 
mutations. Sanger sequencing analysis was consistent with the spanning PCR result 
(see Appendix 10). However, the products of the internal PCR (Figure 4. 21) which 
amplified a region within the ~2.9 kb deletion segment could still be observed in most 
of the clones, indicating that they were heterozygous mutations. Such a clone was 
excluded. Unexpectedly, B10 and C11 which were identified as -/-∆P in all four PCR 
amplifications appeared to be WT type in the Southern blot analysis. As Southern blot 
is more sensitive and more accurate in ensuring the genotyping, we excluded in B10 
and C11 for the phenotyping assessment. Furthermore, it was worth noting that there 
was one extra band appearing in F1, which may be due to a random integration in the 
genome. This is because CRISPR/Cas9 system can cause DNA rearrangements 
surrounding the target locus. Sometimes an unrelated DNA segment could be 
incorporated into the chromosome (Kosicki et al., 2018).  
For the second approach, it is worth discussing why we designed the sgRNA 




reading frame with third one. The rationale behind this is that the third coding start 
(GAGCATGA) has a strong ‘Kozak sequence’, while the first one (CATTATGA) 
(Gene ID: 100302026, NCBI), is empirically predicted to be a weak Kozak. The 
‘Kozak consensus sequence’ is associated with the efficiency of translation (Kozak, 
1984). In general, mature mRNA transcript is scanned from the capped 5’ terminus 
until reaching the first AUG with an appropriate sequence context (CCA/GCAUGG), 
in which the underlined A is considered as ‘+1’. Comparison of sequences associated 
with known start codons suggests that -2 is a purine (A/G) and +4 is a G nucleotide 
for the efficient initiation of the translation process (Sakai et al., 2001). It means that 
if the sequence proximal to the start codon is not optimal, the ribosome could highly 
likely bypass the locus and continue to scan the mRNA for alternative start sites. 
Ribosome scanning can have an impact on translational activities, resulting in 
alterations of protein expression (Faure et al., 2016). Since we are unclear which of 
the prospective start codons is most likely to act as the major translation start site, to 
be on a safe side, we targeted the region downstrean the third start codon. 
After that, we designed a single-stranded oligodeoxynucleotide (ssODN) 
template according to the target site of sgRNA we discussed above. We designed a 
ssDNA donor with asymmetric homology arms. Moreover, a silent/blocking mutation 
of PAM was introduced to inhibit the potential Cas9 re-cutting event. However, HDR 
is still in a low frequency (Section 4.4.3). We detected 2 HDR events and 11 NHEJ 
events out of 96 well-grown cell clones from 9 x 96 well plates in total. Most of these 
mutants were repaired by NHEJ pathway, resulting in the formation of small indels (1-




are not triplets, otherwise the function of the protein could be still retained (Lei S et 
al., 2016). 
Therefore, to precisely insert a premature stop codon into the genome of 
ST6GAL1, HDR is desired. To boost HDR frequency, several methods have been 
developed. For example, we could inhibit NHEJ rate or upregulate HDR pathways. 
For example, we could suppress KU70, KU80, or DNA ligase IV (Chu et al., 2015). 
We could control timing of CRISPR/Cas9 components delivery using cell 
synchronization (Lin et al., 2014). We could use cleavable donor DNA plasmid by 
flanking the donor vector with dual sgRNA recognition site (Zhang et al., 2017a). 
Tethering the DNA donor template to Cas9-guide RNA ribonucleoprotein (RNP) at 
the DSB site has been employed successfully to improve the HDR efficiency, without 
compromising the cell growth and cell different behaviours (Aird et al., 2018) 
Alternatively, ‘cold shocking’ cells at 32°C (1-2 days) following transfection could 
improve HDR frequency, which has been validated in induced pluripotent stem cells 
(Guo et al., 2018).  
Apart from NHEJ and HDR events occurring in ∆CD clones, we found 
potential MMEJ events in ∆CD clones. More specifically, F6 and G2 exhibited a 
sgRNA-induced 55 bp and 8 bp deletion, respectively. The deletion flanking the break 
site was probably due to microhomology-mediated end joining (MMEJ) which was 
described in Section 4.1.1.1. MMEJ relies on 5-25 bp exposed microhomologous 
sequence to mediate the end-joining events at the DNA break site. Moreover, research 
suggests that MMEJ is not a back-up mechanism: it can operate when NHEJ and HR 




After the validation of the mutation events in all the ∆CD cells, we sent all 
successfully identified cells for sequencing. The sequencing results showed strong 
signals and no evidence of heterozygous deletion. Therefore, we confirm them as 
homozygous mutates. In future, we could further confirm their homozygosity by 
performing two sequential rounds of PCRs. More specifically, the products from the 
spanning PCR (Figure 4. 29) can be subject to the second PCR with one internal 
primer and one external primer used in the spanning PCR. The internal primer is the 
one targeting the expected mutation site. -/-CD will not produce any amplicons in the 
second round of PCR, while WT and -/+CD will produce an amplified product. 
In summary, these two edited NPTr cells lines harbouring ST6GAL1 precise 
editing are successfully established. In the next chapter, the functional study regarding 
cell susceptibility to IAV will help us better understand the molecular mechanisms 
involved in ST6GAL1 deficiency.  
4.6 Conclusion  
In this chapter, we have created two pig trachea cell models harbouring 
deficient ST6GAL1 expression using the CRISPR/Cas9 system. In the first strategy, 
two untranslated exons and the associated predicted promoter of airway-enriched 
transcripts of ST6GAL1 were targeted. The obtained cell line was named as ∆P. In the 
second approach, functional knockout of ST6GAL1 was generated in NPTr cells, and 
this model was named ∆CD. In the subsequent chapter, five -/-∆P and 13 -/-∆CD cells 








5 Analysis of sialic acid expression and IAV 
infectivity 
5.1 Introduction   
Sialic acid (SA) is a nine-carbon monosaccharide typically found at the 
outermost positon of cell-surface glycan chains. The conjugation between SA and 
terminal carbohydrate chains can be in α 2,6- or α 2,3-glyosidic linkage, and is 
important in viral tropism and binding specificity. Human IAV preferentially binds to 
N-acetyl-neuraminic acid α 2,6-Galactose (SA α 2,6-Gal) receptor, and avian IAV 
predominantly binds to SA α 2,3-Gal receptor. The planar structures of these two 
receptors are demonstrated below (Figure 5. 1).  
 
 
Figure 5. 1 The structure of SA α 2,6-Gal and SA α 2,3-Gal. The image was original 
from Lauren Bryd-leotis (Byrd-Leotis et al., 2017). The terminal position of sialic acid 
(SA or Sia) can bind to the penultimate position of Galactose (Gal) on the 
carborhydrate susbtrates with two types of linkages, α 2,3-linkage (upper) and α 2,6-
linkage (bottom). The linkages are important in the specificty of viral binding. Please 
also note that the three-dimensional structure of α 2,6-linked SA is ‘umbrella-like’ and 




Lectin staining can be performed to detect the terminal SA residues. Sambucus 
Nigra (SNA), a lectin isolated from elderberry bark, has been widely used to recognise 
α 2,6-SA (Fischer and Brossmer, 1995). The other one is Maackia amurensis lectin 
(MAL), which is used to detect α 2,3-SA. There are two forms of MAL, MAL I and 
MAL II. They differ by the conjugation between β 1,4- or 1,3- linked Gal and the next 
‘C’ site. MAA I is able to identify non-SA residues and may cross-react with α 2,6-
SA. MAA II can bind to a particular carbohydrate substrate containing an α 2,3-SA, 
and is thus selected in this experiment (Kuchipudi et al., 2009). Concanavalin A 
(ConA) lectin is used as a positive control: it can recognise α mannose known as ‘core 
oligosaccharide’ in many serum and glycoproteins on cell surfaces, which we believe 
is not depended on ST6Gal1 expression.  
The newborn pig trachea (NPTr) cell line is a suitable cell model in IAV studies 
thanks to its susceptibility spectrum and SA-containing receptor distributions. It is a 
type of non-carcinoma and non-transformed cell line established from a 2-day-old 
piglet. The NPTr cell line appears to grow uniformly as a population of epithelial-like 
cells with oval nuclei. During subsequent passages, cells usually remain tightly packed 
in the form of monolayers, and seldom vary morphologically (Ferrari et al., 2003).  
With this cell model, we have used the CRISPR/Cas9 system to precisely 
engineer ST6GAL1 (Chapter 4). Two types of homozygous edited NPTr cells were 
generated. One attempt was to alter the transcriptional profile of ST6GAL1 in the 
respiratory tracts, by deleting a 5’ TSS region in the dominant transcripts expressed in 
the airway. We anticipated that in this case the synthesis of α 2,6-sialylated glycan 
structures was altered exclusively on the respiratory tracts. The resulting -/- edited cells 




respectively. The other attempt was a functional deletion of ST6GAL1 in NPTr cells, 
resulting in less engagement of the carbohydrate substrate in catalysing sugar binding. 
The resulting -/- edited cells were defined as -/-∆CD. -/-∆CD1, -/-∆CD4, -/-∆CD5, -/-
∆CD7, and -/-∆CD11 were selected for the phenotype assessment.  
In this section, we evaluated the efficiency of these strategies by the analysis 
of α 2,6-SA expression levels in edited NPTr cells, as well as assessing the cell 
susceptibility to three IAV strains.  
To assess IAV replication, viral genome copy numbers and viral growth titres 
are used to determine viral replication. We use nucleoprotein (NP) as a parameter to 
evaluate IAV replication. NP, as a structural protein, can interact with viral genome 
and viral RNA-dependent RNA polymerase (RdRp) to form ribonucleoprotein (RNP).  
NP is an important factor for viral RNP nuclear transport and assembly, which is 





5.2 Results  
5.2.1 Viability of WT and edited NPTr cells in viral growth 
medium  
The viability of cells cultured in viral growth medium (VGM) was determined 
using the CellTitre-Glo® Luminescent Cell Viability Assay (Cat# G7570, Promega) 
as described previously (Section 2.1.1.2). Given that the quantity of ATP 
luminescence was proportional to the number of viable cells in culture, we measured 
ATP luminescent signals to evaluate the viability of wild-type (WT), -/-ΔP2 and -/-
ΔCD5 NPTr cells cultured at 0 h, 8 h, 24 h and 48 h. The luminescent signal of all 
samples was then normalised to the medium-only control. Subsequently, these 
measurements were plotted relative to the one produced by WT cells (time=0 h) 
(Figure 5. 2). The result implies that there are no significant differences of ATP 
productions among WT, -/-ΔP and -/-ΔCD cells, which in turn suggests that VGM 
culture does not have significant effects on the viability of WT and edited NPTr cells.  
 
 
Figure 5. 2 The viability of NPTr cells in viral growth medium. The relative 
luminescence (RLU) produced in NPTr cells on 0 h, 8 h, 24 h and 48 h culture was 





5.2.2 Cell surface sialic acid expression levels 
To detect α 2,6-SA and α 2,3-SA expression levels on NPTr cells, fluorescein-
labelled lectin-based assay with SNA and MAL II were performed, respectively 
(Section 2.3.3.2). This was followed by the visualisation using confocal microscopy 
and the quantification using flow cytometry (Section 5.2.2.3).  
Throughout this section, ConA was used as a positive control (+ve) since we 
expected that ConA lectin binding would be less influenced by ST6Gal1 activity. 
There was no negative control to take into account the non-specific binding of the 
lectin in cells. A proper negative control could be cells without SA on the cell surface, 
which could be achieved by treating cells with sialidase enzyme (Fischer and Brossmer, 
1995). However, this had not been performed due to the time constraint. 
5.2.2.1 Sialic acid expression of MDCK and MDCK-SIAT1 cells by 
lectin stain 
As a preliminary, we observed α 2,6-SA and α 2,3-SA expression levels in 
MDCK cells and MDCK-SIAT1 cells through SNA and MAL II lectin fluorescent 
signals, respectively. It has been shown that MDCK-SIAT1 cells have an enhanced 
level of α 2,6-sialyltransferase than conventional MDCK cells, and thus increased α 
2,6-SA expression (Lin et al., 2017). In our study (Figure 5. 3), the positive control, 
ConA lectin staining by confocal imaging showed strong fluorescent signal of SNA 
lectin in MDCK and MDCK-SIAT1 cells as expected. Moreover, the confocal imaging 
of MAL II lectin binding showed moderate level of fluorescent density in MDCK and 




MDCK-SIAT1 cells was obvious higher than that in MDCK cells, which is consistent 





Figure 5. 3 Analysis of α 2,6-SA expression in MDCK and MDCK-SIAT1 cells. 




5.2.2.2 Evaluation of cell surface sialic acid expression levels 
All the edited cells in this study were developed through clonal expansion, and 
it was unclear whether surface glycan expression was altered during cell clonal 
expansion. For this reason, we performed SNA, MAL II and ConA lectin-based 
staining in pooled WT cells and single cloned WT cells. As seen in Figure 5. 4a, for 
each staining experiment, pooled WT cells and single cloned WT cells displayed no 
obvious difference of fluorescent signals.   
Furthmore, flow cytometry analysis was performed to measure α 2,6-SA 
expression in both pooled WT cells and single cloned WT cells (Figure 5. 4-b). A 
sample, consisted of unstained cells, was included to set positivity of fluorescent 
signals. The fluorescent intensity histogram showed that there were no obvious 
differences in mean fluorescent intensity (MFI) between the WT cell population and 
the cloned cells (Figure 5.  4-b). Therefore, we conclude that clonal expansion had 
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Figure 5. 4 Analysis of α 2,6-SA expression in cloned NPTr cells. (a) Fluorescein-
labelled SNA (for α 2,6-SA, left), MAL II (for α 2,3-SA, middle) and ConA (+ve, right) 
lectin staining showed similar fluorescent signals in WT and cloned cells. (b) The left 
panel was the fluorescent intensity histogram (B530, y-axis) versus cell number (x-
axis). The negative control (unstained cells) was used to set gating. The right panel is 
the flow cytometry quantification of α 2,6-SA expression levels among three samples. 




5.2.2.3 Evaluation of sialic acid expression in ST6GAL1 ∆P cells  
To determine the expression and distribution of SA in edited NPTr cells, cell 
samples were stained with SNA, MAL-II, and ConA lectin. As can be seen in Figure 
5. 5, ConA lectin staining (bottom panel) was visualised by confocal microscopy and 
showed a similar level of fluorescent signals in -/+∆P (heterozygous edited), -/-∆P 
cells (Chapter 4), and WT cells. Regarding fluorescein-labelled SNA lectin staining 
(upper panel), the fluorescent signals in -/+∆P and -/-∆P cells appeared reduced than 
those in WT cells, indicating that the genetic manipulation of ST6GAL1 in NPTr cells 
caused a reduction of surface α 2,6-SA expression.  
Interestingly, the fluorescein-labelled MAL II lectin staining (middle panel) 
showed that the α 2,3-SA expression level in -/+∆P and -/-∆P cells was higher than 
that in WT cells. This may suggest that α 2,6-SA and α 2,3-SA are in equilibrium to 








Figure 5. 5 Expression and distribution of sialic acid in ∆P cells. Cells were seeded on coverslips and stained with fluorescein-labelled 
SNA (upper), MAL II (middle), and ConA (Bottom) lecints, followed by confocal imaging. Images were taken by confocal microscopy. 




5.2.2.4 Cell surface sialic acid expression in ST6GAL1 ∆CD cells  
We detected the α 2,6-SA expression level in 13 clones of -/-∆CD cells using 
SNA staining. Data shown here is representative of five out of 13 (Appendix 13). As 
shown in Figure 5. , the confocal imaging of SNA lectin staining indicated that α 2,6-
SA expression level appeared lower than that in WT cells, which we believed was due 
to the functional domain deletion of ST6Gal1 protein in -/-∆CD cells (Chapter 5). 
The MAL II lectin staining by confocal microscopy displayed moderately stronger 
fluorescent signals in -/-∆CD cells than in WT cells, providing more evidence that the 
expression of α 2,6-SA is closely related to α 2,3-SA.  
It is worth noting that the positive control, ConA lectin binding, turned out to 
be stronger in most of the -/-∆CD cells than in WT cells, which was unexpected. We 






Figure 5. 6 Expression and distribution of sialic acid in ∆CD cells. Cells were seeded on coverslips and stained with fluorescein-
labelled SNA (upper), MAL II (middle), and ConA (Bottom) lecints, followed by confocal imaging. Images were taken by confocal 




5.2.2.5 Quantification of α 2,6-SA by flow cytometry in -/-∆P and -/-
∆CD cells  
SNA-labelled fluorescent intensities of WT cells, -/+∆P, -/-∆P 1, 2, 3, 4, 5, and 
-/-∆CD 4, 5, 11 cells were quantitatively analysed by flow cytometry as described 
previously (Section 2.3.3.2). MFI was measured to determine the central tendency of 
SNA fluorescent signal, which correlated the α 2,6-SA expression level on the cell 
surface. As shown in Figure 5. 7, cells unstained with SNA lectin (negative control, -
ve) were included to set a gating in the fluorescent histogram graph. In the flow 
cytometric histogram (Figure 5. 7-a), compared with those in WT cells, we observed 
that the peak of MFI was left shifted in SNA-labelled -/-∆P cell 1-5, and the peak shift 
further towards the left in -/-∆CD cell 4, 5 and 11. There was no significant difference 
of MFI in -/+∆P cells versus in WT cells.  
Accordingly, the histogram bar graph (Figure 5. 7-b) showed the MFI value 
produced by SNA binding in each sample. Each MFI was then normalised to the levels 
of the negative control. Compared to that in WT cells, the MFI value in -/-∆P was 
significantly reduced; and the MFI value of -/-∆CD cells had a further significant 
reduction. The quantification analysis was consistent with the visualisation by lectin 
staining (Section 5.2.2.3 and Section 5.2.2.4), indicating that α 2,6-SA expression 








Figure 5. 7 Quantification of SNA binding by flow cytometry. (a) The histogram 
for SNA measured by flow cytometry. (b) The histogram bar chart for quantitative 
MFI of α 2,6-SA in -/-∆P and -/-∆CD cells. Statistical analysis was performed in three 
independent experiments (n=3). Values were mean ± SEM Significantly different 
















































In parallel, we determined the surface α 2,3-SA expression level on MAL II-
stained cells using flow cytometry as described previously (Section 2.3.3.2). As shown 
in Figure 5. 8 (upper panel). Compared to the MFI of MAL II in WT cells, the peak 
was right shifted in edited cells, indicating the increased level of α 2,3-SA binding in 
the edited cells. As can be seen in the bottom panel (Figure 5. 8), the statistical analysis 
revealed the MFI ratios of MAL II lectin were increased in edited cells accordingly. 
The results suggested an increased expression levels of α 2,3-SA in ST6GAL1 edited 
cells. There were two technical replicates, and three biological replicates in each group 








Figure 5. 8 Quantification analysis of MAL II binding by flow cytometry. (a) The 
histogram for MAL II measured by flow cytometry. (b) The histogram bar chart for 
quantitative MFI of α 2,3-SA in -/-∆P and -/-∆CD cells. Statistical analysis was 




5.2.3 Single-cycle infection of IAV  
5.2.3.1 NP expression analysis by Western blot  
5.2.3.3.1 PR8 and Swine87 viral infection 
Now that the SA distribution on WT, -/-∆P, and -/-∆CD NPTr cells has been 
evaluated, the next question is whether editing ST6GAL1 has an effect on viral 
replication. To this end, the levels of intracellular nucleoprotein (NP) production were 
quantified in a single-cycle infection using A/Puerto Rico/8/1934 (PR8) and 
A/Swine/England/163266/1987 (Swine87) viruses, respectively. PR8 virus is a lab-
adapted IAV strain known to infect host cells by binding to both α 2,6-SA and α 2,3-
SA-containing receptors (private communication with John McCauley lab). Swine87 
was chosen to present triple-assorted viral strains. WT cells, and three -/-∆P clones (2, 
4, 5), and three -/-∆CD clones (4, 7, and 11) were infected with PR8 and Swine87 virus, 
respectively, at an M.O.I of 0.2 for 8 hours post infection (h.p.i). NP production was 
then quantified by western blot analysis.  
As shown in Figure 5. 9, mock-infected cells had undetectable NP productions. 
The difference between WT cells and -/-∆P cells in terms of NP productions during 
PR8 (a) and Swine87 (b) viral infection was insignificant. Furthermore, compared to 
WT cells, -/-∆CD cells exhibited similar levels of NP productions during PR8 viral 
infection. However, NP expression following Swine87 infection was found to be 
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Figure 5. 9 NP replication at 8 h.p.i with PR8 and Swine87 by western blot. NPTr 
cells at 8 h.p.i by PR8 (a) and Swine 87 (b) with an M.O.I of 0.2 were harvested. NP 
was determined by western blot using anti-NP antibody. The histograms below each 
blot were the quantitate analysis by the normalisation to Tublin. All error bars were 
calculated with S.E.M and the P-value was determined by one-way ANOVA analysis. 
**P-value=0.0073< 0.01. ns: not significant. 


























































5.2.3.3.2 Cal04 viral infection  
A/California/04/2009 (H1N1) (Cal04) virus was chosen as a representative 
pdm09 virus. Cal04 virus has been shown to preferentially bind to α 2,6-SA receptor. 
It is important to evaluate Cal04 viral infectivity since we would like to reduce pdm09 
replication in pig cells.  
The ability of Cal04 virus to replicate in ST6GAL1 edited cells was evaluated 
by a single-cycle infection using an M.O.I of 0.5. Infected cells were harvested at 24 
h.p.i, as NP production was undetectable at 8 h.p.i (see Appendix 14) and a longer 
incubation was required. As shown below (Figure 5. 10), mock-infected cells had 
undetectable NP production. The level of NP production in -/-∆P cells was 
significantly lower than that in WT cells. Furthermore, NP production was even lower 
in -/-∆CD cells. In fact, we did not observe any NP productions by western blot; and 
only detected a very low level of NP production by densitometry.  
Taken together, our results indicate that, compared with WT cells, -/-∆P cells 
were less susceptible to Cal04 viral infection and that -/-∆CD cells are less susceptible 








Figure 5. 10 NP replication at 24 h.p.i with Cal04 by western blot. Western blot 
analysis showed the viral NP expression in infected cells. All error bars were 
calculated with S.E.M and P-value was determined by one-way ANOVA analysis 24 
h.p.i by Cal04 virus at M.O.I of 0.5. The histogram bar was the quantitate analysis by 




5.2.3.2 NP expression visualisation in infected NPTr cells by 
immunofluorescence  
Next, we used the immunofluorescence assay (IFA) to visualise intracellular 
NP expression. To this end, WT, -/-∆P and -/-∆CD cells were seeded on coverslips 
and infected with PR8, Swine87, and Cal04 viruses, respectively (Section 2.2.2.2). 
The infected cells were fixed and permealised at 8 h.p.i (PR8 and Swine87 viruses) or 
24 h.p.i (Cal04 virus), and stained with the anti-NP antibody (Section 2.2.2.4). The 
stained cells were then visualised by fluorescent microscopy, which allowed us to 
quantitatively measure the numbers of fluorescent-labelled infected cells in different 
groups. These numbers were plotted relative to that of WT cells. The uninfected cells 
(mock-infected) were used as a negative control (-ve).  
As shown in Figure 5. 11, mock-infected cells showed no fluorescent signals 
in WT, -/-∆P and -/-∆CD cells. Quantitative analysis of the fluorescent signals in PR8-
infected WT, -/-∆P and -/-∆CD cells showed no significant differences among them at 
8 h.p.i Regarding the infection of Swine87 virus, WT and -/-∆P cells presented similar 
infectivity. However, if we measured susceptibility by the percentage of NP positive 
cells, -/-∆CD cells were approximately 50 percent less susceptible to Swine87 than 
WT cells. For Cal04 viral infection, -/-∆P and -/-∆CD cells were 20% and 70% 









Figure 5. 11 NP expression by immunofluorescence assay. (a) Cell on the coverslips 
were infected and harvested at 8 h.p.i by PR8 and Swine87 viral infection, and 24 h.p.i 
by Cal04 viral infection prior to IFA using NP monoclonal antibody. Nuclei was 
counterstained with DAPI dye. (b) The values of viral NP in -/-∆P and -/-∆CD cells 
was normalised to that in WT cells. The quantification was based on cell counting in 
multiple micrographs from three independent experiments (n=3). * P<0.01 and **P 



















































5.2.3.3 NP expression quantification in IAV infected NPTr cells by 
flow cytometry  
In this experiment, we infected cells using the same conditions as the Section 
5.2.3.2, but quantified the NP expression by flow cytometry. As shown in Figure 5. 
12a, cells in the negative control were mock infected and then stained. This negative 
control was used to record the non-specific fluorescent signals (more than 99.9 percent 
of these signal was included). Then, NP fluorescent intensities of IAV-infected cells 
were compared to that of mock-infected cells. This was achieved by normalising the 
percentages of cells with fluorescent signals against that of the negative control. The 
resulting numbers were plotted in Figure 5. 12a. Furthermore, this experiment was 
repeated independently for three times, and average percentages of NP+ cells in 
different IAV-infected cell population were reported in the bar chart (b).  
Regarding PR8 viral infection, the normalised percentage of cells with 
fluorescent signals was 43.7% in PR8-infected WT cells, indicating that 43.7% of the 
WT cells were viable and NP+. The numbers for -/-∆P and -/-∆CD were 43.0% and 
41.4%, respectively. The results suggest that PR8 virus has similar infectivity to WT, 
-/-∆P and -/-∆CD cells. For Swine87 virus, the percentage of NP+ Swine87-infected 
WT cells was 32.5%, which was similar to the percentage for -/-∆P cells, 33.6%. 
However, the percentage for -/-∆CD was ~50% lower than that for WT cells. As for 
Cal04 viral infection, the percentage of NP+ cells in Cal04-infected -/-∆P was ~20% 
lower than that for WT cells (37.3%) (b). For Cal04-infected -/-∆CD cells, the number 
was ~60% lower than that for WT cells. Taken together, these data suggest that, 
compared to WT cells, -/-∆P cells are less susceptible to Cal04 virus and that -/-∆CD 





Figure 5. 12 NP expression quantification by flow cytometry. (a) Flow cytometry gating for the identification of NP positive cells. 
IAV-infected NPTr cells (same conditions with IF) were harvested, fixed, permeablised, and stained prior to flow cytometry analysis. 
Representative results showed the percentage of NP positive cells in each gate, which was proportional to the ratio of IAV-infected cells. 
The NP fluorescent intensity in mock-infected cells was used to set a gating (black box) and was recorded no more than 0.1% NP 
expression. (b) The quantification analysis according to (a). Data represented the mean ± SEM of three technical replicates (n=3)
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5.2.4 Multiple-cycle infection of IAV  
5.2.4.1 Replication kinetics of PR8, Swine87 and Cal04 in WT, -/-∆P 
and -/-∆CD cells  
To determine the ability of viral replication in WT, -/-∆P and -/-∆CD cells, 
viral growth kinetics of PR8, and Swine87 virus was assessed in MDCK cells, and 
Cal04 virus was assessed in MDCK-SIAT1 cells. In both cases, we performed 
multiple-cycle infection at an M.O.I of 0.001, and cell supernatants were harvested at 
8, 24, and 48 h.p.i (Section 2.2.2.3). Mock-infected cells contained undetectable virus. 
The viral growth curve was shown in Figure 5. 13a, during multiple-cycle infection 
with PR8 virus, the viral growth in WT, -/-∆P and -/-∆CD cells were very similar, with 
viral titres reaching at 108 PFU/ml at 48 h.p.i. For multiple-cylce infection with 
Swine87 virus, viral growth reached 105 PFU/ml in WT cells at 48 h.p.i. Compared 
with WT cells at both 24 and 48 h.p.i, -/-∆P cells presented 1-log higher viral titre, 
which was unexpected; -/-∆CD cells presented 1.5-log lower viral titre. Regarding 
Cal04 viral replication during the multiple-cycle infection, the viral titre in WT cells 
reached 106 PFU/ml at 24 h.p.i, and 107 PFU/ml at 48 h.p.i. Compared to WT cells, -
/-∆P cells replicated with delayed growth kinetics, showing a 1.5-log lower viral titre 
at 24 h.p.i, and 1-log lower viral titre at 48 h.p.i; Cal04 virus replicated with markedly 
delay over the 48 h.p.i. The difference of viral titres reached 4-log lower viral titre at 
24 and 48 h.p.i, compared with WT cells. To summarise,  these results show -/-∆P 
cells allow the efficient viral replication of Swine87, but less viral growth of Cal04; -







Figure 5. 13 Viral kinetics of PR8, Swine 87 and Cal04. Cell cultures were infected 
with viruses at an M.O.I of 0.001. Supernatants were harvested at 8, 24, and 48 h.p.i, 
and the viral titres were calculated as log10 PFU/ml in MDCK cells (PR8 and Swine87 
viruses) or MDCK-SIAT1 cells (Cal04 virus). Plaque assay was performed and growth 
curves were plotted by Rute Pinto, a PhD student in Prof. Paul Digard group, the Roslin 
Institute. Values presented the standard mean±S.E.M (n=3). No statistically difference 







5.3 Discussion  
Firstly, we would like to discuss the distribution of the SA α 2,6-Gal and SA α 
2,3-Gal receptors on cell surfaces. In humans, the SA α 2,6-Gal receptor is mainly 
distributed in the upper airway epithelium, the paranasal sinuses, the pharynx, the 
trachea, and the bronchi (Ibricevic et al., 2006), whereas the SA α 2,3-Gal receptor is 
predominantly distributed in non-ciliated bronchiolar cells (Shinya et al., 2006). In 
pigs, SA α 2,6-Gal receptor is predominantly expressed in the upper airway (e.g., 
trachea) (Kumlin et al., 2008), whereas SA α 2,3-Gal receptor is abundant in the lower 
airway (Zeng et al., 2013). In our experiment in pig trachea cells (the NPTr cells), we 
observed that SA α 2,6-Gal and SA α 2,3-Gal are both expressed on cell surfaces, and 
that of, SA α 2,6-Gal was roughly three times more abundant than SA α 2,3-Gal. In 
our study, we used lectin-staining assay to measure SA α 2,6-Gal and SA α 2,3-Gal 
expression levels, but it should be noted that we could achieve the same goal using 
mass spectrometry to measure the SA residues by digestion and fragmentation with 
specific sialidases (Zaia, 2010). As a positive control, we used ConA lectin to measure 
α mannose expression on cell surfaces. Compared with WT and -/-ΔP cells, a higher 
level of mannose expression was observed on the surface of -/-ΔCD cells. The 
homeostatic properties of the mannose receptors are known to be associated with cells’ 
immune responses to foreign pathogens (Turner, 2003). Therefore, the functional 
knockout that generates the -/-ΔCD cells might cause a biological deficiency, which 
should be considered whether this would be a suitable solution for modelling host 
resistance in this case. However, these were only observations, more accurate 
quantification, such as flow cytometry, and protein-based assay, such as western blot, 




In addition, we observed that the ST6GAL1 deficient cells displayed reduced 
α 2,6-SA expression, and an increased level of α 2,3-SA expression, relative to WT 
cells. We conjecture that α 2,6-SA and α 2,3-SA receptors complement each other: the 
lack of one might cause the increase of the other. The way they depend on each other 
requires further investigations and is beyond the scope of this thesis.  
An unexpected difficulty that arose during the quantitative analysis of NP 
production by flow cytometry. Due to the time constraint and project funding, the 
conditions and the concentration of anti-NP antibody have not been optimised. Anti-
body NP was empirically used in 1:200 dilution. Therefore, to achieve a more accurate 
and robust result, optimization of antibody and collection of more cells (10,000 events) 
should be the first step before the quantitative analysis 
5.4 Conclusion  
Taken together, the manipulation of the ST6GAL1 gene rendered pig trachea 
cells less susceptible to IAV infection. In particular, -/-∆P cells, which harbours 
ST6GAL1 perturbation in its transcriptional profile, exhibited less α 2,6-SA 
expression, and less susceptibility to Cal04 viral infection. -/-∆CD cells, obtained by 
functional knockout of ST6GAL1, showed remarkably reduced α 2,6-SA expression, 








6 General discussion  
6.1 Overview and discussion  
Influenza is one of the top three economic diseases. An average of 600 people 
die of influenza each year in the UK. Pigs are reservoirs for human, avian, and swine 
IV strains since they have two types of sialic acid (SA)-containing receptors for viral 
recognition, SA α 2,6-Gal and SA α 2,3-Gal. This allows pigs to serve as intermediate 
hosts in the production of reassortant IAV strains, which facilitates cross-species 
transmission, and may even lead to epidemics and pandemics. In particular, the ‘swine 
flu’, pandemic (H1N1) 2009, isolated from pigs, has been widely circulating in human 
populations globally since 2009. Traditional vaccines and antiviral drugs are not fully 
sustainable due to the continuous emergence and re-emergence of IAV strains. 
Therefore, a growing body of literature has focused on host genetic factors involved 
in the IAV entry and infection, which may be useful for building host genetic 
resistance as a prophylaxis.  
With the goal of building host resistance in pigs, we evaluate a strategy to 
reduce the expression of SA α 2,6-Gal receptor, which in turn could disrupt the virus-
host interaction. To this end, we generated functional knockout of the ST6GAL1 gene, 
which regulates the configuration of SA α 2,6-Gal receptor. The resulting model, 
ST6GAL1∆CD (∆CD for short), exhibited dramatically reduced α 2,6-SA expression 
on cell surfaces. Furthermore, the edited cells were less susceptible to swine IAV strain, 
and resistant to a human IAV strain. 
ST6Gal1 null mice showed severe deficiency of the humoral immunity 




(Hennet et al., 1998, Irons and Lau, 2018). Therefore, it is not ideal to generate animal 
models with the global loss of ST6GAL1. In our study, ∆CD cells exhibited normal 
viability (Figure 5. 2), but we were not clear whether the loss of ST6GAL1 would 
cause any immune insufficiency in these cells.  
To be on the safe side, we put a more subtle approach to impair the 
configuration of SA α 2,6-Gal receptors. In particular, we targeted the 5’ TSS region 
of two transcripts enriched in the respiratory tract, with the aim of disrupting the 
expression level of ST6GAL1 exclusively in the relevant tissues.  
The difficulty of the aforementioned strategy was that we did not fully 
understand the transcriptional profiling of the pig ST6GAL1 gene. Very little was 
found in the literature on the functions of the ST6GAL1 gene in pigs, although it has 
been well studied in other mammals, especially human. The limited information of pig 
ST6GAL1 gene in the previous pig sequence assembly 10.2 hindered the functional 
study of ST6GAL1 in a genetic approach. 
To better understand the pig ST6GAL1 gene, we first experimentally 
determined the missing 5’ UTR region of the pig ST6GAL1 gene. The transcriptional 
profiling of the pig ST6GAL gene was then constructed based on the 5’ divergent TSSs 
of different transcripts. 5’ alternative splicing pattern of ST6GAL1 transcripts we 
found is consistent with what was reported in the pig assembly 11.2 released in 2017. 
Moreover, we found out that the pig ST6GAL1 gene has a strong expression in the 
liver, which confirmed the claim that ST6GAL1 expression pattern is conserved 
among species (Meng et al., 2013). Additionally, it clearly demonstrates the use of 
5’TSS and the presence of 5’ UTEs in different transcripts of tissues. An implication 




expressions of transcripts in various tissues. To the best of our knowledge, this is the 
first study on the identification of the tissue-specific expression pattern of the pig 
ST6GAL1 gene.  
During the study, we repeated the 5’ RACE experiments to eliminate the 
possibilities that the expression of some transcripts was instable. From all three 
independent biological repeats, we found out in each tissue, some products were 
efficiently amplified in more than two repeats, indicating they are the dominant 
transcripts in the corresponding tissue. Then, we grouped 24 mRNA transcripts 
identified ten mRNA families according to 5’ divergent sequences. The transcripts 
enriched in the respiratory tract—lung, bronchus, and trachea, were selected as the 
target (FAM 5 and 6). 
It has been reported that the region of 20~100 bp flanking 5’ TSS is important 
for efficient initiation (Rach et al., 2009) and elongation of the transcription (Adelman 
and Lis, 2012). Considering this, we decided to delete ~500 bp upstream and 
downstream of the two untranslated exons in FAM 5 and 6. The transcriptional 
profiling of the ST6GAL1 gene was expected to be disrupted due to the inefficient 
gene transcription in a promoter-regulated fashion. The above deletion of the 5’ TSS 
region yielded a ST6GAL1∆P genotype (∆P for short). We found that the resulting 
model had reduced enzymatic activity of the ST6Gal1 protein, i.e., reduced α 2,6-SA 
cell surface expression. Furthermore, the results of the viral assessment with low doses 
and single-cycle infections showed that ∆P cells were moderately resistant to the 
human IAV strain. 
Initially, we expected ∆P cells to have reduced α 2,6-SA expression. Thus, it 




infect ∆P cells. Our viral assessment with Cal04 virus, a human isolated IAV 
preferentially binding to α 2,6-SA-containing receptor (private communication with 
John McCauley lab), confirmed our hypothesis: compared to the WT cells, ∆P was 
less susceptible to Cal04 virus due to a paucity of suitable SA-containing receptor. 
With Swine87 viral strain, we found out that ∆P cells did not appear to be susceptible 
to this viral strain according to our experiment. This result is difficult to explain since 
the binding preference of Swine87 virus was unclear. A possible explanation is that 
the susceptibility to Swine87 virus is related to the expression levels of both α 2,6-SA 
and α 2,3-SA. ∆P cells had reduced α 2,6-SA expression, but increased α 2,3-SA 





6.2 Alternative methods  
6.2.1 Other techniques 
To achieve the perturbation of the transcriptional profiling of pig ST6GAL1, 
we could have alternatively identified the lung-specific enhancers by investigating the 
histone signatures of the lung-specific enhancer activities. Tissue-specific enhancer 
elements can be identified by the Chromatin immunoprecipitation with massively 
parallel sequencing (ChIP-seq) in various tissues. ChIP-seq is a robust and well 
established method to study the DNA-protein binding pattern (Visel et al., 2009). I met 
Prof. Zhou’s group from the University of California, Davis at ISAG 2017 (Dublin). 
They have established a ChIP-seq library in pig lung, liver and spleen. Moreover, the 
sequences derived were aligned to the previous pig assembly 10.2, in which the 
ST6GAL1 gene was on an unplaced scaffold in the pig genome. The sequencing data 
showed that the region GL894735.1 (46680-46946) was identified to contain a lung-
specific enhancer, rather than a liver or spleen one. This finding is also supported by 
histone modifications, such as H3K27ac and H3K4me1 markers, which are frequently 
used for enhancer states (spicuglia and Vanhille, 2012). Therefore, we could delete 
this lung-specific enhancer region using the CRIPSR/Cas9 system. This would result 
in edited pig cells or pig models harbouring disrupted transcriptional activity of 
ST6GAL1 in lung, and thus less human IAV viral recognition and propagation in lung 
can be achieved. Moreover, this will be unlikely to trigger any excess 
immunodeficiency since the α 2,6-sialyl-glycans receptors are intact on the surfaces of 
the liver and the spleen.  
Furthermore, cap analysis gene expression (CAGE) tags, which can be used to 




be useful. Applying this analysis, the 5’ TSS regions of ST6GAL1 transcript variants 
could be identified in the lung, the bronchus and the trachea, specifically.  
If enhancers or other endogenous promoters can be identified specifically 
regulating airway transcripts of ST6GAL1, we could use co-expression of Cas9 and 
multiple sgRNAs to precisely excise the epigenome markers and regulatory element 
regions from ST6GAL1. Alternatively, we could design sgRNAs targeting the 
regulatory elements of interest. A catalytically-dead Cas9 (dCas9) can be fused to 
effector domains, increasing or reducing the gene expression by recruiting 
transcriptional co-activators or co-repressors, respectively (Anton et al., 2019). 
To improve the efficiency of mutations in the coding region, the piggyBac 
(PB)-based transposon system could be used. This system is based on an alternative 
non-viral mobile genetic element. PB system can carry up to 100 kb exogenous DNA, 
allowing the integration of transposon DNA to ‘TTAA’ sequences distributed on the 
genome, and mediating precise genome excision in mammalian cells (Qian et al., 
2014). In the future, when attempting to introduce specific mutations in the genome, 
we could try to combine the CRISPR/Cas9 system and the PB system, which could 
insert the CRISPR machinery into mammalian genome. The combination of CRISPR 
and PB system has been successfully applied in the study of human immunodeficiency 
virus type 1 (HIV-1) inhibition by targeting C-X-C chemokine receptor type 4 
(CXCR4) receptor gene for HIV-1 in an HIV-1 reporter cell line, resulting in 
undetectable exogenous DNA and off-target effects in the genome (Liu et al., 2018).  
To better understand the susceptibility of ∆P and ∆CD cells to different IAV 
strains, future experiments could include the characterisation of receptor binding 




cells (CRBCs), which could be modified to exclusively express SA α 2,6-Gal or SA α 
2,3-Gal (Glaser et al., 2005). Alternatively, we could perform HA binding assay. 
Purified HA from IAV isolate of interest can bind to NPTr cells. The alteration of HA 
binding in edited and WT cells could indicate the altered susceptibility of these cells 




6.2.2 Other targets 
We could also consider decreasing the α 2,3-SA receptor expression on the cell 
surfaces. α 2,3-SA receptors are catalysed by the ST3Gal1 protein, which is 
evolutionarily homologous with ST6Gal1 protein, containing identical and conserved 
sialyl-motifs (Ortiz-Soto and Seibel, 2016). We preliminarily measured its coding 
gene ST3GAL1 expression levels in pig tissues, similar to the work on ST6GAL1 
(Chapter 3). The results demonstrate the variant expressions of ST3GAL1 transcripts, 
indicating its tissue-enriched transcriptional profiling in pig tissues (Figure 6. 1). 
Therefore, we could perform the same procedure for ST3GAL1 manipulation, and 
identify the airway-specific/abundant regulatory elements. Then, the precise 
engineering of ST6GAL1 and ST3GAL1 can be performed simultaneously, and the 







Figure 6. 1 Relative expression of in eight pig tissues.  
The same procedure of qPCR was conducted as described in the Section 2.3.2.3.  
Forward primer: 5’-CGGGAGAAGCAGCCCAATAA-3’ 
Reverse primer: 5’ GCTCTCGGGGTACACGAAAT-3’. 
x-axis: relative expression level.   
 
Alternatively, we could study virus-host interactions based on CRISPR/Cas9 
genetic analysis, especially the loss-of-function analysis of host factors that are 
important for IAV invasion. Recently, researchers have established the A549-
Genome-scale CRISPR/Cas9 Knockout (A549-GeCKO) library to screen and identify 
various host factors involved in IAV infections (Julianna Han et al., 2018). Of all 
candidates identified, Golgi cytidine 5’monophosphate (CMP) sialic acid transporter, 
SLC35A1, were selected. SLC35A1 can translocate the CMP-sialic acid from cytosol 
to Golgi lumen, where Sialyltransferase can use it as donor substrate for the synthesis 
of sialy-glycoconjugates, which are then assembled into host receptors for viral 
recognition. It has been shown that CHO cells deficient in SLC35A1 are resistant to 
the Minute virus of mice, and that there is no detrimental impact on cell growth, 
viability and productivity (Mascarenhas et al., 2017). However, the role of SLC35A1 




identify its transcriptional profile in different pig tissues to determine whether it has 
tissue-associated promoter or enhancers. If so, we could then perform the 
CRISPR/Cas9 system to precisely engineer the airway-expressed transcripts.  
The mechanism of how IAVs infiltrate cells is still not fully understood, 
especially regarding why hosts are infected in the absence of the virus’ preferred SA-
containing receptors on the cell surfaces. In particular, the ∆CD cells, having 
functional knockout of the ST6GAL1 gene, are less susceptible to human IAV thanks 
to the reduction of the sialyl-glycans receptors on the edited cells, but these cells can 
still be infected (possibly through other receptors). This is also proved by a study in 
which SA-removed cells after sialidase treatment can still be infected by IAV 
efficiently. Therefore, alternative host receptors for the IAV recognition should be 
explored and elucidated in future, and more factors and host mechanisms are to be 




6.3 Future directions 
Following the work described in this study, some follow-up experiments can 
be performed to further extend the story. The first one is to isolate more pig tissues, so 
that the transcriptional profiling of pig ST6GAL1 could probably be enriched. As 
previously described, we isolated nine pig tissues: lung, trachea, bronchus, liver, 
spleen, kidney, stomach, small intestine, and heart. These tissues broadly cover 
physiological systems. The reason we did not include other tissues from reproduction, 
skin and nervous systems, etc., is that these tissues are less associated with immune 
functions than the selected ones. In the further work, more tissues could be included 
in the identification of the transcriptional profiling of the ST6GAL1 gene. This helps 
us improve the understanding of the tissue-expression pattern of ST6GAL1.  
We could also include the detection of innate immune responses of IAV 
infected ∆P and ∆CD cells, such as interferon (IFN) type I and III responses (Kreijtz 
et al., 2011), and the cytokine signalling (Delgado-Ortega et al., 2014).  
Since the in vitro model is not fully representative of the whole 
pathophysiology, the in vitro strategy evaluated in this study can be applied to generate 
an in vivo pig model. If SA α 2,6-Gal receptors for IAV entry could be eliminated in 
the airway exclusively, the pigs could be protected from the infection by IAV with α 
2,6-SA preference, thanks to the lack of SA α 2,6-Gal receptors. Moreover, the edited 
pigs are entitled to retain normal biological functions conducted by α 2,6-sialylated 
glycan receptors. Therefore, the cross-transmission will be reduced in pig herds and 
human populations.  
Although it is anticipated that the edited pigs might not be resistant to avian 




which will be an important improvement over the current situation. The viral 
reassortant events would also be limited to some extent, and this is beneficial to animal 
welfare, human public health, and economy.  
The best method to create a partial ablation of SA α 2,6-Gal receptors 
exclusively in the airway of pigs is the CRISPR/Cas9 system, which enables scientists 
to modify the genome with unprecedented simplicity (Cho et al., 2013). However, 
when performing an in vivo experiment, there are still some open questions: (1) how 
to validate and enhance the on-target efficiency, (2) how to reduce off-target 
possibilities, (3) and how to reduce the cytotoxicity associated with the CRISPR/Cas9 
system.  
The first question is how to increase the on-target efficiency. PAM variance is 
a critical factor (Kleinstiver et al. 2015). Apart from the canonical PAM (‘NGG’) in 
the SpCas9 system, ‘NAG’ and ‘NGA’ are also associated with cutting activities 
(Zhang et al. 2014). Additionally, we could increase the specificity by activating 
SpCas9 with some factors, such as some small exogenous molecules. Moreover, new 
variants of Cas9 have been created that have higher fidelity, such as the HF SpCas9 
(Kleinstiver et al. 2015) and eSpCas9 (Slaymaker et al. 2016).  
The second question is how to reduce the possibility of off-target effects, which 
is the most critical issue for genome editing. To minimise the off-target effect, various 
approaches have been used (Tycko et al., 2016). For instance, sgRNA truncation (Fu 
et al. 2014), 5’ extension (Kim et al., 2015), the use of the HF SpCas9, and the transient 
delivery of ribonucleoprotein complex (RNP) involving gRNA and Cas9 by cationic 




The third question is how to reduce the cytotoxicity and to increase embryonic 
survival rate. To this end, we could directly inject into embryos Cas9 mRNA and 
sgRNAs, which have been shown to be low in cytotoxicity during the embryo 
development (Hai T et al., 2014). Alternatively, we could inject into embryos a low 
concentration of CRISPR/Cas9 RNA. But the possibility of mosaic genotypes caused 
by injecting CRISPR/Cas9 system can lead to unexpected phenotypes of the founder 
pigs. To reduce the bad effects, other Cas orthologous have been developed (Ruan et 
al. 2017) incorporating CRISPR recognition sites into the SpCas9 cassette to shorten 
Cas9 protein expression period. In future, we could inject CRISPR reagents into the 
cytoplasm of one-cell zygote-stage pig embryos and generate gene modified pigs.  
To make the story more complete, IAV challenge will be included in edited 
pigs. After viral infection the in vivo pig models, the significance of ST6GAL1 for 
host homeostasis, and immunological pathways should be investigated in depth. 






The experiments precisely engineering pig ST6GAL1 gene suggest that the 
gene is essential for the biosynthesis of SA α 2,6-Gal on cell surfaces. Moreover, the 
manipulation of the ST6GAL1 gene renders the edited trachea cells less susceptible to 
the human IAV. Overall, our work presented the first study on host IAV receptor 
manipulation in pig cells, and which helps deepen the understanding of the 
mechanisms involved in virus-host interactions; it serves as a primitive but valid 
strategy for modelling host resistance against IAVs; moreover, once applied, our 
‘intervening approach’ has the potential of preventing future pandemics in humans. 











Appendix 1: Positive control of 5’ RACE. The control cDNA, 100 µg of an in vitro 
transcribed RNA from the chloramphenicol acetyltransferase (CAT) gene, has been 
engineered to contain a 3’poly (A) tail.  
The RNA template was then degraded using RNase Mix. DNA was amplified using 
the 5’ RACE Anchor Primer and GSP2 (provided). Mix1 was amplified using GSP2 
and GSP3, and Mix2 amplified using GSP2 and AAP. a and a’ were cDNA products; 
b and b’ were purified cDNA; c and c’ are tailed cDNA after TdT tailing reaction 
(PCR), indicating the successful tailing procedure; d and d’ were non-tailed cDNA 
products; and e and e’ were water control DNA. The c’ product (red arrow) was very 











Appendix 2: 5’ RACE PCR results. All numbered products were extracted and 
corresponding with each other in each experimental repeat. Total 24 transcripts were 
obtained, and the highest expressed transcripts in each tissue were pointed by yellow 
asterisks on the 2% agarose gel. The lung was repeated for the fourth time (c). However, 
we just amplify lung1 for once and sequencing of this sample was failed, indicating it 
might be a non-specific band or other reasonable reasons. Also, we did not include 
heart in the third repeat (b), because the PCR using heart cDNA was efficient in the 






Appendix 3: 5’ UTR sequencing results. (a) Exons were displayed from E(1) through 
























Appendix 4: Sequencing alignment of 5’UTR. Alignment of ST6GAL1 untranslated 
E(H), E(Z) and E(Y), and pig ST6GAL1 untranslated exon E(-5), E(-7), and E(-9). 
The asterisks showed DNA identity. The data was aligned by Clustal Omega. 






Appendix 5: Sequence alignment of P1 region. 500 bp upstream of E(-5) was aligned 
with human P1 region (LOC111242783). The asterisks showed DNA identity. The 
nucleotides written in red, green, and were the promoter elements in human P1 region. 
TCCATCTT (green): initiator element, as a core promoter, is important in the 
transcription initiation. Sp1: specificity protein 1, a transcription factor. HNF1: 
homeobox promoter. TFIII-I: transcription factor. (Lorena et al., 2012). The data was 







Appendix 6: Prediction of regulatory features.  
There are seven predicated promoter motifs predicated and labelled in a circular 
symbol in this schematic map, ranging from A to G. C(1-4) represented four predicated 
elements collectively or individually.  This image was originally constructed by Sylvia 


































Appendix 7: The map of the pSL66 plasmid. It was used to encode for the CRISPR-
Cas9 complex. The plasmid contains an ampicillin gene (AMP, dark blue) to aid 
colony selection. An fluorescent tag (eGFP, green) on the C-Termini of Cas9-2A 
protein (orange) was used to identify the transfected cells. A hU6 promoter (red) was 













Appendix 8: Gradient PCR. PCRs were performed across an annealing temperature 
gradient from 50 oC to 72 oC using primer pairs F1+R1, F2+R2, F3+R3, F7+R7_2, 
F9+R9 and F6 +R6, followed by the visualisation on a 2% agarose gel. They were all 




















Appendix 9: Sequencing results of ∆P candidates. Given that the poor growth of 
some cell clones, we combined all the PCR products from the well-grown cell clones 
in one 96-well plate for sequencing. The samples grown bad were written in pink 






















Appendix 11: Chromatogram of genotyping results of ∆CD NPTr cells. This is the supplementary material of Section 4.4.1.4. The 
bottom is the WT control and others are cells carrying KO sequence. Sequencing result indicates that the stop codon introduced are 












Appendix 12: The expression levels of SA in all ∆CD cells. This is the 












Appendix 13: NP expression at 8 and 24 h.p.i with Cal04 virus. As shown here, NP 
was undetectable at 8 h.p.i so a longer incubation was required (Section 5.2.3.1.2). 
MDCK and MDCK-SIAT1 cells were used here as a positive control. MDCK-SIAT1 
presented higher NP production than that in MDCK at 24 h.p.i with Cal04 virus, 
indicating MDCK-SIAT1 cells (ST6GAL1 overexpression), was more susceptible to 
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